var title_f4_18_4384="Pediatric hip fracture";
var content_f4_18_4384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delbet type III hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ten year old girl who fell from a tree.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4384=[""].join("\n");
var outline_f4_18_4384=null;
var title_f4_18_4385="Azosemide: International drug information";
var content_f4_18_4385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azosemide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F7292211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diat (JP);",
"     </li>",
"     <li>",
"      Luret (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Loop",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of edema associated with congestive heart failure and hepatic or renal disease; treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 60-90 mg/day reported in clinical studies",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 30 mg, 60 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10530 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4385=[""].join("\n");
var outline_f4_18_4385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7292211\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977795\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977798\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977794\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821214\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977797\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_18_4386="Cyanosis algorithm";
var content_f4_18_4386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Evaluation of cyanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 680px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram; PPHN: persistent pulmonary hypertension of the newborn; IVS: intact ventricular septum; CNS: central nervous system; O",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Stack AM. Cyanosis. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4386=[""].join("\n");
var outline_f4_18_4386=null;
var title_f4_18_4387="Hodgkins disease - high power";
var content_f4_18_4387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hodgkin's disease involving the liver in a 58-year-old (high power, H&amp;E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is an \"owl-eye\" Reed-Sternberg Cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4387=[""].join("\n");
var outline_f4_18_4387=null;
var title_f4_18_4388="Scabies axilla 2";
var content_f4_18_4388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies lesions in the axilla of a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George A Datto, III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4388=[""].join("\n");
var outline_f4_18_4388=null;
var title_f4_18_4389="MRI osteophyte L3";
var content_f4_18_4389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lumbar spine MRI showing an osteophyte abutting the exiting L3 nerve root",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 319px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE/AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5tkjYQDeyN6bqqlcAlcqemG6H3rRvGEahHON3YjpXd/Br4c2/xAk1M6hqn9nWNoIoYptgPmXErbY4+eucHOOelAHm277PEAFjy3ock1o6YyLGRtLMRlsrgD8apy2c9nqtxaTx+VcwSNDKjfeV1JBH5ir8LMIlDtwOCBQBU1FoVjyiuCDndnrWXHE1xIBGMux6CtG/kT94EClcdCKj0lMXSOM59AP0NAHW6DcrpVmvyCVz1BHIqtqeqT6gWV1jVV+6a0tP0ya6geSCBjJnluwFY2tWMttJtDDceoFACaDYiS8W4u1B2HIUjKmuz1fUhNGn2q5ilhQfJHGNpX2riLa8nVVtYUOf73rW3Y6d5kW+XHmk9GOBQA+4njkKSxQSAH3yTWzpC2U9hcmYEXGP3a1nNAFYwswjOMsw5FPUusCpLHhWOI26UAdX4UuTZP8A6QJYYyDlF6t+NPlunvrx7mHkxnHlJ/WsB3aGPfG7fIMFt3GaTTbxrVXdJASRucrxge9AD9WuRAxMsckTsc/Ou4H8K9E+GJg1ArHcPbhuq7cBjXimqXt/eLJcxw3P2TdtErKQufrUnhnxRd6NqAidfJeTgTMOg9qAPoX4jW099pN1azW1zJDGMx+RKAox/eFcLoel6B4i+wR2unyade252SPC/mGY+/pVa08am1trgSN5yEEmV8kN9a0v2eLi31zxrfadLptzLbzoZVu7c7UgI55Pv0oA968A/DfStCkF/dabZPqHWObBZ0/PjP0rzH9pHX9LfWLfS7Xa15Cv+kP2Qdl+teufFHxUfBnhdbqM5lZhChIyc4/nXyPrhbUJHup2Z7i4lMjM/LMSe9AC+GrcXmp2xSOPylcD3/Kuc+Lsbw+LzDJhNpBQhcA812/huz8jWrVkdIfJYM5NcH8WpTdePpi0jsryLjf6ZoA+kfGFt9k+HvhWENG91dW6sdygkjaDwfxrH+Dymz+Hfj3XHQSb820WOvAII/NhXbeMba3fRvCglQh4dNzGq9AfLUCsTxBpMvhj4QeHNFtovKn1fUYvtG3gkuS3P4BR+FAHpfw0RP8AhH9OjjgnijitEDpMnBc85B/OuyMcf/PNfyFNtYhBbRRAYCIF/IVV177SdIu0sLmK2vWjYQyy8qrdiaAPm74w6zf3S3i/2Lp8YnnI5kDyqq8ckdK+XGIOq3RwFBd+PTmvZviYJ9P1W4hne2d7ePM0kDHYXPUk+teK2gM985BxuJP60AaKCLgA5OODTdquCQW3j0pZ08p1BHzN6V7p48+DGneFdH8Q3Vrfa0H0lYXWa8s0Ftd78fLE6tkkZ5JGAR+NAHhtuiM43xnA6g1aMjrJtiVVT9aR9vQN8x647U0nbKikZX+9QA9kaVSVUqo6k1G24BWRN6jrmrcjbZVIk+Q9qcyiRgsYLA96AKm0ltwwPUVIV81CB+dS+XgshjYEdMVLBCJhtB2MPWgCqkbrGVRw3vVi2KxxEjB9c08xSIDu2lPakPlx4wu5T1oAIlTJPHzdjT/LGcOOnYd6a8oUgeTkduar3FyxIwpDdhQAlzdh5QkaYZeAp6U+OQR5aYDcfTtURhCESs37wjv2qhcXDmQrx+HNAGtNOqRhoGyT1FQi/kBySI1HXA61nRYPBYqfWpzEhUZcg+9AGkt+rRh1UjPc1BemGR0+cnPNU7dJWONwMQP51fvtoijdUwR6CgCMozqWP+rXp61S88Jkgbs+var8uZEVkJx/Fis2Rf3zKvQegoAsK8Uq7PvNjPNRIEdTscxlf4T3pib+CoJzxnHSpoI/n+cg4oA1tOk8+DyzGCR3oZI0mCSy4TuoqOwYqWKKxHTimXVq/miaAg56hqALdzbKFzb7dp9ayLxBG+5mIb2roLaMLbhpky3Yg8VUvbcXABT73tQBgSRhV8wvuz2pm3aATnyye4rSuLVoxk7SO+Krxp5ysCpCjpgUAViUYEoCMcfhTo4Wc74+g7mpktSo3Ej8utXSDDAMMMHtQBReYngoMjjdUW4E5bGfXpirDqsp+Y7fQUxkKw7gQ46HbQAyJkCODjmoTnOcDHp61I+SSoUDIzj2oiGVAfn2oAQkOoUY49RRQGKBgBkHgk9qKAJ9QYTNEzAGQ8ZB4Ndf4R+KGt+F/DC6H4ajtbF0vTezXLwJM8rYAUYdSBjaCCOc964sxBZPkO7aMn1zUlqqSFZDvJU4JIwRQB0HinVW8UeKdV8QPYx2T3z+Y0MRJVWwAxGeeSCfqaxY/JUMEkkdQeeMHNXy6o5Bkyu3I45qhAxkmDybkAPAA6/WgDP1VtsgZVYgjuOK1PDttAYA84IOcna2cisvWdqzlEZsMckdq19FRViEaKCccsaAO7g18WOmFLZmXeMfd61wes3zXdxvJaJlPII61qSsgXcjFowMFS3GawrpYwpQSNuZuCOce1ACwiRrjzbZmRscA9DV6LXr9QElt47lU7ngil0/Sr6RgoWJlYcBmwTUV/aTWly0U0TRuvULzQBaHiiJZN81tKh6cDirMXiVLqVEMiEDoWGNtZ1vH5iqCBgfdz605bGIu2+GMN1ORigDr0lj1CMJJJCkMY3ZHVjWbfwTRiNCrQRSHcXTkMK517O4s3E1tcGJH/hY5Brah1e/1DSF02C3jM0r4aUHoP6UAfQvhPTrnxL8JxbeRB5u4JCjoNoUfxGvDvG4a58XiSKzhbTtMUQsq8I7Dg4r2nQtTbwb8F7uS4uJRqDAwW0ePlYn0P5mvHdWU6bpVhaPZqLlv9JmZmLBieRQAax4uU+Hf7LuNGjitX5zGPmz25r1v9jux0n7Jq11bz3SamjBHtmf935R6Njuc5+lfPWpyPfhsr+8ZsnB6D0Fel/szavHpfxWgs5UlAvoWiTBwN2M5I79KAPaP2nGL6Hodv8AKyS3eSmfmOBXz7eAfbp52VUghOAM5ya9v/aeuLZL3w4s0pEiGRwi++Bk14PLHGSlsivG7yeY7NypFAGpolw1yAkwJmuJQAvQKK4z4lKsnxF8qJtyrJHGB+IzXY+G0T+19gcOGcKq4/lXIeKoFl+KiW0gcATqNvfrQB9jfELSrp7LwzJp7FTE6W7cZAUgDJ/Ks74rzR3fjfwZoUsiJGDJdvk4GVGFP6Gum8USOx8HQxswMt3GWUHqoTJzWFrOmrr/AMYosrG6afZhGz1G4kn+dAHpWmCRbC3EzK7hBllPB9K5z4g6x/ZFjb7YlZpn2GQpvMY9QK6qJFijSNBhFAUD0AryX4t65Gbiazt9TuGZIiPs9mgJV/8Abb+lAHzl8VJpR/bCrcxTQzTZGEwTXkelDN43bCn+ddn45ee1gAk8xXkfcwc5JPrXEWLH7USBng0AabzIWztO4dDXrWv/ABjn1ga7dWugWNjqWt2v2O7u/tM0uYtoUhY2bYpwoGQP15rycxqvzsevQelC8kIVJFADpB5cZdfmb1qSFC43MDyO9P8AKMg/dsOB0p9pEZGEbyYx60ALb2zkHcm7PT2qaGNopQGJb129qteX5XGSB60SOqKBFneepFAAVOC8ZP40xXLEJtwx6vRKZNuYwScc5qSzP2WIvIBJu7elAEyW/lqV3bs96bNbIsQGOT39KJpJowjxrwecelRzT3JYOYcr6igBzQQLDsbcz9sVEtkFQcEt6GpQWB3gjJ6e1T6cHknZn3MPXFAGTrb+SqR4AY1lEFSGO3OOgrpNXskmk/fBk/ulqyZrC4dtkFsXUdxQBmlC75A5+tOAZ3K7ufTNW/sMkZBkfyM8HdU1tPbWNwoaP7QKAJoLCRoE+U7m79hW99gEVusPnwvK455+7XMXepz3Nxjf5EIPyqKqzSPvIUsuehz1oAv6lHNp1zs3K6dynNVUjSVjI7Fc9qqLO8fU5zwSTSAktlwWz70AW4/lZlWYEehq1a8ygvGNnTdVAYDfOgUf3qv6dqMdtKA9v5kB4O7tQBq7Xij+R1VG6EU9bXzogd3zdc1aEtrMiiNAd/QA9KhO+1mCBlYHt6UAVcPG5DMPLFFijTysscqg9cU6+thOGCkq+Mis/TGNvcGO5hYEfxrQBrLaIC3mglh2oWKJEOOM9sVaSVREzW/zDHOetVrZhIrbiM+hoAjZUdDGyqT2xVa7UQwBDDvk/lWnGigbsAgelQzKlyxyxGOhFAHPNCrSbzw393tTVU2zkfKwfsK0J4EL47e9VLi3EL/uzyaAKMgzIS3ykdAxpJTwMD5fQVNLB5knXbgclqilXy3KI25OpIoAaACnK49xRUiAvly/TquKKAJ7RfLJZZELY5Df0prkFP3zZIbk9KW32lMA7AOQJBmllJOWcI4HbGMfhQBMmXMhc8AfKx6VJaRhAQWYqRksDUUIEsLFkwAOO+fwpNywxmRXLYHORgCgDGv9z3hb7/YV0VlGEsomHLHgj0rnrbDzebgkE+tdNZJ5Kb3JIbtQBYliZLUMQqlzgIB196wrsvHIGCAgNyp4NampXgZVXeSRwEIxtqmIJZYWmaMLt/i68UAdLpFyZJIn8v5UH8YyBUuo2iXNyzo7N3+Xv7VlWUghaJbYqQ4+YFuDXSQLGyBQhWb+8pyKAM5dHWXYYm8kHqj9aT/hHpbeeQgSYYZ3MciuutLWCOSBJ5Qzv94N1Fa+p/Zkmijt50kTbjAXIoA4WHR4Ykia7WPHJ5bJP0FUPDEFvc+LI45srpqygyqDtO0Hnmuzgs4mWUyXludhzgLyorh9TsYjfzSWM29M844yaAPbfF2p2/jDU7GG0l8rwzpijbBt4Zh3PrXK/EWbz4EngSFbYrsDouDgVzXhnUrpBIkitHAi4zuxzWqEj1XS5VhuE+1Rc+QTlnHqKAOMtorZxEynzJUbD47itK4+1aJcWev6RKseoadcLLEevHoabbW8cEirEBEN37xiNxz6VbvrFtdul0XQFa4un/eTheqKO59BQB2vxd8U2vjbXtA1DTuMWIFwjfdV8kkD6Zrl4Y9zi7UgR7SpUHOPeqbW4t7Ehpf3cR8tSozuPeptJsn1G4RYlJHCnHGPfFAHQeBmiGs2ZYBm3kgkYzXK2J/tD9oSJ2CYN6CwI3DHTFewr4Zt9KvrWazeOaOCAuXPZ8V5P8IrJtY+P0A+Zl89pJSO2Of6UAfVnidhL8QPCOnpIcW++dlx6LgfyrO8MT+V8UvEU8mW8+dYFAH3QF61iaVrE19+0LqEDs32fTbV1ye4x2/Opvh7q8l78RLvyZC6zvLI8bL90euaAPZWOFJ9BXzF8U9ame8urg2doU3Hy5bSTnd/tAda+mrr/j2l+79w/e6dO9fKvjyXF/e3nh87raEbZDHBhFbuOetAHhfj6+nvr9JLiRW+TGFFczprbLg5GcqRWl4rlluNTeSfBdufkGAPwrM08A3J9MUAbkcKlV3Ng1YboFCgjpwKrwJ5jhkzkVqWto5bduBB6+1ADbW2+zv5hHBHQ1PLbeWnmSKAG6Y61JMxRNqL5m3qaqQXBbcZssnp6UAOVRc7Yo3JI65okheKYFWCKvXNOVBGu9WwD6daS8xKqvNKERf1oAa88cZYkswPVu1V7q/jjhCBSfes69ujI22M4j9PWoYQp5YFivb1oAvHWLhY9oUBCO/eov7RuFQjeRGT0PWqjBpHLD7vp6U3OMnZkj1oAvjUCMLsJPrVu1124WMxDAX1xWR8suGIKkdQBThJDGfkVmb/AGqANaXVZJ4wt7JuUfdA61T/ALSuGfy4J2ijPfvWeW3E9v6Uo5I6H1oAsTrM+C0hmyc8moJNwk+b5fpUkcbs4JJCe1TS2uSu9mx2oAqFNzfI2/FSIQsgDHP17VbMAAHlgDHX3pFgMWXZSC3TNADlgikJxg565qF4MyKqtgZ6Vb2Yi+YhZD0xSQ2259zZBH8RoAr3UKhlRS+e5PSoZmfyjGQpUHOav3MZljbbMPlrLKMBl+RnFAEkMstvl04z0xXQ6RqcFxbOlzCDcL0bPNc5GybipXOemab5zq4ZRhh6UAdJe3C3ARY22kHkVftog7IgZeR1Nc/BdWu9QyMG71salqdjDp6raKwuD3NAFt44LadlMqiT9KoTJJMzPDImR1rnJ5JN4klLMzc0+KZldizFVI6DvQB0cNz9mUKxUq3BOalVkZvLicKDzmuSLmZTuzxyMGnJO6EHewx+dAHQXEG4EyfMV7iq0sG9A0ecjuarQ3pVPnY89fernnKwDJkex70AZzsQGjIDyHtVZQV3ELz3zWhcR5kD7Dv7c1FNEXQK+AQc9aAKisQCVYFz2oqxLGNwOBtHTFFADLBmZmdnX5BwMdafKYXXd5gaYnkHrTUaIKRwHYf6wdKjUJkmMlUH+z96gDQt1cbWdVU4/vdqg1AAQmIBt0vZjxU9ikc0UhyMehrPvcG6RS4YgcegoApzf6IiKFO7PXtV2w1ST7TCHcEDtUYg8++hiUfK/XcMiu3bwnb6ZoYu5YGWRxkFjQBz2qSJdHLsN5PLBcYFaN9/ZUeiQ2sWoySzN8zxRrj9ax/Jt5UM0kwQA4KA5yKfb2Ia6WSJAIv4TnrQBbsVHmhR5USBeARnP1robSVFtQhdUc87Y+9UxbDASOHJPZDxWhLaJBEgCjePvKf8aAJvtwW2jK/LKx2hupxWnYXKR22yOTa5bGOpY1WTEVpHDBbZD8ncvP4GqckaW8zox5+8pPBz6UAbniOyuLHSDd36FGb/AFZQYLfWuDl1BpYH/dpGegK8E1f8TeItT1Ge3sJ5jIduEiTkKPeuVaSf7eYVSNv4TubABoA9V8O+HdmmRCSRJ7uZN+1jwB/jXPRWmlaffz/2ol+cZCi2baS3pzV/SrmW2sImj1Q5gXLEjHPoPWsmLdrvjnRrRpI0kuZgTcTybUj56ntQB634Z+B2o+ItNs7i4nfw9pUuJZIid9w6n1PRcj1/KrlzL4W8JeA9a0vwFDKbu6m+xyag53zT84OG7Dr0r2DxVfXejfCnULhr2C4uorUotxH91s/LkfhXypoTyx6C4RXkYuWhCt/Ee9ADL21eLytMj2RrCu+Us2fmq74Qu3tZ5pFffuYJgfw+9V4bprbRrpJzBJOX+dSMsD7mqsMnkKfKiCnIZihoA911/wAi9W2srKFnKWxdxG2ATjvXl/7Jlu1z8YtauNuFgtZWPfBLhR/M13vwVlm1DxfrodRJDFpuVVxnk4A/rXK/sfFIdc8b6hIMPDCD7AbmY/8AoIoA7D4cXB1Hx98QNWuISVgkeJX/ALoyRj9K734XaLBFd3GqIoDumzjrya86/Z1u/t/w+8XapcSYkvNRYb8Z9D/WvYfAFvLDDeNOVZtyqrLxlcdxQB0GsXMlnpV3cwQG4liiZ1iHVyB0r5N+Iesanqlpc3V5C1oQ5dVRwqfTaOpr6v143Q0W+/s8IbvyX8recDdjjNfF/j/TBp2nQJcXhbUcsbiJm3bTn1oA8b1SV5L+WUE5J5J7mmaXzdEE4+U81HMSZZGcnBJxg1b8OoZNRICg/ITg/UUAdNpNt5anPLMOMirgSRA0Yj256tSxqSAgkG7+7U7gug2E/L1BoAz7vKR7Y3571WZUYqOVc+nenX8wMirjBJ+6O9WXXYsbum1hyBQAszpBbYdQWHesC+uPN24cbB2q1qc7yzbsc4xtFZapukbPy98GgBucSqX6VNIShLLjnpUZ/eqoBBP8qWRWEY3KR70ANjxkbt2ewFSgp/F8qg802OMsNzMRg9aUEsTj5+emKAJJY0GxrUswP3lqHyiCTtGD2zUqu6EhB94dB2pbaM7sMSec0AWbLTXC+a6gjrg06VI5DiOHy2HU1dKM6qyscDtSLGxfDD5aAIbeFYeJBvDdG9KnzGh8p3yD0qRUQEeYc46LUt2+6NRHEgPqaAK+LdVxt3Y706QB9pfDDstR3CecFONpXrih/k2yiMlRwRQAMh5wgZh09qXajxgy5UjqB0pWlCYZAQG7Uss0RjCtyT1AFAFUqgfdGvy96juIUmAEQITuKthVA/dnC1KuAu0Lt9DigDLfT+Pkwr9gaz50khcpKuGroRslOJPmkHQikkhWe3IkXdKOlAGBGpB+T7x61JEPMds/MwHQ065jMbBNhU/XrU1hp9xNL+6HJHPsKAIFY7tjjev8qbNKjHawOBxxU1wiwSNDklu+2q8g8t1IXJHc96AAsFjxGOvXNLtw+ZVzkd6aAwUnaMZ3Z/pTzIHffKcr0GKAAMi5BRs+/ap7GdI8Bm3H0NQ2q7pGwpwehNLJH824IDt9KANmNVKs5c7iOBVOEBxJuBL9ualgmeW3HlHjGCMUgYW6b9hOaAKx2PGQyMCPeinyrlC4Ygt/DiigCspl+yug24c915qSzQzRKrhxt4yaVd7tHJ8wRuMH1qxJGy8udmOwPWgCYIfs0iqy7T14xms+P52I2ggHAB5P4Vo78xBlIGBhu/6VX09UV5CIwXDZyp5oAdJHsvo0Qlgoznpiux13V0k8NWwXb5y5VlY5JrkEz/aDM2fKI784p13uMWH4UcqwoAxHneG7LyBTGTnCrXR2l/ZmOIRyiMEfdHc1zpZnkByQrHG0c7qfdxRqoyuHJ54xQB21vdqbYxq8Idj/AHs8VoM8b2jEygoo/i7muBisF8n5ZWDdtpokt75UAiuW2jn5m6UAehF7ia2ia3JOxecN90e1LaW9xvL3AD7ULAP3ribfV9UttrBElQDDEcV1fh7xRp87yRzfu2aMhlm/oaALHhDyUaSSWKCa7ncpEGGWT3rK1yw0uz0bUxNC41Uy/u5R0Fanwyu4F14XDlDFFNkK3IIpvi+dfEvjPVrmxkgj02356YTI/nQByuj3sVjE63CNfNsyeflU1mWmr26a1DPf2XnwGT99AzlQUz0BHSkJnS8l+zLmNzyAMA1Q1KMichmG5hzx09qAPvO21bwtrnwxuNO0iQW9jFYfJDKrYQBcgZPXnuDXzto9mll4Bub6aM/aZ5jHb4PKjuwrJ+FnjrX7TQ73Q45XurJozGYXjDbVP909q19ZuZbfS9P0u3Km3iBl6/MCexoA59HWGB7RWRiTvd26k07kzAunmRkfeU4qHTYfMuwG2lWYsS3erNtIktzfyGIlUBCLngUAer/svzs3jPXVkLus9qMA8gbWH+Nc/wDCXboHhn43NGrKLNZYlA6gfvgOa3P2X5oY/FN1G3yTz27FVHQgEVR1a1/sn4S/GW+iBR7zV/s7A+0qg/o5oA3/ANmy0S0+CRlcFmvL9mA9MED+hr6A0q2+zwsSFBchvl+leM/A23Sy+HXg60MrDz1adlUZzuYn+te5jgcdKAOd8eN/xTtxC9vPLFMNjvE+wx+hJ69fSvizx/cQwC7g8qVJ1YhlJyD75NfXXxY1BtM0TzFuR5kp2Q25XO5wCcjHXHvXxl8UdXvL5d1+0X2mRtrbF2k/UUAecjaCTkZ9MdKv+Hn8vUWI5+QjP4iqSYAIViCR19farWiKTeuO4Q/zFAHZRHzJAykB6R7khpEkJDeoqlZ79vzEAD86mFm824qzEH1oAhsyZpTxuAP3jU2ozlVG7OBxVpLNrWEMADj0rA1G8aWYhhwO1AECyn7Q3zHb2zTIJ2QSZQPkcg9qYZSvyqv50SjegfHTqBQA+3jJcKUwCfvelWJJvJujEwDxgYqmsjJtLEk+nap5FM0ZlUYxQBI8sflNFGoG7t6UyACMcHCdzioIiu0Hb81W40WSNw5PA6etAEMwEf7xJdwbgVrR2i/Z4jtYs3ORWfDEjW3zMo56V0EQ2xQ7Jw/HQdqAI3EaqucgDrSzlBbhugPQ1bhika4YsilfQ96WeEOAJF4HRaAMy4y+xl4IpzLvdScFR1omid2JSQDH8NV7dOCuTuPUUASDcsjsOIh0FIC/kNvU5J4qWQLFH5O07j0NMXDRiMsfMFAEJjl+UEjNPIIk+Xb75qyI0DBiSSBzUeC7NtTjs1ADY4suSqkeoppnBLLn2wRUkzSRwjb9719ahkgLshc4J64oAh2bZB5bYc9jVnyjsLknI64qeO1yDuX5QPvVDtCZA3rnjPY0AVb5FeAO4J9Kq+Y8MWLeV8twRmrtz8rhXJ2+1QRRAGSSPnA70AUGjZQwRiXPXPWjG+LcxGVH51G/LfKSzE8k8VLJD9mADncW5AHSgBiiSSE4xtHbFPt138NgKPXqaWW4/dAINh9qrsxkI3dB3FAEqu5LAPzjpTVdogVwSG71GR8vQ7u1WIsCIlsHPTJ6UASWUnkXSq7fI3XFa10Y0B8oliRwCKxLNC94i4yQciuhmVfOBwBgc0AZQYZbY3zY6HtRUjqAz5XBPQiigB0CtOhVfvofvEYApLnG8FyDIO+etTwxYixG29upUGqVyYzJEvUlu/rQBIGVVZm5OOCOKVSUic7UVW5IJwTTGciQrsGRwVNLcrstj8obB43dKAJ9Nj8+5dV37iuBt5H41bvrVINIMiyhmU4ZCOam8JPbw/aJXkERCdewrpfEtm8fhuK7tWtX09ky06kEs3pigDhdP0tbyzWdNyLnnHJWrN5obGJfJmaQ9wRx+NM0eaW1tIGwWWRuccYFdHDch0UPENhb7w70AcyttcWcIR9gwcgr81QzOGO5hsweSRgV6HbQ2t47oqIExgOPlC02+8LXFpAJpmVbZzgb03E/SgDhW8t8HDyHHGxflpr24MhjkVd5XcBjBxXUtAnnhIXkZVHZdtYWu2t8t/G4t1G/5evIFAHQeCbV9P0nUNZEW22dGt0LLwrHuPeobpEsfCX2O1UNJcOZJZSPmPtVGG8mlhi0tXnitUbO3OVJ+lbeoMfs0aPEWaEYVD0PuaAONFhJsQl2jA6tUq2qNNFHKq5ZvvYrcawmId5IQsi/MGB4PtikOjy3LDen7wDepVv50AU1tzp9jf3Uc8sbqwUbPl3D2NaDSNK0BLht0O7Dn+Zqjrl6k4t7dCd4wro33cityfTUtre1EjDz5E3bUOQFoAbp0uY/3jwxswwML936Vc06NGupVjUuvlMCAOWPrVWExlUcqQrgoikdT613XhnSbTTfD0skt3F/bdxlF2sD5an19KAK/wACr77B8UNDjVMrKksLjqykqcE/pVj4/Xj6D4U8VaEGUvquu/a+Dzs4OMfUCnfDSwuNL+JmhzIqndIyvIBnfkHNct+0rfNq3xcOkwtv2TRpwOhOP8aAPevhhpzwP4YEEZa2i01Ds3Y2kjrXsgz3GK848HwGHxZBaxhgLPT0jd8cHgcV6CiLaWxALsqAtyck96APLvjTrNvGgsjez2k0cTOrrBkBj0+bHpXxV4xlkudUSWSUTHByR396+lviX4xk1G+u3ik8yNFKCFwPk9sV8veIJ2n1SRUKlU67RjGe1AGQ/JJIBJ9K0/Cq7tUI6/If5is1yT2O0cA4rX8HLu1aQDP+qb+YoA6eO0Vr0h1IX1FaSgqpWMrtHrRFG2V9upqV080MyD7vUetAFa9dIrCRpD82OMGuHljLEysSSx4wK63XBt0wll2H0NcrbSsyFCQfT2oAjDAsGIDKPXrUpEbksVKE9KjQCQncCXz2qxHJlhHgHHrQBDKroA28EHriiJypJjYEHqppW/5afIdg7imxxPIm7ZwDnI60ASRqV3NMo3HkValiZYFmIby+5FT6faiYqJSAjHGSelWNdtm02EW6XG6KTnB6UAUIwuN5H7lh1qxpBC+ZG8gQfwnvUDMjaf5WPu8kjtXaeG/hf4h1HwVqfjBrc2ml2Nt9ogEyHzLwDBYoOyBcncevAAPJABjROmMuzl16YqzHNI7gbflNZ6bHbzEJzjkVMJcR/uzg5oAmuLbzrn91tXHXmoo7dlnbZhl7mrEAEsIbdtlH60mcAgnLnuKACS1BClRuPuaq3CqJwUTa/QirEMEpbKu2ailZPPwVbeDyaAGtDIgyUyG6ilm2mNI4V8vH3s1aj2l8oxHuaRYAZHLMHHYUAVjG/HG9RTVfDHKjPYVYuMmHa77BngLUTLGEUR8yf3jQBYWYmMI6cHtVKTytzxyMwH8PtViVVWIbmLSHuO1VpkQlQXyxoApTo8cJO7cuetBjEkCiLOMc471LexkRhFfk9KdfW0kGnRkssTH+IHGaAOflO2c7uAG6USM3m7zkDtmp1klIYbYpMdX74quAzoXA3DPSgAjV5QxCFiOcjtUkYgVFZiWYn7vpVnK2+mDaNksnX3FVZFQKildpPU0ANlO6XP8AB2HoKTysoGwQueM96QglyBgrTzIhh2kHd2FADrVSLxSrDr371t3jkr5ZTAx971rEs1LXce0A810N7BvcAseB0oAywzMoXjjvRQDGruV5fpiigCWBwYFCfIyDDMO9U1KyykKVJjOSatx7Y7CQsWBLZHcGqRjiIuJJjhsfKEOAaAJ4m865JbBKnGAO1M1HBzGpPl9WVe1PsZDlXZxExGB3BpskRkumZCZHQ/MB/EKAEvoZrWytY/LHlXHIbuw96Wa6YWAtFcJAx/1ZJremlhP2a71GU2whTEVuFyxNc1eXst5qRklVVAPygL2oAct1cefFDCW8tRgLjk11+nXkUVmfO3mQdMjgVg2UE00PmpxID97pxW2lqY44id0qnnZ/eNAGrBfeUIBsAjLbgkg+Vz71u6r4tN9p4ScLbPH8oQdvpXLo6yD5rSVox/GG4jPuKa/lS7YWlRznO7HSgC5amWSJplYRMWwTJyW98VR1S3uS7zahc5I4QAYJFQ31/Hp8L3Dkqn3QO7/SsiDUxNdxNcCTynPSRuQPWgDotK0/MwKBpWxkbeq0alc3UU2xVJP97ua3fDk3715rCL/RIvvysfve1Y/iqZXuHlClPTtmgDPurmWKSFWGC3LSE9Pas+SS8nuGWCSRFc7RHGCzyfQCuv8AhF4SuvHviC40oz/YUjjMpuNm8gegHrXr+vabpHwR8Nt/wj0X2rxDfMEfU71Q2z12jt9B+OaAPErnwxc6LaxXGuxCF5RlLZv9YB6n0q9dTFra3ht0XcVzvP8ACvvUPiHUbnWtRe9u7qWdFTLPJ/E39BUsFo8WkJc3T+T9pG2ML824UAXNDltEFxd3awslvGRDuPys3tT7C6s08OzzWsLi8nJMmeQPp6VhzyxpafZWTKx8jIwGNFozrp0iqJFyp+VelAHu/wAA7D+05NP1QIHW2DozE8qccV4X4gI1X9pS5WNneL+1tgYDJwDXun7NrTw+DdWa13SXXzbF7Lxx9a8M+FNnJqXx1nkuZyksU80zvjksCf60AfU3h+/WHxdqwkZlJCQruOM12PjVlj8J6ozi5ZVgY4t22yH6GuR0jSzf2RvggE32sHzHHGAetanxgvbuw8C301mlu2dqSCZyvyk/w++cUAfIfj/Xk+ysIkUTkYyPvf8AAj3NeTu5eYuzNvP3q7Dx+0uAXTyCHztAyG981xTEk/KOvfqTQAhJBxzitrwY2NWck4/dN/MVkSEAdAVI6ehrY8FKj6y6ufl8pv5igDufMJVRgopP3vWrESbZmWQkqV4YU903QhI1LQrzzToXMkqsAAi/w0AZetWon0Wc+YXZD6dK4a2l2dxxxXpc8SFLlcjbIDhRXm86G2u5EdOM9DQA+NUWYh2JJ6YpU/1zKice9K5wVIIRiOtJE6I54LSf3qAJJZkSPlce1JHscZVmXIqDKuW3sc+gpY2UoQ02ABwoFAE7uXgITcGU9c1v3Go2l94bSG7jVruPhSOtc3EWCDPC9uaveSn2NmBAc9KAPQ/2eo/A66zLN47uCkiOv2aC4izbMfWRueh7NhfUnpX2newWmveH7m2ilimsr62eESRMGVkdSuQRwRg1+fVlaLY6N51ydrSHhu9db4d1bxh4dgt9Q8G6pJBaKd00eQ0Teu6M5U/XGfegDJXT57WEQSIDPCzRTqRyGUkH9RWfKUDP5aEAdjWjrXiS61jXby9FvDHLcStNOIQQgdjlsAk8ZJPWsn+0sO6TQZRuN1AFpZUjVHTBY8EZ6VNjYd0wGxxxt61nxWpjbdCf3Lc5ap3vViYQywSN/ddRkUASxea8pjBYR9j3ptxEIs4dgp6kio59SiTCtDcFv74XipDfxPEn7zKZ53jpQBKkYSEF43YHkGiJN8nmRrkDqM06TUrY7USVrhAOQg6VLYmCYvLDMNg+8hOCKAIrwcB0j5796gQkgSooOOCKmvJViG63k3hjznoKilLC1O0xjPJIPWgCG4cq4CKdr9/SoHRnYwwo0kv96nRjzyvzOsC/eIFa9vc2aQstks+VHLFetAGdcQmy0wPcDM5PANZuszeZZxrIjiTGeelX579tQuFV33Mh4Uis3VrqWe/WKYBiOFCjgUAQ6Npt3LFNdxxqbaIfPuNVnvXZWEESLF6VpahcrbWv2VgwcjLIrfKPrWOqCRGIbbs7DvQA0P5jASk57DNSTOxI2gbemTUMURk3MD8o60+QltkfKL2NADSqiTC7vqelTbCeZBgH0FRtG2MZ6d6dDK6A9Ng4JNAFzRFE+qIiriMdTXRXKrPcyFMoEGAD3qLwtYLBaS3ci4Zvuk1pyIZI9q43nkmgDlLiIpMcxFcnlqK17q2Ys6nlQOtFAGdHCY4hu4ixz71mXXOxAFClsmtOV82+VPXg1iXoZZArb3J6NQBftl2xyh32Q5yMrn8qrQlpJWKTbB0GByamgRjYOX3SDP3TxUluLePSbi5dQSTtTnBBoAo30vm6iDI7vgBdwOcV0P2NRBb+Uvy4yzdSa5OB9pzlVUctkV0GlapaLbAyySQyA4B6gigDf0uzM92sWNwccBT/ADqzPFPFPwhSSM7UCnhfeqmj6pYu74ukVx0xwTUl1q0ERkJlUkc7s5zQA6RZYj5gcNIx+Zh/F7YqjLi3uJGdDtI4X0q7p2q6aszfabqVdy7hsAODTJZ4bpzI8kbK3p94igDIt7QapqMb3swFpAMiMnBY1qxaVC1vcXF/AUibPlP/AHfaqOsTjTRHc2Qint5PlMUg5zXbySWHiP4Zx3GnWE1tf6W2bqPflGU96APMrLWJbA3USzyIjnAGe1Q3muXErIjsxC/dc8salvrIzQC5SzCxSHK4b5jXrXwT8H6FB4B8a+NPGWmQX2mWkJtrSGckbpFAZtrDlSWMaBgc8sKAPPvA2qXy6g8sGq3umTthTJbnDEV9O61odn4u8B2R1DWra5uLZBtlmOMnHVvQ18k29w1s8M6PCk46becmvo34GfEHQzdW+iatZw291cjaZXG6O4PYexoAw/EOkaPpfhoadptxZXd0TvnuI5N3HoK4G6ndbRJj8yJ8qJnAr0f4k6SknifUTBosWjWlv/y0i4Eo9R2rzO4JuImjLBY4zlQeuKAHSfvmgjBdgRkgDPNXmge30qRMN9qY84PAX3pdFSJ5I/L3hY/mbHU1LZlL2TWpiGjkVMxrjO6gD1L9nC+ksYdSt0KsXjLsjtjpnpXlnwZWW7+IXiS/idY5gJdgPJyz9q6jQL86BbC4gRWe5sXBkYY2tg1V/ZTsWvte1TequJD8xI5HPY0AfUmhk2OjaBaEIZJsFt5wcgbiQO5rm/j7ME8GxxYVnlnUKrfd4HU10epojeNdBt3jDLFBNLGcdGAA6/Q1zXx0Eq+H4pRHbyQjK7ZOoY9xQB8Y/EfzY7lEaTzIyRtx0HtXHKqbSc/MTwtdP48YtfRlmRhnnb0rliOeny+nWgBABnByO1dB4Dj3664PaFj+orBBLEqTlcd+K6D4fpI+uyCP73kMf1FAHfLPlso+wDgrTp3AkAtsSMeqio4LZ3ZnBQ7TyDWrawLDIs2xA56BaAKEdqBKpJIkPUelRXvhyDUZm4USY+971vqkk0hZjHt7gdagkB83y4I2C929KAOI1nwhfWNv5oKSk/dA5xXMmzuI5QlzbSBz3PSva4o0S1eO6ViwGVOaoTSWTJGLy33HOAzEDFAHltvpV3PudYWiVf4zTjFaxROjSB5+gIFepyafePOINI0y+1KKQfcgtXkA/ECobD4WeNbyd5LLwfOmTw1yyQ4/B2BoA8wtNPlkUNchlTPBbgVtSaZlELsjKBkbOa9b0j4B+OrqUTak+jwKf+WM1wzAfgikfrXR2v7OV/hpNQ8VW1kh6pa2ZYD/AIE7j+VAHzXqC3O1Q8Fw1u5KxuykISOoB6HHtW/4Rvfs0UlqsjvGw+dPSvsv4Y+ENE8PeFbrw/a6rH4gthcNLOLgxS7GYDKFVGAOM4PPJrw7472Pwz8L3tyvh+2mh8VlTug06bFvGT/z2VsqP91AD64zmgDyS4NpamZ1nXyyfuqeRWVLdWMmP3rY9KwfMaaQlsBmYkmnLbO1wERSx6+lAG5ZaxDbO8Qj+0QkdDV1fEcbwC3sVSGVjx5gzXLbHaUxwRuXXqKettLH+8MeMdm4oA7v+ytfuoUI1SwjDD7uQM1Xk8Ga88bSTNBNCe8ZHNP8MWTtYNPOnmKegz0robLUZNO2wlC8bHgKelAHEx2GseHrtZbawJJ6qy5BFT2ctheagxvrK4sLp+pHCk16NqjXjeXLBdx4AB2P1Fcl4v8AFYniW1vLOIzKMCRFwaAM+60WRVeJX+/9056iql5a2+n2ixOkjXB/izxWFNqF+7q4uGwOi56U+HUpTOBeFnU9yelAG3ZfbQu1ZoY0xwrd6ll1q8gi2AxAqcHC9aqJJC+POx5XZyelathpi37jZcw/Zl5Ld6AG6rcwvaWtwtvHFcN1K/xVzGqoV1SPzN0ZbnIre8R3FsjpHDtZYTxg0l/a/wBq2cN7AAWQYKjrQByt1lbpsOZR0y1RckARn25qxeBjeMZIzGBx0qtj5yxyRntQBNF8isoBB7k0SOu5S+TT7W0aaZQquwPJ9BSyROb7yo8Er1oATzDONiGpdNsjfXKxKhwp59DWzp3hiS9k80yrGP7o710lho8dpA/kg+YvXPegBYYllhSKNdoiHTtVRi3mMRwB2FXEcGUYyuPvCm3CM0paFlVP7vrQBTkjkaIkDCHvRU6IxyocqT69KKAOSeUvGkYUt/uVTnDSzthMuBgEVfCRhhJEhwo+8G6fWqaRb52mYl2b3wRQBbiVodOVGXPB47msWZv9A8sLjeSeRW7dQOLBZVRtqnAcnvWDPGdxe43iHqp6DNACW9vI0DbgVVe3rVpURoQshXIHTb0pLaVZT5TRzN3Qk1Ya2ka4wkbFsfNk8UANt4IYwCIhvbsOmKme0tskFQeM5zxV63095AjzKkQPBJPT6VNNpzRLsDHYOeVzkUAYiWFoI1LqzIT0VsUraZGXDQTvEV7bskCtOKzkAfhWVvujHIpIbNjcqBsHHVR1NAGZFaEyL5s7zIpyN3atzQNbm057q0UM6Xv7t1BwuKoEebcYVlO04I6DNaWn6dC0ySyP5lwG4RT8ooA19Y0mOxW0itZXvbqfCJAq9GY4C+5ya9N+PbQ+Dfhp4V+HlqVZxELzUAjH5yCT+IaUu3/ABUXwP8Py+I/iJb3OoIFsdDH2xw3/AD06RDP1y3/AK4T4m63L4z8aavq8Txm3nlMVsxB4hT5U/MDcfdjQB5mhEU0SMj7c5XA7VsxzJaFbmyWSMQuHAc/MD7VU1XTTbvGvHmLyCr1PFK5ikWbbJG4wdgzg0Aer+MfFNz4n03SpGd1zDiVSeGI71wogKwCNWU+Y/JzzWh4OYHSbhnb/AEmAfuoyNwIpkg3RSB1XzWO5hGOgoAlsXlKTWtsT9okYIMDnFegeDPD9xLrevLbRNPBaaeTcOwAAbHb34NcJoNzb22sCaRXdI03ZT71ewfA2HUta1TW7/wA+OK1nhKw2LN/x8H/aPp/jQBwXiKc/8I5YSOTGot3VUjX9TXWfsW6e8tlrV++fKSRUT0LHOa574qTS2Wg6p9qsVs5rdjbtFE2UUn0Neofsf2AtfhW0/e5u3f8AIAUAel3GszHx5a6XF4fvZYxAzSaqQFhhB52jP3iSB0ql8UrFNR0SK3k1KLTlLljJJFvDADlfau0rI8U2/wBo0eRfs8tyQQwhjxlvz7c0Afnv8QFhF+wjmEyCVgGRdoYetckw2qOcgng16N8WLBbe+1JVga2aK5OYDzsB9683Iyp+bI64AoAGGAxJ4P8AOuk+HNzBaeIHlumCx+Qw+pytc2FByVbgDJqbTGC3eW6YoA9L1XxNp6B/Igbr1HeqDeM2EEa21kFf1J61z5ncxMsqKYyeMdajSKCTaqq4x0INAGvJ4r1BZ2kiiEb4+Y5rqPhfrttq/jLT7XxfdC00CTzPtE/m+VtIRimW7ZYAfjXDLZIsbSSNubOAuetdXDpllqmnWdnpNpNNqTH5ljHFAHu934n+BWjH5m/tGaMcL5Vzc5/76+WoT8ffAunQZ8NeDL6V14TbaQ26n8QSf0rza50O28OaRJFeaXDNqpXgsd2z61z+g3Fxq7/ZdQvbbTbCAlnaOP5vpQB7fD8e9evo99v4UtdOTqGu7xpOPoFX+dc5rnx18Yssn2AafF2Bit84P/Ai1cBNGNdiupYbiaLSLQbVuX43ms8RXOm21nI0a3FrLIMMpycZoA7BPFfja7hF34g8XaknnfchtZBCAPpGFrk/t76x4ge0s5LzWbj/AJaPfTNJj/vomt/xU8r6/YHTVX+zBEDJxyDjmuT0zUF03Wr6S2Tb5uVVh1oA9C8I6vqXhHSNZg04x6fDeFTM0Yw+VBGFPb7xzjn6V5NqLtc6hPM6K28nvXU2k0kjCyvJgzTHIGc4zXJ6rYPpevyW94swJ+51xQBhSqYLg4Ax2zVq2luXy4wFH8Qpt7bE3RSV9rnoPWnwzrbwOMk444oAv6bE0zmaOXHqTwTWzPYteQkNFuAGcjvWBYXSzPHHsIGeccV1NrdAXP2aRyqAcUAdD8NRFLZXlrNEhCKSAx5pLHUrWzvZI5YUf5uAOSK52KWWwumuLQdDkqT96prW60/VdTEkkbWNx3JOVJoA6DV5o9UlItYThBkvnpXm2ojzNTc72kwcBQK67VLuKy32lnO8s0vBZBxVDT7QRT5uAFcc7vWgDnn0qSSNnuWMOeVBFZtzaSwqS2SvrXfXupxTK32pUO3hSBzXLXZF5PtWQhfccUAYzh5ECruZAO/St7QvEH9nWUkD2sbqeFNQWENuZXibdI3YDpT59HdLqNpojHCTQBftYIrgG41C0MMTn5StJBa3lhembSpf3XZW71o29nPNfxxW7E2gH8Z4FSfY7m2vHCBbiDPY8rQBR1FrCeAtqcEyXrH/AJZ9DVC/0OKGCKaydpC3WM9au3haS/GHEkK8sMcikjcLdNe2LNKIux7GgC74e8P6k8bT3BFrBj7r8FqsW2iQ210ZWGwse4zmsy48X3dzcxHVAzw9FA4xUmq+Kp7WdIrNVMJGf3o5oA7BIRFKrbUIxxipIR5rPhQGrkbL4hbImjvNPRwBgOvWrlh4u0pnBZJ0dz1PagDT1WwNuA4zk9qz0IOV6P71rXOqWM4UQXiOuOQ/BqtcWW8LNAElU9dp5oApNkpyM7aKuxxkSFdvlrjq9FAHEMjbiGI5HQDqKrQR42ZcmRm4PYCt+WOKGD5pBuaPA3VjOvl+V5QGVBySaAHX5C248lmkO7BHvT4bqA6RNb3aLtDAkMOfzqKSQPHGwI3A84qEXi2thKmwTb3+bcuaANibSdMa2GoeHL5Z0jjHnQynaUPf61QsmimuYlmYFG5YIen41WS3+3W6iQw28Lcg/cbHuO9XrCGGxtJUtpVkJ6MBwfpQBq21tbNv8sySRA8ITVufzlgwsco3cZA4H41c8L+HH1bwv4m1mC4S3TRoIpWhKbmmLswxnI242nsa2PBdlHrf2uDUtYttL063tzNNPKpkf2WOMHLt7D/AUAchJOIApEqhvutxyKvaIlhcXSW8sV5dXB+5HChJP5VZ+I/hubwl4muNMuJFkjiRXSeNTtlVhkEg8qfUH9etL4S1jUNCvdP1TS7qKCW0fzFBXPmjujf7JGQfrQBZ074da9qmstHp/h3VGg3ZZprdolx/vNgfrS3enWlre+T9neGCM/vFXnp1w1fSviv4l6cnwbvPFmny7DNCIIoyfniuHITYR6qTn6DPSvIvhj4e0r4j3t5aXVzc2z29qjxvbuPmG7DBgQc9R6UAdjcmw8H/AAUnn023MF34jxFEGOXKOpAJP/XMMw9C1fO01v5AdIZN+3hY06Ka9+/aIgvbXUtLeT7KmhQWxgs4ElAk80/eJT+6FCAEZA9s186XWrxG88iO28jZzIytkk0AZWpboZd5U+Z1ZmFaXhi5j82eKVo47aSMs+V5Jqhq8+x4txcFzliedwqNnZ5GW2G1MfO23tQB2XwweJ9VlLTOhmLIi7c5FVGvG/tK+3RncrmNFHVq6TQbFPDmhQazMhW7uUKWUJ5zngvXHjzlSZAwaUP5jOTyT7GgDS06HEjZG2eQ+XtHXJ7V6x4Otn8E2cGq3M5insJgJ4FfdmNvUfjXm3gPTxqniO0j1K7ubW3LedLJBEXIC88Yr0r4pXXhg/DLXdY8HuZhcstvcTTs292BHQHn9KAOd/aauxJCxtU/0TUSl0m3uT3Nev8A7LFwD8LbazO3zLaQhto/vcjPvXlvxZskuvhJ8K7kcSzGKB2U5yGQHB/KvRP2YXaKDxdpxZmSy1BUUsMcbT/hQB7cRlgcnjtmmzRLNE0cgJRuCASP5UxrmBbpLZpUFw6l1jz8xUdTj05FSSKXRlDFSRjI6igD5C/aG8PfYdWu2s7oXKXJLMuB8hHbPrXzmgyzL8oYDkmvor412Utvrkke5Hhhd03BsgnuxHrXzxLHtZiSrDJA/OgBpDEllUcDkZ6UloxW4JGM4NI7bWBHUjn0p9gV+0kuRjB60AaYnUbC+4+q1c01IbuZxJOYo/Yc1JoWhX+tXo+yQ+TCo5kk4UfjXf21hoPhSyW8vo/tF2Oo6o1AFDwp8PLnX7pZP3sOkJzJduMDHtXdFrbw7pl7F4TjZZkXZ9rYZZz7Vztl8SjfeYt8xstIQHbBCMBvar2g+JdN1PSb6WWUWCQcxhur0Acsh1u2tDdu8kmpzv8AdnOdwrrNFgTXbNdIutNt7K/cbpplHUU+81fTtT0GG+tB50tuf3jucYFZyeNtI3vLp4Im2bZGPrQBkeL9QtbazPh3SmZreFiZHxgMag+FmlT3mvxSNIbq2tzu+zlvve2KpweH7nULe+1e0vYmQElo2PzflXT/AAu0640e5TVXRvIJ+aXsKAOmvNP1t77UNS1jTI9O0QAgLwGx7CvNPEDWhtiNER2LN95+v4VoeP8AxRqviDxVNapqD/YI8lVLfKfwrD0e/a60/UTfR73gH7p4+MGgCbwhp76j4nsraF3M+4Fyx+7Xa+Nb8al4pj0ki3eG2AUzgDjHvVX4X2a3+hXc9upa95DTDgqvtWe6l7q5stPtJEjXJmuZepPsaAOO8U28ltrTGSPMKfdlXoarWkNpf+aZJvIIGVO3IJrpNPaHUXlsbt9scZ+Uv/FXSDWNM8PaeqJotlMy/wDPXndQB5xpenGRjJcPIiIeHQcGruqzrZ3MEud6nAyetaGreK7vV2b7JY21jAOkcQ4rE1G6+3WZWSPMydCKAOna1SW1SfzNwkHAB6VUFtI/7vyyFXneaZ4WKTab5bMWnB+6O1dIIltQqbZLiRh0A4H40AVIIGitPNV4Rt4wepqpcTpcOPNnWFF+96mm6rOtuxSNf9KbpHVWPTFikjupiLy8b/l2TnH1oAydWv4ZJysMi+UvHuabFMLy0ESr8oP3sYNdJbaHearqyImhRQyt0BOBSeLPD2r6VcolxawxKBnMJyKAMOQNHbqtogSVOdx6mtPW9btJfDlvFESdTU4dfasV7S+ubtWkEnldAVFauq+GrjRrOO61G12LOMo7Hkj6UAPt7ySL7DHKxVZMbmHaovEJOk66pjnfY4ypU5DVRWSR/LaM5jXnaaZPI11fI5bew4CHtQBt/wBmw3VuZRctDqUv3ExwwpV0nVtNjWC/tsK/PmR/xfWvQ9H0aN/BkjwNbPq7j5N/VR7VkDSZtP0Jn8Uam9vIzZUD5s0AcpJpUF8yrOfsUqf6suMK5qtrGnXaqgvLNJgON0fUit/UvD17r6QTQ6hFdadCMqQcN+Nc2f7VTWTDY+asifKok+6RQBmrZaY92sTztAD1B7Grlx4a1GJGmtzHdWgGVde1bv8Awi0OsqVuZIrHVupLn5W+laGlQv4SgnGql2AU+WByjmgDzKbzBJ5ZVw464qxZ317bE/ZZ3QgdGPFW9R1yS/unluIYoQSceUtZ1xcM642cHow4oA2I/EN4YiLotKw/iFFYtu9woIjKlT1BooA6/VQPsyooVmHVz1rGx5twWTAVfXpVq4l8+MJvOc8t3NVFSGI7pS3PRqAE81y7M20AcFgOK0fDEQe3mwEVjINskgyKou8ZtNsgDruxk8Yqs2oyxxx2sbxosbcnH3vrQBteKrm1uNR3yvm4hQJvSMbTVCztzJbhGcNzkbRjFLNZSTqPNfcznLBeABWhYxy5eMDnGFGO31oA9G+Gd3odv4V8Y6LrWqQ6Ncatb28UVw8TyhtrOScL6ZHp1rQ0fRvDenavm18aol+kInstRjtWSCKdW4WVWBPIwQRx1z2B86upEtod1vlWUYJdcnNLHdSzRROIg23knPWgDt/jDqWm674o+0aS7XO21iS5vFTy47qZQQ0gTtkbR+H4nzpRqV5PHp2jQFpSc+YV6VtSiS5mVomTAX5sdvao5hcaNCmp2aySBDkqhwT+NAHGy3WppZX+iPeTzWbXS3UsZbC+cqlQ4HrhiPfj0Fdj8KvHn/CtvEuoagkZ1Az6Y9vBAGwolLowLn+6Np6c9vesjVb/AEnW/wDStMt5Le9YZmhlPGe5BrBurSIJFJEAsp+/lqAN/V/G2oeKdVv7zX7557mYZBXgKB0RR/Co9P65Ncvostudfh+1I/kuR8hbGT6Gs5FdZ32Iu7PJHUVoSqSEaSNcfwvjkGgD1Lxb4esbvwpbeKNHszE6P9nu7Vn3CL0ce1c/oWj6nfM8GkRG73EZ24Yt7V0vgnxRpMttp1nHHHZ6mp8uczkvBcqf76+tez+GvAz6VqMmoeHtBs1jmXMkttd9Sf7oPSgDz7WdAvtM0yGK/hIvo7fLhjlYE9B715rsiW0ztLjccH1Fer/FrX4rLRxotuswvLibF35zbpAM9M15DM6i+EMYfZCMLtoA9m+G0kmgeBrq7sJUiv7vKWsUoDHOO1cTr0dtJ4e+wv8AaYdSd2N3DKvyMx7rVnwvfJBPbp5oeaPmKNuQSaqxXt5Pe3Nk8iz2qzedI7/eU+gNAHXarbQa78HfBFtBsSbSNTVG3PtCjJ5P5iut/Zume38cfEjTJSjsl5FMGVsg53jj9KyfgfFaaxq+ueHtYtUls7gC6jVu2COh/Gpf2f4WsPjn8SLGS2NsyBcRZyAofgj2IIP40AfQU3lLqluf9GEzo6/N/rWUYOF9snn8KuVkaxau2q6TeQ3EEBhlaN/Mj3NIjr9xT2OQp/CtegD5P+Ldm6azeRQqyETu5gX5vKyc8tXzfdoUvLlgT9819U/G+5C+Kk8owz7ZWWUQHac8YDivlnW+NWvk2eWS5yB29qAKrJuUupJYcAAcVr+BYLGfWJv7UtZbqFLd3WOLruBGPw61l5AhAYkY7D+dWfDN9LYanJJbOUd42j3exIoA7RvEeqt4SvVhmgj01ZAv2bgSD+tWvFFlc3/g7QnsV3Qyg+YGIyDXDzgwxTAnzHdsk5xXT+ILK4g8N6PLLJMIG6bTwKAMKe3a1v0gP75I1BcDpU3nb5hcxxbbZODF2NKsMMmoFpZWjtQvPqamMFl/Z8p0qaS4cnBRhytAEOkO02rOkZdIJeDDng0y6jnsdUYQ26RGM5CHndVeMLZorJI7zZ5/2akuPPkuYFMgcyn7+eRQBb0/ULltXjnsoib12C/ZV+634V7DcTSu2n+HZLWVL+7w0sFvysefXHSvNNNurXwzdyCzjW7vWTmdh/qj6ivQ/g1qqaN4W8U+JLi7Et9sKxyzckE54FAHEfEW0stD8RtpunROZ4x+8lY8ZrlN80SSLCxUSfeC9DSy3s+ox3l5dztJNNKSWfqcmmW8UjXMalvKhAzk9TQB3nwyvEttK1OKSeSE+WWUoO/vVFvEF7caNc22pzKPn/dOowW+tavwoUX6a1bQ+WVSIsTIPT0rgtQMl19ohCfJE5wwoAsyXfmJDbiPdP6io9UEu1Y7tGlz05+7TNKuUF3E0kTFkwD64rs/G+kWU2lWd9olwrCQfvYmPzKfpQByNjBEVSCEnafvHrinvp5W6KpG5tjx5o9a6fwtoi3FlN5cZSQJkk1p+GY4r110yTiQScDsaAOT8N20umaz9nmjJSf7rk816LDps1paXLNdLFFEpY5HJrD8eRLafELTogmFhC5RK6fxReRQ+F9VuoSuZV2bH6j6UAed+FLGbxBrlxPGN0akjf6V1Gr6FB4S0uaawuPOv7gfNIedg9q1PhJp/k+ArqaELHLM/wAznrj2qj46lk1SwS20YecIF/fMOo9aAOAsJb9pBcQXNzI6Nuf5q7dfEmlT26m9E27GHUnOTXCSXyWWnmC3ZxI33+1ZRlTeEd3Un05zQB2cetPNqRiiZIdPU5UEc1zPia9vNS1YfaLqee3U4QclVFWZhLZ6akt7EIon/wBXn7zVPpOtXMcL272kBicfKXX5qAMWcCA7BKWGM4Han6bJHbSm7uMMAcBaiZZBeySlkZM8j0p7mFrhC67oT1X1oA9o0LUrJ/D8dxPBtDD5ZEPQ15Z4u1m8vNVeOScy26H5QeRiux+G19Fqk9zpEMSpEYztDngHHWvOtUimtdcu7VirAOQW6igCNbq4LZiupLePuEPFdHD4yvn006VdRQ3Fqel0FxIn41zVvttrlS4DRj+HsaVyLm5kkhjMQ7IDxQBo3EsSiFIbqS4l3ZBJ6V3R1PT9YWx0u7kLzhQrIf8AGvLAdiqJDslzwa1dCWWHUftFypdQPvjqKAN3xn4KOlyNLZSQRxnnyy4LVxrqR8jK6sOxHWrdz9pfUJLtWmmhDZ3sxIWtg64l0YVubWFwBgSKMYoA5dMYc4ZW9KK1Nb02e2LXUY82CToy/wANFAEqmKG3BLEgty3vUDyKoYbGbbyTnIqG2cvK6KA+05KHpT/urIyqoTPKg96AIpiBpzy/ODnO3vWdCpnT5w5J5yO1aR3zWl0HQFiuQR6Vl2/mLEgLgK397+VAF+zvrm0kIO+eE8ZPOBWgniLypGBSR1A+U46VRtl8tN6RlCTjANSuypuaNh75WgCWXxFcSj93DMxPAJFRx69exLza+w56GlkWX7MZVWR4x26HNNttpkAcDOOc84oAnsdV1WMNILcjPqeD+FEmuatJaGFovLXOevWpEdreJVjw5foxqewspLpGRkUEH5mY0AZ1tGFDFiTck7gc8CrmspHqVvBe2tmsbxfJcbG6++O1I1tFbXciNIAF7561VuXW0gkhglLtc9QlAGW7Sx3Ei27cYzz3rd0cpIAk80YJGQX6VmWFq5UrPGF2jrntUSkCdQrDGcAMOaAOlstHOpXn9n6dK8t8QZImVcYI5x716x8CfiNd20lxpt88rTE+U+WxgjjiuG+HNqsmsxS5P2pARES2AKwoDLpXj5xBMvlyTYZv4Qc+tAHUeO7i4vvF98ko/eLIRnqce5rCiYwXTswO0fLzXqOqeELy6eTWbe0ja2hXMsqSZ3H1ry6aSW7u55W6RN06A0AdH4Kmhj8RPOwOYIyV7gsRWjotuLI6lLemJpbhWZkJ+ZB1BxXPeHtseoxPIMIGDy5OBitS7uBdXGr6izIN2FhRRyVoA7/4csukt4Y8VwTypA9+dNvOMqVk4XPpziu202A6V+1dqu0bY9X0FJzkfeZGVeP++K8/+B8ia14b8U+CLwgTTgXtlnrvGDx+KqfzrpfFOs3dt+0h8PpZdyPPp5tJ4yOjPvz+pB/CgD6FIB6gHFFFFAHj37QXhuC+0dNRj0ZZpIPnlu45RGy9AAw6sK+M/HFqltrkjxxBElQOoDZBPc5r9FPEmnwXFrLcbrSG7ERijmul3RqG7FcgGvhv4saJLBBNLIkUtxZ3LRSTW5BRlz1A7CgDzDeeevTnFWtBto7vU0hll8oNwG98iqwUPGz42lew9Kl0h9l+jYyc/L7HIoA6iTw9rMuqnSU0+RrmQ/IxGNy+tdx4utNJHhHTtF0TVJbrXrXm6tmHyoe4B9q5jxT4g1M6/p0rahIXijVRtOCo9KztdD2OqG+t3/4+BkyDrk9aAIJbpbtPLuY/Iu4flwBw1O0ZSryzSEQRgHcwqrNP5gAK5k67j1NWtEQ3d15LTBAeob7tAEMkUCQvLFOZd7cKByaau1r+EbDEEGTV1ba5GoTRRJFtQcN2qs8htreRJgpuJjgP1oAiedG+1OxfY52Bh3rudR02TRPhla291IFF+3mImeSPeuS062Mmradp10pETOGYgdq6H4oXVtfeJraz0x5Hs7RAo3HgYoA5BbZzCoYBViGR71JKWKx3LOd44A7VNLNJOkijaI14HPWq7bjFGcbgvbtQB3vwW0++v9Z1B7VfMjEDGQDjjFcXk/2hqXlqQFcjk16j8DtRawu77ny0nhKHateY63B9k1nUbdnLLI5IYfWgCBZWgmhnhH73PTsatyX+++eaeMqcdFPGaqWEb3LxWiZMg+6O5p80JW5mtpgyuBzntQBvaT4kk0/Qb1C7mef5Ux2FbHhu8Gm21kzRlrueQZPcCuS0qNrmMAhfssDZZq6bw1qenx+Kbe91B2FonypHjqaANHxRC198SLOIS+WHCjzM5IrV+KP2Wx8NPpgdpbzcCZMYyKz9S0zPxDs8Ca1nvZAYHk+7gnitv4t20sXjLS9EJhkuGRfNfoGzQBueFDcaH8IIdRayW5iXO5kOcD3ryO08UNbavcTQYSK6ypA7Zr2rSluLHSNS0cWsltphhbc8p+QnHavnNgtpqlwu0Ha52elAGzrmhx2k0c8spktp/n46isy2e3tr4ywHft5QSDvT7nUZ7lkaeUMFGAg6Cqskj3Uh3FOBxtGKAJZWub6cz3k5nnzhU/hUVUv2l+2Rh2G4enSprCUwiZ2AOOKt2VuFs5bqaDer9HJ6UAVJpEMHlxqCx6j1qtIrI0av8p7LUty4jhD/ACqSeCOtIJBNdRLNlVxkuRQB2fwniW71q6jcFAYyC47Vzeu6c9tqF4EdpLfef3g5rd+G8cz6pqTWrFYo4mLH+8MVzkOozWk96GIlhlYgq9AFAuzIipjyx/HRApWRn+d3/hAqaGEm6AVgFbkKelSQssE7mbd5wPygdKALdiLRnWXVMLKnKxf3qlS+N9dXFxEBEqjaIVHWsuVna9Esqo59fStO0uJLO2lnit02P8pbHSgDLhdpC1vbyvvkbmI9BRqtubRkt45kJ6sFPStHSY47Kd5vMikSYHMjfwVnNCD58rw+Zbq2fPBoA9D8I3GnQ+Db5dWif7v7okcE/Wis7xV4kjvPh7plhYRRwRI3zkj5mNFAHNwIjTS/u9gHIUdTVaUbllfGwFup71s2tmVkkliYux7kVRMKeZMoYs2d2CKAKVuP37JIWRCvCZqhAgV3jlB2q3y9zVu+2xXEU+4kOcEHtUssca3qsgG6RePagCY2hQxBQwfruJ4rRs7XLvFIT8/JIUcVRuvtI8hpDF5S8CQZxn3q7BcRu4YsdwGGKd6ANKKzTz4xF5pjAx5h6H8Ku22l2N1dpCjSJ3kBTmtfwRot14oW+tLaWG3Gn2kt+xlB+ZExkDHf5hVK0czRQtamSW5ncJHFGuZHYnAA+pOKAIhpVmd4+0F4kb5VCYqtq8dpaCKW0jYFzh1PNdb8QfDt94Q1C1stZuIWlktUum8kEhNzMu0nuQVPNcbfRQ3OySGV5B19KAKWo6dBfqvlwqsp/iz1qFtIeNoiwCkHaAK2F1iDT7GRGEaTEcbxlh9DXP22stcXISWcOjt8oPBBoAZqkf2N54Ch8xuhbj8qwNri6JkX5lHGT1r0fUrI3Vus11IANu1DjJrgb2CZJPLeBnUvt8xfvGgDT0PVhpl7bzB3cA/LGvUn0zXbeB/CEnj/AMT6iUvodEs7OI3MtxKNwBz06iuRurC10+JIIS7XiqHf1Qf416+Xs9X+DQtfCFu8L71GoADM8x7nPpQBufBvXX1TxbceHZr6O6snhZFaOLCSEfxVgeKPDn2Se4ZNJW8trSdjdTwyY8sA91qf4Mmw0bx1bSX8MqyW9sVto1cB3c8cr+ddv4r0IL8S7S7jvSJL6N5rizUfIFx0b1oA89uvD1lf+Cj4j01DK8spjIB+VFHr6V53YXq+ZcQyvli2wBf4RXovgPU1N7rugrppvdNv5WzFFIUFucn5gK8xTSLi38exaZG+4yXOxQBzjPSgDu/D00+gXWleK9PkZvsV0sNwAP8AlmeDn8M13Px1d9O+LvhHX8/6E3kyRTL04bn9MH8a5NLNoPFeu+HbmMwRXiCOOPtvHIOK6fxEbnxV8DNSSSEHWPC7CJj/ABeWo6/kP0oA+mo3WSNXQ5RgCCO4NOFcP8EtdPiL4WeHdQc5lNsIZMnJ3ISh/wDQc/jXcUAQ3lrBe27293DHPA4w0cihlP4GvnT4z+Co9P1J/wCzrfTYLK7jP7pSVKkfxMDxX0jWT4m0O08Q6Nc6fexqyyoVDY5U9iD9aAPzX1W0ewvri2lCllJGU+6w9RVfSjHHqMbXDFEVgSRzjmvVfjf4WubFYL42ciyW7Na3EqJiLK8A15bovl/b8zEbACSPXkcUAd18QbJfIstWt4gbGZAolUd6zrUwS6YtleS5MnMbjnFXdA1OO4v5F1ok6DGpxbqeh7YrBc/6TNcWYIg3/ulYdBQAskItZjFISwUYz3osMokrhgI+5YcitHVTFex2vkBmuVGXK1UmkM0TwyqqdulAC2f2iQGKwRrh5vlHNW7uxk8OGO3vYRLqL/MIZOqVDewKllZW+nyu1wWyzxfwVb1/U7e+e2tWjea8tkxJfOTmgCfwrZf2j4k867MgRBl2A4jqlrdokF/eTW9w1xabj+8FWNMubm20i7uYJ5JYpBsYRr1rHjJt7MxJKSsp3PG3UUATJpd62nG7t7KW4tT1kXotQ6fGzxskcg8uM7nz29q6LwdeOdRhE+pNBoUJzcxZxvHcAetWtX0bQ9a1y8v/AArdiy0pBua3uGw7+oHrQBv+FPFrWFv9q0zTofsUS7JZCPvH61x+qT2N/cXc84eGadiYyB8oqzqniqG68KtoenWUdlbwvuYr96U+pNAiku/DkDx2eI4xg56n3oAx7NptH1qwnbafLYHd/eFaPiQXOp+IZ7u1iWN7kfKh759Kx7acbJoLwGSM/cI6oa6T4d6dqviLxdp2mWluLueN9yB22/IOSSfTigCK1tYdH8L3NlMzHU5myyY+6KyJIozbwCdzmM5G3sa77x9Bff8AC1pdHv8AT47G5EYwqfMHGMgg981zSWdpaafqc11KFkiOEU9SaANG31HUdd1zRkupmlW2ZRGx6qBWp8S7h5PiVaXU8oe2hVQxB54FQfDCzlu7CfVpXXEX3Qepq149t7efw3JqoULJu2nnmgCrqXjTU59W8qS8afRydqwk9BWR480L+xri11GFE8i7XcozkCuYtFLQRqMsG5HrXoZ0v/hJPh7dzRs5l0wZKk5OKAPL7fcks6lcyPyMdKn/ANVaxs5USbsYFJDG40tbvfxu2EHginPCUIEki+W4yD3oAnv7GZYFSELmYZ4rXv8AWLVfClvottZMLtG3SXDHg1TFvcadpi315G4jJxHu71TjdGug96jskoyqL1NAEMghieJpYvMx78UqEPe75mV0PRPStrRNJMtlfz3VtIsUYzGrdaw5poEtBmPbIWxx1FAG/wCFLxdO1acK/lxSqVPPasG52y3t7C5AhyWU0+0zLqcEMXO4fxUmpxNb6k9oqFpD146UALbIJdKMjnY0J+Qnq1OjjS5t/Na4AnH8J702AbmW1VhK3dBV3SNMgm1Fzqcy2sMYJ8s/eagDJZkWB/MQtJnAVTya17t/L0CFIUKs33oupNRJLYNdXFzHGyRQ8Lu71FPGXsm1NZ8EnAQ9fwoAzjAGeNZUaOPr5ZPWrlsTeXsVkWNvZg8xr3qi26RozK7yzyHCp3FbXlDw/amWV45byUfc6lKAOi8EaTp+u+KLrTZk+0WEELMFzg5A7UVzGg63NoF4by2+b7SCjsP4QeDRQB1dgqrC0hwcD7q9vrXO3KMt7OYycMMg1v2smIisiqrSKMEdSKzNUCJeJlsnbgDGKAMC9VCiAtt2/MSeaWEGazDohMiH5SOuKbMVVp4tuVJwcDP607Tma3ufKXIiIzg0Aal3dJJpXyXYgnxjyGTIY1X0OXavkXT5brjFSy20LwvFaxb1wXaRj936VS0uFJ03ElhuIyDyKAPXfgtq1nBr+t2+oala2MVzotzaRT3jiOLzXaPapP5n6A1e8MWOj/DnX7XVNZ1Oz1xjbyxwNodys7WkxAAlKuAo+UttznntXmOm5RCIxht2Dk5zWuheW3kO1soepPLUAeh/FzUtA1i68Nf2TPd3xi0qKOZ5ZlcKoztVyP8AlqCW3duR7153dxbLWSa22KIhuZOuBVi3ZtrsyhlbAMfcVE8X2kXYBCAqFK9ARQB57qMc17dJc3IMcbk+XweRV3UPDd1beEYPEkGPsj3P2fOfuvjPSvR9Lv8Aw9fwx6H4qSS0a3TFldonyZ9GNWvjYtpaWfhzQrGKNdPEPmnyj8kjn+KgDzzQNZlubSW3kJaWPBIPcU3XtQSJ/MEbJJGARtPH1rH06f8AsvU/tMY3Rh9sqkdvatHWwt0Hk2kq5yoC9VoA1tR0q5jhs7zc3lajHuWZ+Ax7jNdp4B8L6trcU1poT6gqbMS/ZxtUt6FzgCuJ8DahFpuqWdvr1ub60gkWaCGZzsUZyRivvbQrqy1TQLe60doktbiLdGYQAq5HbHp/SgDyi40Dw/8ADzSdI1DWbK2n12QCEuzEtnHOG9vWodc+y2enya/HNJbu0TCKNjvYk+hrlvjFqOqahZ2VjqMEou7O6KOoG4OueGzWfrF3feJLrRtAsk+RCAxUfoaAOY1WTUtLg0m/gQJcXTOVkjGGJ98Vm6LeHUfiD4GvJjHcamuqJHcrjaAN4wTXuur+Ere5fTbIqkc1qwDor5YceleA+MoE8P8AjJJbdNn2XUEcA9chs0Aez/FHRJ9B+KUHipTtsGuLYyu65VMkKf5V0+u2OnaV4t8WaVdyR2tr4o0xpYZCcK0qqyso9+Q1dZ47sLfxh4L1fR0ObuexE8ad1bBZCP8AgQxWJ4SXTviX8L9Gur2JJr+3i8lncYeKdBsfntnGfxFAGb+y1qJu/hZDZOsay6dcy2xCjBIzuDH67j+Vev183fs6+TofxR8VeHbprpL9Yy0SZxGyK/JI/vcjHtmvpGgAooooA8I/aQ8JJe6S08BhRJlYsslx5YVwM7gv8Wa+MLGNxevGpXcMjPbrX6Q/EDR49X8NXaG1tZ54kLxmdN23HJx74zX513qiPxNqaQRZjE8qhF7LvPSgDdv57aXQo7OC38ucHMk+eDVH7S0WnhEXds4yB1rQ03Rby+8PXlxYH7XHCMyRL99B64qnpFrLc2BaOdIreM4lD/eWgCwulSR6Supm/W2VzjZ3NaGk+Hb3WZI4tHmhurlhkxuQGNVvEVnaW1hAdI1A39q+N7MuPLPfiqdrLcWV5bXGmzBLiHDfaFbAHtQAl8k2l3ksILQ3cZxKB0HrWnomnDX7myhu2/s/TWkAnvHHDDvWrY6DeeMbbUdd0qRru8thm4gVfvn1r2D4O6EYfBc978Q9NjFhG261tJAFLEdyKAMf4g+G7fSl0pfC+q2C6GiAGFcGSZvXHevNvF3heTSkk1TUbm3h88ZitwfnP4V6h4D8aeGdS+Kc0usaNDYmEeXYw9UBHTPbNYPx08O3sfiX/hIdXtysdxJ/o8a/6vHagDyuGaI6QIpYxuzkKowTTC0MsJlceSUGABxVzxXNuv7Uw2q2zbAW29DVTTzGs7G4t3njc4DEcLQBoQrFdeHSDYrbMGyLhjgvTDfXavaQxyOrIPlRvuvVvxVp93p1vZrIGu7SQBkaE5VPrWLulvrmK2DvKoIAKjlKANtpNI1aSWDVS+hamo+RgpMcp9PbNTadf6r4J1zTtd+w39rcR8Q3SIdki9O/BBFekfEXwWbL4e6JP4etYdTulAkuJZQDInGfyrC8O+PfHXiMR2yWkFzo2koDOjW4KoF9Tj2oA5XWfEGtX3xDh8Q37PdXFywZZCm3YMYC46AAVkeMHMd9OJJFk807zjsa6Tx18VdR8RRG0XTLC0toztEkEeHX6mvOJTM+JpN7I3Rj3oA0NE1y70uUJDIxg3ZKZ4xU3iLxFda221m8q1TkIOhrEckkbj+NKxXncCfQigDV0MXNzd2qQAYRsMSe1em/CbUli+LqJDKi6Ptb7TFMRscAc/rXlmkTww3UP2mQiNjglD0r0a7+Fvii3t/7b0TyJtGnj3m580Dg9e9AGB8Q9SsNe+IGpSaBYGHS1kIiigX5TjjOB2zVaTSri1W1uL5YjATkBWBZfqKh0rVdQ0OS7sdPMcZm+WVym5iPY1INOayC3bmZomOW83pmgCHWtRm1W82eY0tpCvyxngCqtlby6g6yxJMxiP3wPlSpGniXUC2z5ZBgBRgVq6DqF7aW95ptouYrgfOqjJFAFe51G/udQVZbwm3QYO3oax7+aJ5HWIbBngt3qxYhklntVTcMnjvUcieVKI2i85s/6vuKABjNby2crR5cEbWXvW/4ys7y0u7G9aIN56AsEHOPesuzu1fUYYp1/wBHjOSo6itWfxMRrwkBDaeg27HGeKAMXzE+1PNZhbYqMknrmh7G9n0+TU3kS4UHGd3zD8KmvJLaO+muoYC6TfdDdBWerMJniAfDc/IflFADraTzRFDsyHPzH0rS8YWNrpzWEenXq3bMAXjX+A+lQ6GtutpdG4fyph/q8/xGqJjkjCgwFL6Q/K56EUAbHhS8jt/GNtO1il2yAHa/AFUPGs63ev3N1FCsUjvzGpyOtT6ZY3M941rbQzXl+y8pAOais/D+pGe4trmBrK5B5kuOCtAG14tlsv8AhCdKt7azhgnBzIR99z70VoeKdC0f/hDtOOj3x1nW0b/SvLyfLHpiigDC1K+KMqZKqg+XPesq71FJgnmsxkJ4ZTTNaIby5djBNuMDnNYG9t6lj0P3TxigDqZ9r2qOhyVPzAdPxqi/mLqBA3lyufk6KKdZT+YksJIJI445p8IEc4kxgsNp9DQAW1/Iy3CyOCQcIOx+ta2i2RKOSFRsZ254Nc9ZTR2k02+zaRQctzwK14NftVA2w7TnJPXigDfgVbYeXE6AsORjkGrUjBLSNN43ZyWzzXI3uuTzzNHa220sOGI7VVRdQZ1d5WiUn+Hk0AdcusW8CS+e4G7jeDgmn23iDTbYpumiMh+8zHJx9K5X7DAZGWcvKuMgt61KLe1jAZbaADbycZJoA6HU/EGmzRyqskc7MMKhTj6in/2idf8ACy2F2h/teyJe3Kc5j9K5nyYJPJMgCBh1UVe0Of7NrukTYb/XiJh03AnHNAHMsxnl3zRSb84IB4zXY6BdJefuWfaFGCcZwKtePvDbaP411rSrdVVdonUA9ARnArl9AkmiuGhBAD9uhFAHaaIFs9fjuYUjuY4zt8udQQRXpvgbxvqfhrxsNOvJXi0aQebFaD7uT2WvE/OupLx47RTLLjBHp71av/EF89/ptxLL5xsGUIjjGcHpnvQB9xJpmleK7a31SS3dJGXADcEH3rG8GfD620LxBdanIC0jMfL3NnHuK0NP8SW2neAtN1yS2nazkgjln8hd5hDDlivUgHriuo0+9ttRs4ruxnjntpVDJJGcgg0AVhptsXvJRaxxTzn5pQAWbjg57V8p/H3Q303VWyhj+2APlx824Hrmvr2vF/2mNPtzoWnalPIE8uU2xBGd28ZH5YP50Acf4Q+Iv2LxL4Tv7yUiyayXStRduisD8kh9s459M17h4c0610DXtTtLOExW2ov9vj2j5C54kA9/unHvXyDazE6P9nu086GCTbKqjBkjP9RX1F4B1qDTbLQdHu7hri0uoR/ZN63PmKq/6pj2dRx7getAHE+KIk8PftU+FbxQY7fW7KWFyBgNKFYY9+ifnXvVeCftIXkelfED4T6ncNtt7fVX81vRS8OT+Wa97oAKKKKAM/X7W5vtFvLaxnEF1JGVjkboG7Z9ux9q/OW9g1O28ea1bxJF/aEV3PHKE5QMJCGx7Zr9Kq/OnxLDdS/Fnxgli/lsNRvd5H9zzmzigDQ0aeKSGTTdNl/svWZcie68zEbD0NRXXg7UzHIYL6yuFi5d45Bhq5uSKM3DW9mZAQMs0nGas+Sh0tY7KSaG6LYYbuGoA29Btb+xd5zbW13EPlNsOd34VveEfDlhc6nLeaxpl29ryz2cfyjH19K5dDfeHruzmEUjzoA5xyDV7XPG2uawHu7q6a1gbEYSIbf5UAet+A72w1HUrq30m8tfCfhy2G6dBzJJ9WNcb8V/HMOuvJp+jPdNptqdsdyWIEh9RWt4r8Paz4Y+DtjEsGmzQa06yNcg5nUEAgfl6V5lBCsdxY6TdyyLaQkPI4WgCeHTtT/suDVktyIg4Bmbhq+s9HtLb4gfCaHTLofarwW+YpXH3XA4Oa+ZtU1yPVvEVtp5neLQFxGvljnHrj1r6m+GehG08LNpVvdSrp5HmQ3CcP64oA+SLjw9rl1q2o6bPA32/Td2YxyxUenrWBDql2tlOjTJFAG2yQsMPX1R8VvA0r6a/i7wFLOmv6bnzlcHNwo68HqcfnXFaR4Y8H+JvAl34n06OO88ZvGfP05pQu2XODiPr756UAeJafqN3DGtrZXxWym++svP5UyTFj58mn3w81Oen3jWl4p8Ma54ct4m8R2sVr9p+aKNMFlH4dKm8OeA/FPikB9G0qS4s1wJJVXGPzoA9ZsLTU/FnwBk161eW31bTWbfg4E0a9f0P6V5n4R8VeOItL1SDwlYmezmTyrwwQbw2RjJ44r3HxJdWvwl+A8uk/b1n1PUwYVicjMZcYfj0A/WsP4C6p/wgnw41O/tbWW/1rVbkfYdOHBkCjAYnsCSc/QUAU/h14N0v4e+CNR8U/FWGAG9AFnp8o3MxxkfL/ePH0HWvKvFWi+ItT0weJrjTFtdEkYiFYVACr24Havo3T/DdkNVg8T/ABe1a2k1aRWeLQ53VobfPQBSeT+n1rUn8W+BdLmvr9Z/tUNxGIzpypuhQey4wKAPijgybY3BHoafGuZUGN5H8KjPTrmvZ/GOifDnxLtPhfVk0W/MheaGVG2kegPavT/h/wDD3wZpcmmeIdK1GyvLeNfJvTckYZiMEgHpQB8z6Z4ZfUfD+p65FIkdtZ4+Q9ST2xXrvgXw1rXjH4BXsSX00MdtOXs4hJjzAOq/nTPif4Di8M+P5Ib1nsfB2vSYiuofmjiY84I7YP6VR1z4KePNCsr1tK1lJtAgjN0ssU+xWUDOdueuKAMDQdJ1/TdXspdZsLSJbc8JLjc4HqKofEDWbjVdWmjkCQQ5yqqMKK6f4AeEP+Es1jUfEPiO9lXSdIjzPJLISHbGR+AAzXn/AIjuIrrxDqM9vOsunGVvIc+meKAI9Khj1eUR3d3HZrbDOcYL49Kvm8hsopZNJEiMRtaSTv8ASsGRPtNzArvEYs/eXg/jVua1l897R5TLCeUK9KAKy3DWVzHPAfMlc5ZjXS+FNIuda8TRC1j+13M5x5SdRVLw9Do8Gowz+LUnSytzlVhHMhHQV6n8F/EGlaZ43vdf17Tn0XRZoylhclW2ls9M454oArfFPwVonw58OJNdwSyatfdDnISvH7jTbi1s4pJWRorj5l5yRX1D8Rre01v4f6pc+L7uOS0kkL6dfLgtj+EYr5/0PRry+sJYHCmxjUmGdx1+lAEfhbTR4mY6X58dtJEuQ8hwp9s1n+INM1HRMxzQBoydqyQncD+IpPD08tqNQtVtjPccgDkNj2ptpql7pU8QhZ8O3zwzjO36ZoAdNaf2Pa2rahELh7gbkQHLJ9RUYEksj3V0zfuh8i+lb9vo9v4t16C10S8WxvXGZri+fbEnrg9qr+ObK20m9h0TTL6PUriPi4v4j+6J74PpQBn6NrUumTNf2lxJbX54WWLqKSCfUdclu7m/upS5BJuZzwxrMuWS1l8pJ1YY5KjOTVixuWv7drGVWkQ8gdMUAWNKYx2pisEa0vQ2TeK3yMKKtaVoWqapY3Vno1vJPFAC0rj7qAe9FAGO/wC90qRAS5TnnjFYycRksFyRnIOa3Yo0jnZiAS52swOQRWfqVlJDKREylc5HGKAI7KQwEyK+5h14rVLD90ynAYZAIzzWNBuiBzKIyeMY+9Wlalng8o5Z1ORg4oAqwOgvZxITl8jatSC3McbMmzcOCD1NRQsYdUYvtUY5zVmNg5JGHfPGBQBJBu8r96wYr0APNKgPEjuV5xgnnH0q9YaRPPcK67cS9fWtQ6VDDud/LBX5SJDlh9KAMsMCcjBwOB61Pa2NxdZgK7MgspcYFdBpNhD9ohSZo1Rjw+2vQja6PBYyrFAl1LGu7czcigDzHQNEdWW7ljUxQt8xk6E+wq/4gaCK60u7hSI/Z5xNIu3AIBroJLSS/nhFi7zW8g/eRBcbD7VqXeiaX/YbNrBnUQnGY8ZPsaAOUv8AVB46+Kd9fDy7aG7hEceTwuFx1/CuI8TaXc6Rq0ixgGOPjfngn2rptIazg1R5kH2aJTtiDjIb8a7nX/D15e6Etl5dux2mcysuCBjpmgDxzwnrtxp/iWK6+0CJWUrJuXO4Y6YqxHGmpa/ZRyyrbxXNyFMh6Lk9TTIfCWo3l8sNpaSSzhuPLGQAKfNZSiaO2MRMsEwY4HIweaAPtm4nPw48M20l5K19pSBIJAB9wH+ID0ry7TfG6+HfFztomf7Akm3PGeFVX/u/SvQfFOpR+NfhTM2iQy3EMkQR2ZdrIwA7d8GvGfC3ha9vND1GKQN9os4id0o+XHt70Ad54h8U6/F4pYWF6sNta4uIpriTCyxHqpz1Fcl8VfEd5dWN9p9xqEWq2UxW8tpIxkQt3XP51s+DtFtdfl01JdKu9UvraErJ9sYpAB2x610F/wDDmx1zw0lrNcC2v4JXxDAm0hf7oHegDzf4PaDD4r0/xP5chN9DaCSBE5y/PH5gD8a6bwlrUemaP4Mm1Jmk0m5uSdso5trhG7elb/7MuhR6WviRzBJHNFcC23OMEgZJGPyrf8feC7BdIvLdIWFjcyNcoQMi2uD/ABD0BoA4j9sK0P8AZvgzWkKmK11Ly2B6HeAwP/kM/nX0XXzd+04t1Y/AHw9aaofOvxd26vLnPzLFJz+XFfQmiOZNGsHOctbxnk5/hFAF2iiigAr4c8HWv2v9oTxhEEidjd35VZfuk/aK+46+JPAFpHd/tFeMkl3ZW5v3Qr2YXHBoA7rXfhdb3++61Z4bMdhAMc+leU+Jfh/r+l5uI7ZltAf3LsPvelfR1zdXukaZMviy0TUNMn4SW3+/H6E0abrdlf6UdKmKXekn/VPKMPHQB86f281j4deG8sGl1IjaZNudq1lf2Rda54YaTRYvNkD5kjIwR9K+iLzwfqOgxPd6ZNpX2Sfo10Awx6UG0tLbTV/tvTLdAeftGlD5T7nFAHJa/wCF7iT4HaRcyWV5L4jtT8qhyyxpk9V7cYrya3ZtSVoZ5G+3Yw4CV9FaDqGmWsE50TxBIjyjaYrzkD8DWzoekPp2J7bT/D94XbfJOMbjQB4B8K/AWseJfECKIvJgt23F3Q4Ir7G8PW62to1pHMxmVdu7ZgKRWXcazf2OnG6FtptlbL1Jkzn6AYrBuPiNujUWV7YvcH/lmQcH8aAO7tFvLe1aO6uYpr3JKYXaGHYEV5N49+Dllr+pHxN4eWXSfEqAM0MTbYpXHc+hPr3rWHjvxOz4g0zTLpuwjlPH61n3XjrxhdvJp8mjCFnBzLZbndB7UAeZXtt8T7HVAdV8D2msSjiOSZRMvH0OKgt/jn44sb5/Dv8Awj2nWF8SY1jhgZTGfXGcV1mm6Z4p1q8mGn3viJHhPLXTMo/Wu60n4X7pbTVNQuQmsAgu5UMW9iaAPnvwpoOseKNc1Ky8R2Ums6k4LxCViBE3rXtnhX4Z6tceE/sXii+GmTRN/o0tow8yJf8Aer1oaXb2cn2mxsrf7aQFaQKFLD3NWb23We0dJCgyPmZh0HegDg9B+F/h6HTpI9X8zX7g5zfXh3OR6A5q7o/gjRtG0m4t7TTrKGKYn5rkBjj6msTxh4qbUpl0TwRrNlDc2Z3XbyNhQg7A9z9K4HUvjHYaRMwu7RtbMfyEB8IG9RQB6Pp3w/0KC+aLUvC2lzI43C6QA59sGquveC/C/wBguLGbRJ7XSZT8zwZXY396vm3UfiRq9/4xXUYtSmsYA2+OyWQ7FHpXrfgf9oCXVdVNjrWmxi2A2tLGc59yDQB1j+G55vDU3hPWpBr3hyWL/Qb4Y823I+6G+nY159puq6vP8JfF/gp7mRtUsI2W2OfmkhB5UfgD+de8aTp9lfQ/b9DuGt4pediYKH8O1eX/ABN+G2oXV6+veDb1ofE1t8zWoGFnHt9aAPLfhx4kSD4OeKvC2mWnm61MxmYZ5kiYAHA65GCMV43aQCS4gsGDQOzYO8EKG969bfSE8Qa5bPoCt4c+I8MmZ9NuB5cNw47oTwCe4PBzXQeM9Q+Jmq31pZXPwxsEuoT888Fp5izH/fzgD8aAOJvvgp47s9P+2QaTBqcMqhozZSqxx64zmsUeGtM0uyEni7WLrTNSjbjTkiLO3sfSvZtD0D4w6xcrZ2yHwfp7Lh3SUFR9FyTn6V3XgH4E6Xoepy6p4mvm8S6i53B7uL5VPrgk5P1oA8m8DfCa9+JU0F7qDS6V4ctwPLwv72f6Z/nXtnjHQfDmoaTp3hR08qKx2i3jYfewMda9NjiWKIJEiKqjCKq4Cj0rx3wxoesXvjPV7u/vo/s1uxAeQZKH2oAqJ8P/AAxHq8ela5qV6bmdCLexlz5KccEdqxI7aX4VTzweIdAGuaSzboZ7dMiEehBFey3ct1pPhmS63Ra1eLzCzhU3gngZryvTbrxPr2qyabH5SQud15A5yFU9RzQB5D4tuLW28bW3jLS7eJ7CZwRZxD7p9GrJ8f8Ag3WrONvF/iOJYtN1D57dICCVJ5AIHSvXfF2s6X4SuBY2Wg289i52lyMkv7Vymp3Wr6DGJQZLme7G6PTL5CyBD3ANAHlDW12vggzTxqYZpPkkBxJj3r0/Q9Y+G8Pw3sNB16Ge2kkO6a7gTdJn61HqeveCn0a1+yeH7m48TswFxbuxW3jPfAzVH4jWEMNjp7aPY2UM88YaWAsG2n0FAHHapDpdlr2dEtTd+Hkb5JWH7xh/jV3T9JuZr5rq10qSLT5/lWV+MVc0SVoLNVi01ba/jPLSn5G/A1r6g0Ml3atcXmoXmvXBCRWdsn7gZ6dKAC18E/2Bp99NrXjKGx06dCRb2b75H9iBRXe+HfgxFYAap40nihlf5ltDJuH40UAfPkqnyzgjjoVGAaXyxcWgSRCSPzNRxzFFJkJwMAg/0q1Iz7UZE+QDKlT1+tAFf+yHuUZU2jYMgN2qggLKISAHVvm7HFdp4fdJCpmI81uNpHFVfGOiJDIt1ZAsD/rFIxigDjbpUkvAYlJI45rT0owskiyTJGU7MME1RuFdpdpG3aMgnqa1bGOxv7OWO5jVblBlHzjNAG7b7iUFrufC8lfu1seHNN/tbWNM0uaRYjeXUcBkC7igdwuffGelcloc2Fe3+0MUHQLwRXT+FZ49J8UaLqlzcuLK1voJpmUFsIsis3A5PANAGtrmkXek+KdT0y3P2u3sbhrdGZQpcg4HToa7jxx4a0jwbC0DX+pSX7TJF82mSRwy5wWCTEbTgHsT0xWf4nvvBlzrWo65pHiq7mu7q7F2tkmnyRE5cEhZW4UgZIYjqOlaHijxRpMfhrV9OtfEeseI5dZuoJIFvYmB04IwY5ZuCxxj5QB0/EA6XTrnTIreKK1WJYZY9p+TDq2Opr5/8f6jqKa1PaCZmhgcjI+6RmundrmGWdLK+b7Qfvq7fKR7VD4f8FS+JL2aKbVFidjkhzkZoA4fw09/O95bxW/2uQAyrHjIUDnNeg6H8QJNT8LS2EsJ8xD5Tynt7ZrttJ+F1x4U8PeJb+WXzHFowjlj4KjHNfPfhy4udPkmk3Ry2bMS8ZON596APQdG8Q6p4Rvje2qxuu3aUflcGsi2tb7xl4uf+xoY/wC1Jw0yW8bhd/cgZ4q34X1Dw9qc0dtqsjwxsTuIOQB6V0Gt6D4f05LWfwHrLHxBBKJoPLb5gB2zQB9KfCGz1O18B2Vvr+nLYXwLLJBkHjOATjua0vDHhiPQ/wC0ovN+0W1zKZEWQZKg9V9xXjPw6+MuuvLM3iXSmurJMLPPZqS8LDgsy+le/aVqNpq2nw32nTpcWsy7kkQ5BoA5/wAPeFjoHiK+urW7nksrxc+Q/IhYHoD6Vz/xg12DwtPo+qOkYleUxLJnDA8H8RXpEsqRBS5IDEKMAnk/SvCP2r7dp9N8Mgbipu3UgeuBg0Aei+CrzT59SuL6wYLHqirKw3f8tVHPHqR/Kp/E5k1Lwdr9hdFre5iidNwON64yrr7EcfXIr5e0PxDqtlcRxRzSrHHOq7h8rIQeDXrer+L31vwheazPZQDVfDd1F9o+fKTwMwDYHv6HoRQBzPj+ceO/2X7i5mdpNS0CZN+OSWjYISf+2cmfqK988A3IvfAvhy6U5WbTreQH6xKa8Yg0y2tW+LWiaWCdJ1fRP7WsuPlXfC4IH/AiPyr0v4F3aXnwf8IyxNuVdPjiJ90Gw/qpoA7qiiigAr4g8C6za6J+0f4pnvplhhmvr2DzH+6pa56n24r7fr82fiFJ5XxQ8WnnnVbwcf8AXZqAPu+HyHlVlW21S3f7r28gZR9RWreeGdKuolhl0uMCX7zp8pWvgbQ/Fd7oL28ul6ld2xJG5Vc4r23Qvj5rmhJDLqwh1jTWxuK4WVPx/wAaAPf4PA2lWVu8Zje8tgCfIuX3L+HpTdM8NR2oFxpdulrE3/LpIdyEVyGofHXwVc+G47qOW4nefAa02FXT1yen5Gu28J+OvDHiG0X+x9WtXZIwWgaQLJGMd1PP40AWpfCehXpE15o1mJj97CD+lZ03w48NvcebFaSW5PVIZSqn8Ks2nj3wxcvIqaxaIY22nzHC8+2a3LHU7K+XdaXUMo/2WBoAxNK8F6bp9zI+HuIWHyxTneEP41qP4f0dlIOlWP4QKP6VfWaJkLrIhVepDDArlr74j+ELHUDZXWvWaXI6qCWH/fQGP1oA0oPDmlCSOcabBbyoePL4/PHWteKCGJi0UUaMepVQM151r/xm8JaS6xR3Ul5cMcLHCh598nFYXiH476Vb3ENnoVm99fMu50kbYqe2e9AHs1ZGoavp8N7BAxE95u+SOIbmU+p9Pxr5vn+OWva/c3ttBc2ejxwKcqq5dsdgx/pXFeGvi3d6M+ovH8lxLkGVvmZqAPorx38XtN8MaqNNWxlvr1eSInBC+xrxz4p/FC+8V6cIJ7ptB09Dlo4mJeY+5/pXiuu+IJrm9kubSWVZpmLSOx5Oayr64lvtnmMzgfxOaANXUte863FraqyRHrMDhn+tZCXEroYS7CBTng8moGKJjktJ0yelREnPJxQBMG/f7xnjpmrmkX82mzs6syrINrVnKMnAPNWY9kkbowJ9PrQB9G/s5ePLPQtVl0nVNUle2vcGIyZKRv8A0z0r6lt5I5gZImR1PRl5z+NfnL4W1P8AsmXz5QjCI5CMK9++H/xo1KxhN7eWq3eh5CyKjASRe4oA9z8f+AdI8Y2Ti5hSDUwv7jUI1xNER0ww5I9q8/S2+JXw1td8U8njXTO8b58+Iex5J/WvXfDut6f4i0i31PSLlLi0mXKsvUHuCOxHpWlQB5rpfxh8MtBB/b002iX8gw9rdxt8p+oH+FdtpOv6Vq67tM1G1ulAyfLcGqev+DPD3iCXzdX0m2uZf+ejL8351yerfBvw/eHNlPfad6C2kAA/SgD0vPGRzUSwRxs3lRRKJCTJgYLH+teJTfCfxXZyuujeMNRt4UPyfvT831Gals/DfxQ00sItSW7J48yW55/KgD1nUtHs7l453t90kAJRFbaufp0rzDVvAWvQavNe6ZqqWcl82xgmTgemaSPwf8R9VsJ4dV8SraK3SNG3Z/EU608O/E3S7SGC21PT7tYj8pmckgfiKAL2ifD+ePUre21u2hubGD999pLfMz/SuC+MVn4y1P4iRXGlaek+i2qqkU6oCAO/P1zXon9l+OVuoZro2t1uAEqxzYUfga7PSNOu4gv2yRPKx/qF5ANAHztq/wAPdG1mwkYzX0OouMssMfVqyNI+Dfie7kh+12xtbCD5luriUbgvrtzmvpifRdLGrNcG8eGcDmNZVUD8MU611XSJb57S3v5L6ccGBWMgH14x+tAHiEnw68L3Wq20N/qurX85AGy0hJU/jiu48P6J4n0m4fStD0jT7XSApEd/d4M6Z74HJP1r1QIFjIiVUOOOOAapxxXdpaSYla9u3JI8zCKD6cdB+ZoA47Q/Av8AZlteT+IL2XXLlwW8ydzhB7AmitSfwpPqe+bXNUu5XZT/AKPbv5cK+wHU0UAfAbgkHj97xkE8VdstzP8AMQUH8Iqldt++KRjcSudw7Ve0NvIA8xcknknpQBoZNvIDEWx191qQa9ILny5SZImG1t5603UGADtENuRzg8fhXMzRs11lEdUYdWOeaAL/AIitmtLtJ9hKsvygH1qLRYkuJiqAmYfNzxitvSQusaRJC+PtNsCcv1x7VVs9NGnyW80ruYpTtJ9KAKl/E0V6tyg2RHhgvGDWvHeAQwjarFzjCnj8ah1CPBubcyK5hbcjD+IVDZxLLsl8xUibjDDgGgDZtY4kYs+Cin7q9a6K1a1ZRNb5DRjOx6xVRltyFkiVx+ORT4tREA2yMkW0ckjO6gCa61C3N1G+wRuHywAyGoaZri8unsALYj58RsccVzuq67asWW1UvLnhU61kC41SYkiY2cbDn+8aAPUrP4q6zb2epaHeX631le2xgDEfNCSMda8nvrW4gshGVX5GJZx/EKltLaEXZy80j46txk13fgbwu/jiyvdPtdv9p20ZkEWcFlHpQB5nCEAUxvsYjqe1bvgiz2+ILGZr1lt1k3SSKeQveqdvo8iXN1Ddht1uxRlxyCO1VY7trON/IUblOOR0FAH1vocWiyWLa5YQ7NHkfypZA20uehLVifBz4i6P4f8AFWt+H5lmg0iW4LWk4JeJWJ6H0zXkfgrxhc2HgvVNIkvZPJu+Uj2ZCnviksLKa1sEaB3+wu295mGMNQB9zWN7FeiRoNxRG27iMBuM5H514f8AtW3A/szw7apzKbl58Z5AUAZ/Wuo/Z61m/wBY8HXD6ir/ALq5KRO4wWXA5qX47+GE1rwpJqCY+1aajyJx1BxkfpQB812Il1K5eGOQieUBkYeo7GtiHXLvQ9RvjeWL2kN1a/Z763Iyso/vgHvXO6BeNbS29wh+du545Br1H4ttZ6lL4auLdSXvrIxTbB8u4Djn1zQB3/w81Wz1vSLzww+1rhNJCwTBQJHt3BXGfYkUn7K9ys/wV0eEf6y0muIJB3Dec7YP4MK86+Bl/Mvjjw6biEKzWtzpxYdSF+cZ/wC+a734C7tN8WfE/wAPeWIoLPXDeRIP4VnBIA9sRr+dAHsdFFFABX5pfE7j4l+Lcf8AQXu//Rz1+ltfmj8T/wDkpfi3/sL3f/o56AOb3N6n86f9om2bfNk2+m44qKigCYXM4AAnlwOg3mpbbUb20kMlreXMMhGC0crKSPqDVSigC2dSvuc3lzyc/wCtb/GrcHiTXLcg2+s6lEQMfJdOvH4GsmigDbXxX4iWN411/VhG/wB5ReSYb6jPNZzX94zbmu7gt6mQ5/nVWigCy99dyOHe6nZx0ZpCSKQXt0JvNFzOJf74kOfzqvRQBL9om3s3nSbm6nccmmmRz1dvzplFAD/Mf++350GWQ/xt+dMooAdvb+8fzo3sf4j+dNooAdvb+8fzpRI46Ow/GmUUAPMsh6ux/GpYr26iiaKK5nSNuqLIQD+FV6KANnT/ABRr+m2/kadrmq2kOc+XBdyRrn1wDVn/AITjxZ/0M+u/+DCX/wCKrnaKAOi/4TjxZ/0M+u/+DCX/AOKo/wCE48Wf9DPrv/gwl/8Aiq52igDov+E48Wf9DPrv/gwl/wDiqP8AhOPFn/Qz67/4MJf/AIqudooA6L/hOPFn/Qz67/4MJf8A4qj/AITjxZ/0M+u/+DCX/wCKrnaKAOi/4TjxZ/0M+u/+DCX/AOKo/wCE48Wf9DPrv/gwl/8Aiq52igDcfxd4kkYtJ4h1hmPUteyk/wDoVNt/FXiG2cvba9q0Lnq0d5IpP5GsWigDov8AhOPFn/Qz67/4MJf/AIqj/hOPFn/Qz67/AODCX/4qudooA6L/AITfxYRg+J9dx/2EJf8A4qiudooA6RgPM3PgIRkAHrV6CdoJk42oR93rVOWPy4M5AQdS3NWbA+bCylXGRwT3oA0JbgyxYSOMITyxPIq/Z6SLmxkdcK45zngj2qlDEHtvLkIWTptC84rahvItP0lIyhEg6Kev1oA5uGWTRdaQhW2P1z3rtNWCan4Y81CpWM5AjGMVjajpw1XTI7o7/PVuCa1vB8n2K3mivwZEJxtPb3oA4oXRHzuwVR8uSK0dOx9jcSpIYc5zjINS+NtPS3aT7KG8uX5vmGOK537Zd3USwxTJFGq7SEPNAHTG/trOMbxuYDKjPWsK6kv9Vl3s4toSflVupFVY4Ps8SnmWbqXY9KubiUDSYC46k0APt4ktWaKJUyR94j5j+NX4InEm1EEu4Z9dp+tGm6dNKquUITPA6lq1EW8RPsqYgiLZKqPm/GgCHTrZIS0/mpc3ZBVkIwE/xo8Fa5d+CviDpXiDzpHs/O8q4A4+U8EYrXGjniZIZJlGOWO0E0/VLK2vdJubTyTFPjco64NAHSXlnpEHxW8QWV6zRaZrEJuLS5QZ2sw3D9c15B4hsTp988SzByGILY6ivWrfRZ9R8DWGrF3kvdMHlkvxlB0Fed6xpGr6jPPqmnadLc2qcyiNC22gCLwnaPPcWxgJuJHkCbO+D7V6L4m8KeIrTxlp3hK1R7uS42XESRjhUPUt6AYOa8+8E65qPhvUZL/SYIYriRCpNzHuMfuoPevoX9m+y12/1WbxHrl59rlnVohJJIGcr6Y6gZxQB2TWdx8PPHGjGz3y+HtYxZXAZuLecD5GA9G5/Wu48cuD4N1wxx+cVtZAUB/2f8mte9tIb2ER3EauqurrkZwwOQax7hxPqWs6WSAJrQSBe53AqT/KgD4ltXSNGjUNmLMhJ6V7HfNc33wh8J63Cd0VpdFJ02gEKSRnP4frXk3ktFaPNKjMwleFlHt617Z4ZaS//ZpvyYQn2N5G2LySEYMf5mgDlvg+00PxCihhVJIo7/zAxYZVXBX+teleEy1l+0943tgR5eoaTa3hHvGEjH8zXg3hCZYNXiv0k2vFcRTFQ2CVDA17eJvsn7WkZkcGPUfDe2HHfEm7/wBkY0Ae20UUUAFfmj8T/wDkpfi3/sL3f/o56/S6vzR+J/8AyUvxb/2F7v8A9HPQBzNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAd1NbororICAueD1qxpVsJbgMFYqDwoPAqOJkd1T7yDp61t2ZS0AjjOyR/4sZoA1NMtIRO2MM8owQw4/OuV1q2lk1r7IpGAeqnOK0X1CU+dBFKAV6tinaXGHt5LtiBOnqM7qAHtdvplvHbwZyOXLcg1Ti1fzr93woQjGF61RnuA0skmW8xuMk8D8KrRTMJFSONSQc7umaAO3eJtZ8PTxookmi5VTyxFed6bava3k4mjMZ5+UDmteLULiyv0aCdocnJC962PFSW91FbXunnM0i4mVhj5qAMCNllmjTuTxx1ro7PQI2kL3iBW6iM9qw/D9xHZaiTfLuePlR1FdJNqO+9F18zFueTQBbW6tcR2yqYXB5dev4VdjS3MgnjVnhX5WP8AEaxI3ae4knjRB6k9R9K2NEurU747p3WPHyOoyS3vQBbnijjUwwlyc71AyeKfbaRfa15skMUzJEv3Y0wTVO01GRdRmY52KMeYvBP4V7V8MLW5k01JfNSAMC27GWYe9AHjmp+KLrw/p0elJsQH5jE45+hrufgvfXPkT6nZQzzaJKfLvo1APkt/eA9K8g+Jki3XinUGdsyRTsp44PNd9+ynrJ03x7qekSys1re2+8LyRuXnp9M0AetfEP4c6R4yt7bUdHvLK1ZU2+ZGoG/647187XPh/WPDOpsbfUrqzubaQg3NpMQwX2r6S8V+FLTQr1/EGkagbSzjPmXNg6M0MhPdQOhrivFev6VrYj0LxHZG0WciW1vLVQSPZh1oAsfAz4uTzagPDHjK8kmupZdun38wwZ89Ef39D3zj0r1/WkNp4ijvkI3yWUkAB7kHdx+dfMPjHwzbWViIY1aO+ixPaXSNydvOfavYPCvic/ET4ULqV3JJbarp0hEkkXG50HJH+8DyPWgDynWPD80Ggyttw09yzpx8xOelegfAKaW40LxHoN+V+yeWxMRHzqWUq35isvxLqMB07T7gPMBFIHCkDk+tXNJv4IPEdxdW4KCSIPLs+UtQB5Dpul3Flf3lpLGB5G4B2+9gHjIrvZ9WeP8AaH+Gd/Ny1xpgtWzwMskifzYGm69Fp+nfGGwu5k8zTdUt/wB7HznJGM/yqt8TY7fRPEfwt1a0kLW9vqAVTICWCCVTg9yMZoA+raKi+0xf3/0NH2mL+/8AoaAJa/NH4n/8lL8W/wDYXu//AEc9fpSs8ROA3P0Nfmt8TiD8SfFhHIOr3f8A6OegDmaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Sagittal T1-weighted MRI of the lumbar spine shows facet hypertrophic changes with osteophytes (white arrow) abutting the exiting L3 nerve root (white arrowhead) in the right L3-4 neural foramen. Note the lack of facet hypertrophic changes at the level below, L4-5, where the exiting nerve root is surrounded by hyperintense fat. B) Axial T2-weighted images show the facet osteophytes (white arrow) encroaching on the posterior aspect of the neural foramen, adjacent to the exiting L3 nerve root (white arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D. Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4389=[""].join("\n");
var outline_f4_18_4389=null;
var title_f4_18_4390="BM aspirate B cell ALL";
var content_f4_18_4390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bone marrow aspirate of acute lymphoblastic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate shows lymphoblasts with variable sizes, scant cytoplasm with vacuolation in a few cells, and convoluted nucleus (L2 morphology). Wright-Giesma, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4390=[""].join("\n");
var outline_f4_18_4390=null;
var title_f4_18_4391="Clinical applications of the signal-averaged electrocardiogram: Overview";
var content_f4_18_4391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical applications of the signal-averaged electrocardiogram: Overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Michael E Cain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4391/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/18/4391/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 300,000 individuals succumb to sudden cardiac death per year in the United States alone, predominantly from ventricular tachycardia (VT) or ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signal-averaged electrocardiogram (SAECG) is a noninvasive technique that enables detection of the pathophysiology underlying reentrant arrhythmias such as VT. It has therefore been applied to identify individuals at risk for sudden cardiac death, particularly in the context of coronary artery disease, acute myocardial infarction, and left ventricular dysfunction (",
"    <a class=\"graphic graphic_table graphicRef80458 \" href=\"UTD.htm?21/6/21611\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with the substrates for VT, slow conduction through myocardium disrupted by inflammation, edema, fibrosis, or scar tissue results in electrical potentials that extend beyond the activation time of normal surrounding myocardium, but which are too small for detection on the surface ECG. The SAECG uses computerized averaging of ECG complexes during sinus rhythm to facilitate the detection of these small microvolt level signals as ventricular late potentials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A broad overview of the settings in which the SAECG may be of value (",
"    <a class=\"graphic graphic_table graphicRef56366 \" href=\"UTD.htm?3/18/3372\">",
"     table 2",
"    </a>",
"    ) and of the relationship between late potentials detected by SAECG and ventricular tachycardia (",
"    <a class=\"graphic graphic_table graphicRef53211 \" href=\"UTD.htm?32/40/33419\">",
"     table 3",
"    </a>",
"    ) is presented here. The data supporting the use of SAECG in specific clinical settings are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM AND RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late potentials are low-amplitude, high frequency signals that are thought to reflect slow and fragmented myocardial conduction (",
"    <a class=\"graphic graphic_figure graphicRef72380 \" href=\"UTD.htm?19/22/19808\">",
"     figure 1",
"    </a>",
"    ). This abnormal conduction, which is most likely to occur in regions of prior infarction, provides a substrate for reentrant VT (",
"    <a class=\"graphic graphic_figure graphicRef82329 \" href=\"UTD.htm?31/47/32499\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The prevalence of late potentials in patients with documented VT and coronary artery disease ranges from 70 to 92 percent and the predictive value of late potentials for VT increases with the number of other clinical risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Late potentials are present in 6 percent of asymptomatic normal subjects, but their incidence increases progressively when examining patients with a recent myocardial infarction (MI) without VT, patients with a remote MI who have not had VT, and patients with a remote MI who have had sustained monomorphic VT.",
"   </p>",
"   <p>",
"    Late potentials are primarily used to reflect the presence of substrates for VT rather than a dynamic, time-varying predisposition to reentry. Reentrant arrhythmias require a critical balance between conduction delay and heterogeneous recovery of excitability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although late potentials reflect slow conduction related to arrhythmogenic substrates, episodes of VT initiation in such patients are uncommon in the absence of additional triggers such as ventricular premature beats, electrolyte abnormalities, increased circulating catecholamines, or ischemia.",
"   </p>",
"   <p>",
"    However, some evidence suggests that late potentials may indicate dynamic predisposition to ventricular arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diurnal variations in late potentials correspond to those reported in both the incidence of myocardial infarction and in the relative resistance of acute myocardial infarction to thrombolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite variability in the characteristics of late potentials, they consistently correlate with the subsequent induction of VT [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is an ongoing debate about whether variability in late potentials reflects a dynamic susceptibility to VT or influences such as autonomic tone without direct arrhythmogenic impact [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/15\">",
"     15",
"    </a>",
"    ]. The synergy between slow conduction and additional clinical triggers in initiating VT is supported by the improvement in predictive accuracy for VT when combining the SAECG with assessments of left ventricular ejection fraction, autonomic tone, the presence of complex ventricular ectopy on ambulatory ECG recordings, or ischemia on exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. A new potential area of study is in correlating late potential on the ECG with intracardiac ventricular late potentials that are increasingly used as targets for the ablation of ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technical factors must be considered when interpreting the SAECG. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL SETTINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Association with ventricular arrhythmias and sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAECG abnormalities are associated with an increased risk of ventricular arrhythmias and cardiac and sudden death mortality in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmyocardial infarction (MI) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in ischemic heart disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ischemic, nonischemic, and hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (",
"      <a class=\"graphic graphic_figure graphicRef70822 \" href=\"UTD.htm?41/42/42670\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/26-29\">",
"       26-29",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brugada syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/30-32\">",
"       30-32",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While studies have shown that positive SAECG significantly separates patients with from those without ventricular arrhythmias or sudden cardiac arrest, for instance post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], prospective studies have not yet shown that it can be used to guide ICD or other therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other associated cardiac disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAECG abnormalities have also been observed in some patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/33\">",
"       33",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=see_link\">",
"       \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Assessment of the efficacy of antiarrhythmic medications [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/34\">",
"       34",
"      </a>",
"      ] or of arrhythmia surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/35\">",
"       35",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Noninvasive diagnosis of transplant rejection in cardiac allograft recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"       \"Acute cardiac allograft rejection: Diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Identification of individuals with paroxysmal atrial fibrillation prone to frequent recurrences based upon abnormalities in the P-wave SAECG [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/38\">",
"       38",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=see_link\">",
"       \"Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these clinical uses, abnormalities in the SAECG have been identified in patients with a number of cardiac diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/39-49\">",
"     39-49",
"    </a>",
"    ]. However, results from SAECG testing in these divergent populations, with quite different pretest probabilities for ventricular arrhythmias and other end-points, must be interpreted with caution. Further prospective studies are required to validate the clinical utility of the SAECG in these scenarios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GUIDELINE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008 American Heart Association",
"    <span class=\"nowrap\">",
"     (AHA)/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC)/Heart",
"    </span>",
"    Rhythm Society (HRS) scientific statement on noninvasive risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/50\">",
"     50",
"    </a>",
"    ] and the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/European",
"    </span>",
"    Society of Cardiology (ESC) guidelines for management of patients with ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/51\">",
"     51",
"    </a>",
"    ], which concluded that the SAECG may be useful to identify patients at low risk for SCD, but its routine use to identify patients at high risk for SCD is not yet adequately supported.",
"   </p>",
"   <p>",
"    Similarly, the 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    scientific statement on syncope concluded that routine use of T-wave alternans combined with signal-averaged ECG and assessment of heart rate variability in patients with syncope and a negative initial evaluation is not yet established and currently is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4391/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13310646\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signal-averaged electrocardiogram (SAECG) detects subtle abnormalities in the surface electrocardiogram that are not visible to the naked eye. One example of such an abnormality is the \"ventricular late potential\", a low-amplitude signal near the end of the QRS complex which can be used to stratify risk for ventricular tachyarrhythmias in patients with cardiomyopathies of various etiologies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late potentials are primarily used to reflect the presence of substrates for ventricular tachycardia (VT) rather than a dynamic, time-varying predisposition to reentry. Although late potentials reflect slow conduction related to arrhythmogenic substrates, episodes of VT initiation in such patients are uncommon in the absence of additional triggers such as ventricular premature beats, electrolyte abnormalities, increased circulating catecholamines, or ischemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism and rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SAECG abnormalities are associated with an increased risk of ventricular arrhythmias and cardiac and sudden death mortality in various clinical settings including post-myocardial infarction, ischemic cardiomyopathy, nonischemic cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and the Brugada syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Association with ventricular arrhythmias and sudden death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/1\">",
"      Bay&eacute;s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/2\">",
"      El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 1977; 55:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/3\">",
"      El-Sherif N, Hope RR, Scherlag BJ, Lazzara R. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 2. Patterns of initiation and termination of re-entry. Circulation 1977; 55:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/4\">",
"      de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/5\">",
"      Pogwizd SM, Hoyt RH, Saffitz JE, et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992; 86:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/6\">",
"      Richards DA, Blake GJ, Spear JF, Moore EN. Electrophysiologic substrate for ventricular tachycardia: correlation of properties in vivo and in vitro. Circulation 1984; 69:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/7\">",
"      Gardner PI, Ursell PC, Fenoglio JJ Jr, Wit AL. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. Circulation 1985; 72:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/8\">",
"      Breithardt G, Borggrefe M, Karbenn U, et al. Prevalence of late potentials in patients with and without ventricular tachycardia: correlation with angiographic findings. Am J Cardiol 1982; 49:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/9\">",
"      Denes P, Santarelli P, Hauser RG, Uretz EF. Quantitative analysis of the high-frequency components of the terminal portion of the body surface QRS in normal subjects and in patients with ventricular tachycardia. Circulation 1983; 67:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/10\">",
"      Brugada P, Wellens HJ. Entrainment as an electrophysiologic phenomenon. J Am Coll Cardiol 1984; 3:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/11\">",
"      Goldhammer E, Abinader EG. Circadian fluctuations of late potentials detected by signal-averaged electrocardiogram. Am Heart J 1996; 132:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/12\">",
"      Muller JE, Stone PH, Turi ZG, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/13\">",
"      Kono T, Morita H, Nishina T, et al. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol 1996; 27:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/14\">",
"      Kulakowski P, Malik M, Poloniecki J, et al. Frequency versus time domain analysis of signal-averaged electrocardiograms. II. Identification of patients with ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 1992; 20:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/15\">",
"      Goldberger JJ, Ahmed MW, Parker MA, Kadish AH. Assessment of effects of autonomic stimulation and blockade on the signal-averaged electrocardiogram. Circulation 1994; 89:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/16\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/17\">",
"      Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. Circulation 1991; 83:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/18\">",
"      Kuchar DL, Thorburn CW, Freund J, et al. Noninvasive predictors of cardiac events after myocardial infarction. Complementary value of exercise testing and signal-averaged electrocardiography. Cardiology 1989; 76:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/19\">",
"      Ja&iuml;s P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012; 125:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/20\">",
"      McGuire M, Kuchar D, Ganis J, et al. Natural history of late potentials in the first ten days after acute myocardial infarction and relation to early ventricular arrhythmias. Am J Cardiol 1988; 61:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/21\">",
"      Kuchar DL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction: natural history and prognostic significance. Circulation 1986; 74:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/22\">",
"      Denniss AR, Ross DL, Richards DA, Uther JB. Changes in ventricular activation time on the signal-averaged electrocardiogram in the first year after acute myocardial infarction. Am J Cardiol 1987; 60:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/23\">",
"      Middlekauff HR, Stevenson WG, Woo MA, et al. Comparison of frequency of late potentials in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy with advanced congestive heart failure and their usefulness in predicting sudden death. Am J Cardiol 1990; 66:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/24\">",
"      Poll DS, Marchlinski FE, Falcone RA, et al. Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy: relationship to sustained ventricular tachyarrhythmias. Circulation 1985; 72:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/25\">",
"      Cripps TR, Counihan PJ, Frenneaux MP, et al. Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/26\">",
"      Peeters HA, SippensGroenewegen A, Schoonderwoerd BA, et al. Body-surface QRST integral mapping. Arrhythmogenic righ ventricular dysplasia versus idiopathic right ventricular tachycardia. Circulation 1997; 95:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/27\">",
"      Kinoshita O, Fontaine G, Rosas F, et al. Time- and frequency-domain analyses of the signal-averaged ECG in patients with arrhythmogenic right ventricular dysplasia. Circulation 1995; 91:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/28\">",
"      Blomstr&ouml;m-Lundqvist C, Hirsch I, Olsson SB, Edvardsson N. Quantitative analysis of the signal-averaged QRS in patients with arrhythmogenic right ventricular dysplasia. Eur Heart J 1988; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/29\">",
"      Blomstr&ouml;m-Lundqvist C, Olsson SB, Edvardsson N. Follow-up by repeated signal-averaged surface QRS in patients with the syndrome of arrhythmogenic right ventricular dysplasia. Eur Heart J 1989; 10 Suppl D:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/30\">",
"      Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 2001; 37:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/31\">",
"      Furushima H, Chinushi M, Hirono T, et al. Relationship between dominant prolongation of the filtered QRS duration in the right precordial leads and clinical characteristics in Brugada syndrome. J Cardiovasc Electrophysiol 2005; 16:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/32\">",
"      Tatsumi H, Takagi M, Nakagawa E, et al. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol 2006; 17:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/33\">",
"      Rozanski JJ, Mortara D, Myerburg RJ, Castellanos A. Body surface detection of delayed depolarizations in patients with recurrent ventricular tachycardia and left ventricular aneurysm. Circulation 1981; 63:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/34\">",
"      Freedman RA, Steinberg JS. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators. J Am Coll Cardiol 1991; 17:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/35\">",
"      Denniss AR, Johnson DC, Richards DA, et al. Effect of excision of ventricular myocardium on delayed potentials detected by the signal-averaged electrocardiogram in patients with ventricular tachycardia. Am J Cardiol 1987; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/36\">",
"      Lacroix D, Kacet S, Savard P, et al. Signal-averaged electrocardiography and detection of heart transplant rejection: comparison of time and frequency domain analyses. J Am Coll Cardiol 1992; 19:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/37\">",
"      Keren A, Gillis AM, Freedman RA, et al. Heart transplant rejection monitored by signal-averaged electrocardiography in patients receiving cyclosporine. Circulation 1984; 70:I124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/38\">",
"      Ehlert FA, Steinberg JS. The P wave signal-averaged ECG. J Electrocardiol 1995; 28 Suppl:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/39\">",
"      Vacek JL, Wilson DB, Botteron GW, Dobbins J. Techniques for the determination of left ventricular mass by signal-averaged electrocardiography. Am Heart J 1990; 120:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/40\">",
"      Raineri AA, Traina M, Lombardo RM, Rotolo A. Relation between late potentials and echocardiographically determined left ventricular mass in healthy subjects. Am J Cardiol 1991; 67:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/41\">",
"      Pringle SD, Dunn FG, Macfarlane PW, et al. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1992; 69:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/42\">",
"      Yotsukura M, Ishizuka T, Shimada T, Ishikawa K. Late potentials in progressive muscular dystrophy of the Duchenne type. Am Heart J 1991; 121:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/43\">",
"      Milner MR, Hawley RJ, Jachim M, et al. Ventricular late potentials in myotonic dystrophy. Ann Intern Med 1991; 115:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/44\">",
"      Moser DK, Stevenson WG, Woo MA, et al. Frequency of late potentials in systemic sclerosis. Am J Cardiol 1991; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/45\">",
"      Yang Q, Kiyoshige K, Fujimoto T, et al. Signal-averaging electrocardiogram in patients with diabetes mellitus. Jpn Heart J 1990; 31:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/46\">",
"      de Leonardis V, Bartalucci S, Cinelli P, et al. Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity. Cardiology 1991; 79:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/47\">",
"      Hsia J, Colan SD, Adams S, Ross AM. Late potentials and their relation to ventricular function in human immunodeficiency virus infection. Am J Cardiol 1991; 68:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/48\">",
"      Stelling JA, Danford DA, Kugler JD, et al. Late potentials and inducible ventricular tachycardia in surgically repaired congenital heart disease. Circulation 1990; 82:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/49\">",
"      Zimmermann M, Friedli B, Adamec R, Oberh&auml;nsli I. Ventricular late potentials and induced ventricular arrhythmias after surgical repair of tetralogy of Fallot. Am J Cardiol 1991; 67:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/50\">",
"      Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/51\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4391/abstract/52\">",
"      Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF scientific statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation In Collaboration With the Heart Rhythm Society. J Am Coll Cardiol 2006; 47:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 984 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4391=[""].join("\n");
var outline_f4_18_4391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13310646\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM AND RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Association with ventricular arrhythmias and sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other associated cardiac disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GUIDELINE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13310646\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/984|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/22/19808\" title=\"figure 1\">",
"      Positive SAECG following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32499\" title=\"figure 2\">",
"      Late potentials in diastole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42670\" title=\"figure 3\">",
"      Late potentials in ARVC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/6/21611\" title=\"table 1\">",
"      Noninvasive methods for arrhythmia risk stratification after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/18/3372\" title=\"table 2\">",
"      Potential uses of SAECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/40/33419\" title=\"table 3\">",
"      SAECG and VT after MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10872?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_18_4392="Musculoskeletal ultrasonography: Clinical applications";
var content_f4_18_4392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal ultrasonography: Clinical applications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4392/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4392/contributors\">",
"     George AW Bruyn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4392/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4392/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4392/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/18/4392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US), sometimes referred to as ultrasound imaging or sonography, is an imaging modality that utilizes reflected pulses of high frequency (ultrasonic) sound waves to assess soft tissues, cartilage, bone surfaces, and fluid containing structures. Ultrasonographic imaging, once the sole province of radiologists, is becoming more widely available in rheumatology clinics and in other ambulatory and emergency settings. However, the widespread use of US by clinicians who diagnose and treat musculoskeletal disorders has been hampered by questions related to the reliability, validity, standardization, methodology, and the ability to detect changes over time. Technical aspects of musculoskeletal ultrasonography, the validity and reliability of image acquisition, and interpretation in rheumatic disorders, primarily in patients with rheumatoid arthritis, are addressed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of ultrasonography to assess patients with rheumatic diseases in the clinic was fostered by the development of compact real-time US systems in the 1980s. Synovitis of the knee was the earliest musculoskeletal disorder assessed ultrasonographically in the clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrasonographic assessment of synovitis of the small joints of the hands in patients with rheumatoid arthritis followed by a decade [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/2\">",
"     2",
"    </a>",
"    ], aided by the availability in the 1990s of high-resolution transducers that made detailed assessment of superficial structures feasible.",
"   </p>",
"   <p>",
"    Selected clinical applications of musculoskeletal ultrasonography are discussed here. An overview of imaging modalities and guidelines for selecting imaging studies (eg, plain film radiography, computed x-ray tomography [CT scan], magnetic resonance imaging [MRI], and ultrasonography) for musculoskeletal problems are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=see_link\">",
"     \"Radiologic evaluation of the painful hip in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=see_link\">",
"     \"Radiologic evaluation of the painful shoulder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic imaging is only one element in the assessment of patients with musculoskeletal symptoms. The clinical approach to such patients, including, in most instances, suggestions regarding the role of diagnostic imaging in their assessment, is discussed in the topics that deal with the initial evaluation of patients presenting with pain in various parts of the body. Examples include shoulder pain, hip pain, and knee pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACQUIRING IMAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the musculoskeletal ultrasonographer, the selection of anatomic structures to image and the planes in which two-dimensional ultrasonography is performed is primarily complaint-driven. Standardized scans and disease-specific protocols for imaging are alternative approaches that are used in certain settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complaint-driven image selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complaint-driven image selection means that decisions about which images to acquire and the order in which images are obtained are determined by the clinician&rsquo;s assessment of the likely causes of symptoms and by the examiner&rsquo;s assessment of the usefulness of particular images in supporting or excluding such causes.",
"   </p>",
"   <p>",
"    Complaint-driven ultrasound scans focus on a specific region of the body (eg, the elbow in lateral epicondylitis or the metacarpophalangeal joints in rheumatoid arthritis). The position of the transducer depends upon the body region, while the view is manipulated by a combination of angulation, pressure, and rotation of the transducer from the same position.",
"   </p>",
"   <p>",
"    The type of ultrasound (US) imaging to employ (eg, B-mode, gray scale, Doppler, color Doppler, or power Doppler US), as well as the size and frequency of ultrasound to use, is also dependent upon the size and depth of structures being imaged and upon the type of pathologic changes that are considered to be likely causes of patients&rsquo; complaints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Standardized scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized scans are time-consuming and are more appropriate for training sessions and for use in clinical trials. Standardized scanning is typically the method of image selection that is utilized by an ultrasonographic technician. Images obtained using standardized views are subsequently interpreted by a radiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disease-specific scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-specific protocols specify particular areas of the body and types of images to obtain based upon an established or suspected diagnosis. An example of a disease-specific protocol is scanning of the hips and shoulders for a patient with suspected polymyalgia rheumatica (PMR).",
"   </p>",
"   <p>",
"    Scanning of the temporal arteries might also be considered part of disease-specific scanning when PMR is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of giant cell (temporal) arteritis\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ULTRASONOGRAPHY FOR SPECIFIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of musculoskeletal ultrasonography by the clinician may be valuable in disorders of the following structures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tendons and muscles",
"     </li>",
"     <li>",
"      Entheses",
"     </li>",
"     <li>",
"      Bursae",
"     </li>",
"     <li>",
"      Peripheral nerves",
"     </li>",
"     <li>",
"      Joints",
"     </li>",
"     <li>",
"      Cartilage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, real-time or preprocedure sonography may aid in needle aspiration and injection of bursae and joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tendons and muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography and MRI are good imaging techniques for tendons and muscles. Tendon pathology in inflammatory rheumatic disease is very common. There are two factors that contribute the frequent involvement in this setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, many tendons are embedded in a synovial sheath. If the synovial sheath is involved in the rheumatic inflammatory process, the tendon itself, although poorly vascularized, may also become inflamed. In inflammation, the tendon may undergo neovascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/3\">",
"       3",
"      </a>",
"      ]. In sheathed tendons, the nutrient vessels enter the tendon at specific sites called vincula, whereas, in unsheathed tendons, blood vessels enter the tendon at randomly distributed sites. Sheathed tendons have a wide distribution (eg, the long head of the biceps brachii muscle at the shoulder; the extensor tendons and flexor tendons of the fingers at the wrist; the finger flexor tendons, which are sheathed starting at the MCP joints all the way down to their insertion; the separate sheath of the tendon of the flexor pollicis longus muscle; and all the flexor and extensor tendons around the ankle joint).",
"     </li>",
"     <li>",
"      Second, tendons, either sheathed or unsheathed, lie adjacent to bursae and joints, structures that are lined with synovial cells. Thus, tendons may become involved in the inflammatory process as innocent bystanders. This mechanism probably plays a predominant role in inflammation of unsheathed tendons, including the rotator cuff tendons, which lie adjacent to the shoulder joint and the subacromial bursa; another example is inflammation of the Achilles tendon, which is adjacent to the retrocalcaneal bursa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Normal tendon and muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography usually depicts a normal tendon as hyperechoic and fibrillar (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58273 \" href=\"UTD.htm?29/58/30626\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63350 \" href=\"UTD.htm?19/32/19983\">",
"     figure 1",
"    </a>",
"    ). However, a normal tendon may demonstrate the phenomenon of anisotropy (ie, areas of decreased echogenicity due to oblique beam artifact). Normal muscle is characterized as being predominantly hypoechoic with interspersed hyperechoic connective tissue on sonography and as having an intermediate signal on MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Abnormal tendon and muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal tendon or muscle is characterized by anechoic areas on sonography and by a fluid signal on MRI. Full thickness tears are characterized by complete tendon absence or muscle disruption with retraction. The presence of an accompanying hematoma is characterized by anechoic or hypoechoic areas or by heterogeneous abnormal mixed echogenicity with a mass effect on sonography and with a fluid signal on MRI.",
"   </p>",
"   <p>",
"    An essential part of ultrasound examination of tendons is dynamically moving the joint or extremity (eg, finger tendons should be examined while bending and stretching of the fingers, and the rotator cuff tendons should be examined while rotating [internally and externally] and lifting [flexing and abducting] the arm). During dynamic examination, tendon movement and anatomical integrity may be assessed. Examples of pathologic features that may be observed include the snapping phenomenon accompanying trigger finger and the bulging of the supraspinatus tendon on the antero-lateral edge of the acromion as a result of shoulder impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Shoulder tendons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendons of the shoulder consist of those of the rotator cuff and the biceps brachii tendon (",
"    <a class=\"graphic graphic_figure graphicRef72709 \" href=\"UTD.htm?15/28/15814\">",
"     figure 2",
"    </a>",
"    ). The rotator cuff is best examined with transducer frequencies from 7.5 MHz to 10 MHz, although obese persons may require lower frequencies. In young athletes and older adults presenting with shoulder pain, cuff lesions should always be sought.",
"   </p>",
"   <p>",
"    The most important and vulnerable tendon of the rotator cuff is the supraspinatus, which originates from the upper dorsal part of the scapula and inserts on the greater tubercle. Almost all cuff lesions occur in the tendon of the supraspinatus muscle, whereas 1 percent is present in the subscapularis tendon. Complete cuff tears are easily visualized, whereas partial tears may sometimes be difficult to diagnose. Sonographically, the rotator cuff tendons are best examined dynamically and in a standardized sequence, starting with the biceps tendon and then moving medially to assess the subscapularis tendon; subsequently, the supraspinatus tendon and the infraspinatus tendon are examined [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraspinatus tendon &mdash; The vulnerable part of the supraspinatus tendon is a region of reduced vascularity, which is near the enthesis of the tendon at the greater tubercle of the humerus [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/6\">",
"       6",
"      </a>",
"      ]. In rheumatic diseases, inflammation of the shoulder joint or the bursa may result in chronic cuff edema, in impingement, and, subsequently, in a tendon tear.",
"      <br/>",
"      <br/>",
"      The presence of a hypoechoic discontinuity within the contours of the cuff is diagnostic of a tendon tear. A full-thickness tear is present when the discontinuity extends from the joint capsular side to the bursal side (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50236 \" href=\"UTD.htm?35/35/36402\">",
"       image 9B",
"      </a>",
"      ), and a partial tear is present when it is limited to a part of the tendon thickness. More subtle signs for rotator cuff tears, including both hyperechoic and hypoechoic areas, have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Synovitis of the glenohumeral joint is often present, and signs are sonographically detectable fluid in the axillary pouch, in the subscapular-subdeltoid bursa, in the posterior recess, or in the biceps sheath. When fluid is present in the bursa, one has always to look for a rotator cuff tear.",
"     </li>",
"     <li>",
"      Biceps brachii tendon &mdash; The biceps tendon is an important stabilizer of the glenohumeral joint. On sonography, a normal biceps is round in cross-section and produces multiple echogenic dots (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72784 \" href=\"UTD.htm?7/0/7173\">",
"       image 2",
"      </a>",
"      ). An inflamed biceps tendon is often thickened and hypoechoic, appears less round and more flattened, and may be surrounded by a hypoechoic rim (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86315 \" href=\"UTD.htm?3/3/3123\">",
"       image 3",
"      </a>",
"      ). The synovial sheath may become thickened. Power Doppler ultrasonography (power Doppler US) may demonstrate positive signals in the hypoechoic rim, but the signal should not be mistaken for the normal flow adjacent to the tendon within the synovial sheath consistent with the anterolateral branch of the anterior circumflex humeral artery [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/10\">",
"       10",
"      </a>",
"      ]. Rupture of the long head of the biceps tendon is a frequent finding in longstanding synovitis of the glenohumeral joint, whereas dislocation of the long head is infrequent. Both conditions can be diagnosed sonographically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Finger tendons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finger tendon involvement is a common feature of both early and late rheumatoid arthritis. Ultrasonography of the finger tendons requires a linear transducer of at least 13 MHz. Grassi, et al were the first to describe in detail the sonographic findings of both normal and abnormal finger flexor tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/11\">",
"     11",
"    </a>",
"    ]. The sagittal diameter of the finger flexors at the metacarpophalangeal (MCP) joint varies from 3.4 to 4.2 mm.",
"   </p>",
"   <p>",
"    Sonography usually does not allow the superficial and the deep finger flexor tendons to be distinguished at the MCP joint. However, when tenosynovitis is present, the fluid may separate the superficial from the deep flexor tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid arthritis (RA) &mdash; The most common ultrasonographic sign of flexor tendon involvement is widening of the flexor tendon sheath (1.7 mm versus 0.2 mm in controls), which occurs in about 80 percent of patients with RA, followed by altered tendon echogenicity (in 60 percent) and irregularity of the tendon margin (50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/11\">",
"       11",
"      </a>",
"      ]. In RA, there are two different patterns of tendon sheath widening, namely a hypoechoic enlargement correlating with effusion and an irregularly echoic widening due to proliferative synovitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63571 \" href=\"UTD.htm?39/33/40466\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75992 \" href=\"UTD.htm?4/60/5056\">",
"       image 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trigger finger &mdash; Trigger finger (also called stenosing flexor tenosynovitis) may be assessed by US. Usually, the phenomenon of trigger finger is due to pathological thickening of the A1 pulley, a strong fibrous band, at the site of the MCP joint. Power Doppler US is able to distinguish between hypoechoic fluid around the tendon and inflammatory or infectious tenosynovitis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/10\">",
"       10",
"      </a>",
"      ]. Blood flow in inflamed synovium is indicated by the colored regions in the peritendinous tissue (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63571 \" href=\"UTD.htm?39/33/40466\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=see_link\">",
"       \"Trigger finger (stenosing flexor tenosynovitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Achilles tendon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The archetypal unsheathed tendon is the Achilles tendon. This tendon is the strongest of the human body. It connects the calf muscles (ie, the gastrocnemius and the soleus) with the calcaneal bone. It can best be examined using a probe with a frequency between 7.5 and 13 MHz. Longitudinal sonography permits measuring the length and the sagittal diameter (",
"    <a class=\"graphic graphic_picture graphicRef59054 \" href=\"UTD.htm?19/47/20209\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73849 \" href=\"UTD.htm?43/22/44384\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86266 \" href=\"UTD.htm?41/47/42737\">",
"     image 7",
"    </a>",
"    ). The mean length in adults is about 15 cm, and the sagittal diameter is about 4.3 mm. A bursa lies deep to the tendon at the enthesis, which is sonographically not visible when it is not inflamed.",
"   </p>",
"   <p>",
"    Both partial and complete ruptures of the Achilles tendon may be assessed with US. Partial tears are more common than complete tears and are more difficult to diagnose clinically. Sonographic examination of artificial cuts in cadaveric tendons shows 81 percent accuracy between the size of the tear and the sonographic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/12\">",
"     12",
"    </a>",
"    ]. In patients with Achilles tendon injuries, full thickness rupture is suggested by absence of tendon at the site of injury, by proximal tendon migration or retraction, and by posterior acoustic shadowing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/13\">",
"     13",
"    </a>",
"    ]. A common site of complete tears is about 5 cm proximal to the insertion onto the calcaneus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Entheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendons, ligaments, and bone capsules adhere to bone at a specific region, called the enthesis. Histologically the enthesis consists of an area of fibrocartilage (close to joints where tendons or ligaments are bent by shear forces) or of fiber-bone interface. To underpin the significance of this anatomical complex, the term enthesis organ complex has been coined to include not only the portion of the attachment between tendon and bone but also adjacent structures including bone, bone marrow, bursae, and adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Enthesitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral enthesitis is one of the hallmarks of all of the spondyloarthritides (eg, undifferentiated spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, and reactive arthritis). Sonographic findings of enthesitis include thickening or intratendinous focal changes of the tendon insertion, edema of the tendon insertion, calcific deposits at the tendon insertion, spurs, erosions, new bone formation, or periosteal changes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57940 \" href=\"UTD.htm?31/48/32514\">",
"     image 8",
"    </a>",
"    ). In addition, adjacent bursitis is considered a sign of enthesitis. A positive power Doppler US signal consistent with increased vascularity may be found in active enthesitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bursae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal circumstances, bursae consist of two lining layers within only a very thin fluid lining between them; the fluid serves as a lubricant. Sonography usually depicts a bursa as a hypoechoic cleft between two hyperechoic lines. The hypoechoic cleft corresponds to the actual bursal sac, and the two hyperechoic lines correspond to the interfaces of the bursal sac with the surrounding tissues. However, under normal conditions, the subdeltoid bursa, the largest of its kind of human body, is hardly visible. On sonography, a dark semicircular line of 1 mm surrounds the rotator cuff in transverse view.",
"   </p>",
"   <p>",
"    Bursae may become inflamed in inflammatory and degenerative rheumatic disease. There are a number of bursa that most commonly become inflamed (",
"    <a class=\"graphic graphic_table graphicRef50703 \" href=\"UTD.htm?10/18/10539\">",
"     table 1",
"    </a>",
"    ). Some of these bursae communicate with the joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Subdeltoid-subacromial bursa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subdeltoid-subacromial bursa is often visible in patients with inflammatory rheumatic disease. Sonographic images show a distended bursa, filled with anechoic or hypoechoic fluid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86316 graphicRef50236 \" href=\"UTD.htm?19/61/20440\">",
"     image 9A-B",
"    </a>",
"    ). On a longitudinal view, the distended bursa often takes the form of a droplet hanging over the lateral edge over the shoulder beneath the deltoid muscle.",
"   </p>",
"   <p>",
"    As mentioned above, when sonographic evidence of subdeltoid-subacromial bursitis is present, one has to assess the presence of a rotator cuff tear, visible as a communicating cleft between the glenohumeral joint and the bursa (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50236 \" href=\"UTD.htm?35/35/36402\">",
"     image 9B",
"    </a>",
"    ). Such evidence should be sought if not already noted when this area is examined.",
"   </p>",
"   <p>",
"    In patients with RA, subacromial-subdeltoid bursal fluid may be present without an underlying tear in the rotator cuff. A distended bursa may also be noted in association with advanced age, with longstanding osteoarthritis of the glenohumeral joint, or with osteoarthritis of the acromioclavicular joint. In the case of acromioclavicular osteoarthritis, inferiorly directed osteophytes arising from the proximal acromion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the distal clavicle may result in increased friction and fraying of the rotator cuff, resulting in edema, impingement of the tendon, and, in some patients, subsequent cuff tear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Olecranon bursa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effusions within the superficially located olecranon bursa may be due to trauma, to infection, or to rheumatic diseases, particularly RA and gout. Sonography of septic bursitis or chronic bursitis due to rheumatic disease often shows a fluid collection surrounded by a thickened bursal wall. When the bursa is filled with fibrin-rich material or when the bursa is septated by fibrinous bands into several compartments, needle aspiration may result in a dry tap. Under these circumstances, ultrasound can be useful in steering the needle to an exact location or cavity filled with fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Baker's cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;The semimembranosus-gastrocnemius bursa, also referred to as Baker&rsquo;s cyst, was first sonographically demonstrated in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"     \"Popliteal (Baker's) cyst\"",
"    </a>",
"    .) The bursa deep to the tendon of the semimembranosus muscle anteriorly and the bursa below the medial head of the gastrocnemius muscle more cranially posteriorly may individually or jointly contribute to the formation of a Baker&rsquo;s cyst. Thus, on transverse sonograms, the Baker&rsquo;s cyst may take various forms, which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is no connection between the medial gastrocnemius and semimembranosus bursae, only the medial gastrocnemius bursa is filled with fluid and then takes the form of a half-moon (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50397 \" href=\"UTD.htm?40/58/41888\">",
"       image 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the two bursae communicate, the sonographic appearance of the cyst is similar to a so-called cross of St Andrew.",
"     </li>",
"     <li>",
"      In patients with RA, Baker&rsquo;s cysts can become septated and can have the US appearance of a bunch of grapes.",
"     </li>",
"     <li>",
"      If fluid accumulation is minimal, a fourth type of Baker&rsquo;s cyst (ie, the slit or crescent shape) is recognized [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A slit-like connection with the posterior joint space may be present in 30 to 50 percent of cases but is often difficult to detect sonographically. The communication pathway is through a 1.5 to 2 cm long tunnel in the medial part of the dorsal joint capsule, near the medial femur condyle, where the joint capsule is thinnest. The connection with the joint space accounts for the pumping of fluid into the bursa while bending the knee. When there is also a valve mechanism, the Baker&rsquo;s cyst will extend superficially and laterally into the loose connective tissue surrounding vessels and nerves.",
"   </p>",
"   <p>",
"    The Baker&rsquo;s cyst position in a transverse view is between the tendons of the medial gastrocnemius anteriorly and the semimembranosus tendon posteriorly, adjacent to the femoral bone. Rupture of a Baker&rsquo;s cyst allows fluid to spread out downwards into the calf, usually following the fascial planes within or between the calf muscles. Sonography is able to detect the extended fluid collection within the calf area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Peripheral nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral nerves may be imaged using a linear probe with frequencies between 10 and 16 MHz. The longitudinal sonographic appearance of a normal peripheral nerve consists of parallel linear hypoechoic bands in a hyperechoic background. On transverse section, the image consists of hypoechoic rounded areas in a hyperechoic background. The hypoechoic structures correspond histologically to the neuronal fascicles. Typical applications in clinical practice are the entrapment neuropathies, including carpal tunnel syndrome, ulnar neuropathy due to entrapment at the cubital tunnel, and tarsal tunnel syndrome. Moreover, neuromas such as Morton&rsquo;s can easily be visualized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography provides images of various joint components including the joint capsule or synovial membrane, the joint cartilage, and the bone surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bone erosions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In RA, pathologic changes may affect soft tissues, cartilage, and bone, but the hallmark of rheumatoid disease is bone erosion. Although plain film radiography has long been the standard imaging modality for detecting erosive disease, US and MRI are each able to demonstrate bone erosions in an early phase of RA with sensitivities that are significantly greater than that of conventional radiography. The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study compared conventional radiography, bone scintigraphy, US and MRI in 60 patients with various forms of arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/20\">",
"       20",
"      </a>",
"      ]. Both US and MRI detected significantly more erosions and synovitis in finger joints than did conventional radiography.",
"     </li>",
"     <li>",
"      Greater sensitivity of US over conventional radiography in the detection of bone erosions in MCP joints of RA patients was corroborated in another study in which sonography detected 6.5-fold more erosions than radiography in early RA and 3.4-fold more erosions in late disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/21\">",
"       21",
"      </a>",
"      ]. Moreover, the sonographic erosions corresponded to MRI bone abnormalities.",
"     </li>",
"     <li>",
"      The sensitivity to change for bone erosions was also assessed in a follow-up study, showing that US was superior to conventional radiography [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/22\">",
"       22",
"      </a>",
"      ]. At sites at which US has limited access to cover the entire area of cartilage (eg, the shoulder), US is significantly inferior to MRI and is only slightly superior to conventional radiography in detecting bone erosions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically differentiating between a thickened synovial membrane and joint effusion is, at times, problematic. The ability of power Doppler US to demonstrate active inflammation suggests that this imaging modality may become an extremely important tool in assessing the amount of inflammation and the response to therapy in patients with inflammatory joint diseases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86268 \" href=\"UTD.htm?39/59/40880\">",
"     image 11",
"    </a>",
"    ). Several studies suggest that US is superior to clinical examination in detecting synovitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When knee arthroscopy was used to determine the presence or absence of synovitis in patients with a variety of different arthritides, gray scale US was significantly better than clinical examination in detecting synovitis in the knee [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study that utilized both gray scale and power Doppler US but that did not utilize MRI or arthroscopy as gold standards, US detected more synovitis in finger and toe joints in patients with RA than did clinical examination [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thickening of the synovial membrane, whether detected by clinical examination or by US, does not necessarily equal inflammation. Power Doppler US proved to be a reliable modality for assessing active MCP disease in RA when compared with dynamic MRI as the gold standard [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence of a correlation between US detection of synovitis and actual pathology was provided by a study comparing the results of power Doppler US and histopathologic examination of synovial biopsy samples [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2198667\">",
"    <span class=\"h3\">",
"     Cartilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is able to visualize normal and pathologic joint cartilage. Normal hyaline cartilage appears as a homogeneously anechoic band delineated by hyperechoic margins. Crystal arthropathies such as chondrocalcinosis and gout cause characteristic changes in cartilage that are visible with ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4392/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, ultrasound is a valuable technique for evaluation of the various abnormalities in patients with osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The selection of anatomic structures and the planes in which to image them in clinical practice is driven by the patient&rsquo;s complaints. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complaint-driven image selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of ultrasound equipment (eg, transducer frequency and shape) and the mode of operation (eg, brightness or B-mode, gray scale, color Doppler, or power Doppler) are also dependent upon the location, size, depth, and type of pathologic changes that are being assessed in the structures of interest. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=see_link\">",
"       \"Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Musculoskeletal ultrasonography can provide images of tendons, muscles, entheses, bursae, joints, cartilage, and peripheral nerves and can detect bone erosions and synovitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ultrasonography for specific disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Power Doppler signal from inflamed synovium may correlate with the severity of synovitis as determined by biopsy. If confirmed, this suggests that ultrasonography could play a role in diagnosing and monitoring goal directed therapy for chronic forms of inflammatory joint disease. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Synovitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/1\">",
"      Cooperberg PL, Tsang I, Truelove L, Knickerbocker WJ. Gray scale ultrasound in the evaluation of rheumatoid arthritis of the knee. Radiology 1978; 126:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/2\">",
"      De Flaviis L, Scaglione P, Nessi R, et al. Ultrasonography of the hand in rheumatoid arthritis. Acta Radiol 1988; 29:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/3\">",
"      Fenwick SA, Hazleman BL, Riley GP. The vasculature and its role in the damaged and healing tendon. Arthritis Res 2002; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     Bruyn GAW, Schmidt WA. Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, 2nd, Bohn Stafleu van Loghum, Houten 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/5\">",
"      Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/6\">",
"      Ling SC, Chen CF, Wan RX. A study on the vascular supply of the supraspinatus tendon. Surg Radiol Anat 1990; 12:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/7\">",
"      Crass JR, Craig EV, Feinberg SB. The hyperextended internal rotation view in rotator cuff ultrasonography. J Clin Ultrasound 1987; 15:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/8\">",
"      Middleton WD, Edelstein G, Reinus WR, et al. Ultrasonography of the rotator cuff: technique and normal anatomy. J Ultrasound Med 1984; 3:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/9\">",
"      Mack LA, Matsen FA 3rd, Kilcoyne RF, et al. US evaluation of the rotator cuff. Radiology 1985; 157:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/10\">",
"      Breidahl WH, Stafford Johnson DB, Newman JS, Adler RS. Power Doppler sonography in tenosynovitis: significance of the peritendinous hypoechoic rim. J Ultrasound Med 1998; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/11\">",
"      Grassi W, Tittarelli E, Blasetti P, et al. Finger tendon involvement in rheumatoid arthritis. Evaluation with high-frequency sonography. Arthritis Rheum 1995; 38:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/12\">",
"      Kovacs P, Behensky H, Lottersberger C, et al. Can the dimensions of artificial tendon lesions be predicted ultrasonographically? A cadaveric study. J Ultrasound Med 2001; 20:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/13\">",
"      Hartgerink P, Fessell DP, Jacobson JA, van Holsbeeck MT. Full- versus partial-thickness Achilles tendon tears: sonographic accuracy and characterization in 26 cases with surgical correlation. Radiology 2001; 220:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/14\">",
"      Benjamin M, Moriggl B, Brenner E, et al. The \"enthesis organ\" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum 2004; 50:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/15\">",
"      D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, et al. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003; 48:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/16\">",
"      McDonald DG, Leopold GR. Ultrasound B-scanning in the differentiation of Baker's cyst and thrombophlebitis. Br J Radiol 1972; 45:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/17\">",
"      Guerra J Jr, Newell JD, Resnick D, Danzig LA. Pictorial essay: gastrocnemio-semimembranosus bursal region of the knee. AJR Am J Roentgenol 1981; 136:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/18\">",
"      Pastershank SP, Mitchell DM. Knee joint bursal abnormalities in rheumatoid arthritis. J Can Assoc Radiol 1977; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/19\">",
"      Martinoli C, Bianchi S, Derchi LE. Ultrasonography of peripheral nerves. Semin Ultrasound CT MR 2000; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/20\">",
"      Backhaus M, Kamradt T, Sandrock D, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 1999; 42:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/21\">",
"      Wakefield RJ, Gibbon WW, Conaghan PG, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000; 43:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/22\">",
"      Backhaus M, Burmester GR, Sandrock D, et al. Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis 2002; 61:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/23\">",
"      Hermann KG, Backhaus M, Schneider U, et al. Rheumatoid arthritis of the shoulder joint: comparison of conventional radiography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003; 48:3338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/24\">",
"      Karim Z, Wakefield RJ, Quinn M, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 2004; 50:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/25\">",
"      Szkudlarek M, Court-Payen M, Jacobsen S, et al. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 2003; 48:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/26\">",
"      Szkudlarek M, Court-Payen M, Strandberg C, et al. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum 2001; 44:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/27\">",
"      Walther M, Harms H, Krenn V, et al. Correlation of power Doppler sonography with vascularity of the synovial tissue of the knee joint in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2001; 44:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4392/abstract/28\">",
"      Howard RG, Pillinger MH, Gyftopoulos S, et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken) 2011; 63:1456.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1832 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4392=[""].join("\n");
var outline_f4_18_4392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACQUIRING IMAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complaint-driven image selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Standardized scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disease-specific scanning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ULTRASONOGRAPHY FOR SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tendons and muscles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Normal tendon and muscle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Abnormal tendon and muscle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Shoulder tendons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Finger tendons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Achilles tendon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Entheses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Enthesitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bursae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Subdeltoid-subacromial bursa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Olecranon bursa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Baker's cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Peripheral nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Joints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bone erosions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Synovitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2198667\">",
"      - Cartilage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1832|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/58/30626\" title=\"diagnostic image 1\">",
"      Transverse view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/0/7173\" title=\"diagnostic image 2\">",
"      Normal biceps tendon sonogr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/3/3123\" title=\"diagnostic image 3\">",
"      Long head biceps tendon US in RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/33/40466\" title=\"diagnostic image 4\">",
"      Finger flexor power Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/60/5056\" title=\"diagnostic image 5\">",
"      Posterior tibial tendonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/22/44384\" title=\"diagnostic image 6\">",
"      Achilles tendon US long",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/47/42737\" title=\"diagnostic image 7\">",
"      US post tib tendon RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/48/32514\" title=\"diagnostic image 8\">",
"      Tendon erosion sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/37/42579\" title=\"diagnostic image 9A\">",
"      Shoulder bursitis US PMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/35/36402\" title=\"diagnostic image 9B\">",
"      Rotator cuff tear US trans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/58/41888\" title=\"diagnostic image 10\">",
"      Bakers cyst sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/59/40880\" title=\"diagnostic image 11\">",
"      PIP synovitis US in RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/32/19983\" title=\"figure 1\">",
"      Volar structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15814\" title=\"figure 2\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1832|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/47/20209\" title=\"picture 1\">",
"      Achilles tendon US exam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/18/10539\" title=\"table 1\">",
"      Bursae assessable by ultrasound",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=related_link\">",
"      Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25210?source=related_link\">",
"      Radiologic evaluation of the painful hip in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36425?source=related_link\">",
"      Radiologic evaluation of the painful shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19141?source=related_link\">",
"      Trigger finger (stenosing flexor tenosynovitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_18_4393="Granulocyte transfusions";
var content_f4_18_4393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Granulocyte transfusions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Dennis Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Qun Lu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4393/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/18/4393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of modern antimicrobials and supportive therapy, bacterial, fungal, and viral infections are still major complications in patients with prolonged disease-related or therapy-related neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/1\">",
"     1",
"    </a>",
"    ]. An increasing number of clinical disorders are being treated with aggressive chemotherapy and bone marrow or hematopoietic stem cell transplantation. Neutropenia is one of the most frequent side effects of these aggressive treatments and the risk of infection increases rapidly when the granulocyte count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of infections in neutropenic patients has shifted, with multidrug-resistant bacterial infection and fungal infection such as Aspergillus, Fusarium, and Zygomyces emerging as the main cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/3\">",
"     3",
"    </a>",
"    ]. Since these infections are the direct result of neutropenia, granulocyte transfusion (GTX) as replacement therapy is a logical therapeutic approach and has been available for the last 40 years. The history, indications, clinical efficacy, and complications of GTX will be reviewed here. In addition, we will discuss donor selection, qualification, stimulation, granulocyte collection, processing, storage, and transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY OF GRANULOCYTE TRANSFUSION DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although GTX to neutropenic patients makes intuitive sense, just as does RBC transfusion to anemic patients or platelet transfusion to thrombocytopenic patients, it remains, in our opinion, an underutilized therapy. This is largely related to the difficulties in collecting adequate numbers of viable, functional granulocytes.",
"   </p>",
"   <p>",
"    Although normal individuals produce approximately 6 x 10",
"    <sup>",
"     10",
"    </sup>",
"    <span class=\"nowrap\">",
"     granulocytes/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/4\">",
"     4",
"    </a>",
"    ], their half-life in the peripheral blood is only six to seven hours. In addition, these cells cannot be stored for more than a few hours as they rapidly lose viability. Thus, granulocytes need to be collected and transfused on a daily basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link&amp;anchor=H17#H17\">",
"     \"Normal neutrophil development and kinetics\", section on 'Blood compartment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collection of adequate numbers of viable, functional granulocytes was almost impossible before the invention of continuous flow apheresis blood collection devices in the late 1960s. Even so, such devices permitted the collection of only 1 x 10",
"    <sup>",
"     10",
"    </sup>",
"    granulocytes (10 percent of normal daily production) from a donor during a six- to seven-hour apheresis collection. To increase the number of granulocytes collected by apheresis, corticosteroids were used to increase the donor's circulating granulocyte count and hydroxyethyl starch (HES) added to the donor's blood as it entered the centrifuge bowl to create better separation between the RBC and WBC layers in the centrifuge.",
"   </p>",
"   <p>",
"    With these improvements, collection of 2 to 3 x 10",
"    <sup>",
"     10",
"    </sup>",
"    <span class=\"nowrap\">",
"     cells/unit",
"    </span>",
"    was achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the steroid and HES use and time spent on the apheresis process created a huge burden for the donor, it could be solved by having more than one donor to support a single patient.",
"   </p>",
"   <p>",
"    Initially, GTX met with great enthusiasm. A number of clinical trials were performed from 1972 to 1982, but in terms of efficacy, these trials yielded mixed results. Six reports showed favorable responses to GTX, with 59 to 88 percent survival in patients receiving GTX, compared with 20 to 36 percent in control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1982, a randomized controlled clinical trial of therapeutic GTX was conducted in patients with gram-negative sepsis, which showed no benefits among treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/10\">",
"     10",
"    </a>",
"    ]. Although this study appeared to be well-designed, the dosages of granulocytes used in the study were far too low, averaging one-half of the minimally acceptable dose of 1 x 10",
"    <sup>",
"     10",
"    </sup>",
"    cells per transfusion. Any expected benefit of GTX would have been precluded by such low granulocyte dosage. GTX gradually disappeared from clinical use from 1985 to 1995 due to improvements in antimicrobials and general supportive care, combined with the difficulties in collecting and transfusing granulocytes.",
"   </p>",
"   <p>",
"    Several early studies showed the importance of granulocyte dose in achieving favorable outcomes. As early as 1975, it had been reported that patients with good clinical responses received four times as many granulocytes as patients with poor responses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/11\">",
"     11",
"    </a>",
"    ]. Meta-analyses of clinical trials of GTX suggested that higher doses were provided in the studies showing clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Therefore, when collection of larger doses of granulocytes became possible after the discovery and availability of recombinant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF), interest in GTX was renewed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In normal humans, G-CSF causes a rapid increase in the granulocyte count which begins within two hours and peaks at approximately 12 hours after administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/15\">",
"     15",
"    </a>",
"    ]. By stimulating donors with a combination of G-CSF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , collection of 5 to 10 x 10",
"    <sup>",
"     10",
"    </sup>",
"    granulocytes at one sitting became possible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. With these larger granulocyte doses, one can achieve significant increments in absolute neutrophil count (ANC) in severely neutropenic and infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, neutrophils collected after the administration of G-CSF appear to be of better quality. They exhibit prolonged survival after transfusion which may be due, in part, to the fact that these cells are released from the bone marrow early, thus representing a younger population. They also appear to experience delayed apoptosis and improved in vitro function (eg, respiratory burst, chemotaxis, and bactericidal activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/17,20-22\">",
"     17,20-22",
"    </a>",
"    ]. Evidence of in vivo granulocyte migration and activity has been demonstrated using multiple techniques, including buccal neutrophil accumulation, radioisotope labeled neutrophil migration, and the skin window test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/17,19,23,24\">",
"     17,19,23,24",
"    </a>",
"    ]. Thus, we can now collect adequate numbers of viable, functional cells from a single donor after cytokine and steroid administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CLINICAL EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Minimal criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the extreme difficulties in recruitment of donors and the huge burden on these donors (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Donor issues'",
"    </a>",
"    below), we recommend that certain minimal criteria be met before initiation of GTX, regardless of the cause of the patient's neutropenia. Minimal criteria include all three of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute neutrophil count &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      except in the case of chronic granulomatous disease (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic granulomatous disease'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Evidence of bacterial or fungal infection (ie, clinical symptoms of infection, positive cultures, pathological diagnosis of infection from biopsies, radiographic evidence of pneumonia)",
"     </li>",
"     <li>",
"      Unresponsiveness to antimicrobial treatment for at least 48 hours (except in extreme circumstances with life-threatening infection) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neutropenia from chemotherapy or transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;By far, this is the most common indication for GTX. Most retrospective clinical studies and prospective clinical trials of GTX were conducted in this patient population, including adult and pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/26-33\">",
"     26-33",
"    </a>",
"    ]. Chemotherapy and hematopoietic stem cell transplantation can severely suppress bone marrow production of all cell lines and cause severe pancytopenia.",
"   </p>",
"   <p>",
"    While anemia and thrombocytopenia can be supported with RBC and platelet transfusion without significant difficulties, severe neutropenia and associated infection remain the most important complication and limiting factor of these therapies. G-CSF may be used to stimulate patients' bone marrow production of granulocytes, but response to G-CSF in this patient group is usually poor. With the advancement of modern antimicrobials and supportive therapies, most bacterial infections and some fungal infections can be controlled, but multidrug-resistant bacterial infection and fungal infection are the main cause of morbidity and mortality. It is for these patients that GTX should be considered.",
"   </p>",
"   <p>",
"    A number of non-randomized phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trials of GTX with the addition of G-CSF in adults and children with neutropenia-related infection have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/19,27,28,30-32\">",
"     19,27,28,30-32",
"    </a>",
"    ]. Two representative trials are noted below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of leukocyte transfusion in neutropenic patients with severe infection included 30 patients whose infections were not controlled with adequate antibiotic and G-CSF administration. Following GTX, bacterial or fungal infection was controlled in 82 and 38 percent of patients, respectively, with 100-day overall survivals of 82 and 54 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study demonstrated resolution of infection in 8 of 11 patients with invasive bacterial infection or candidiasis after receiving GTXs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/19\">",
"       19",
"      </a>",
"      ]. Eight of the 16 patients who received GTXs following transplantation survived until engraftment. Although none of the five patients with invasive aspergillosis cleared the infection clinically, no evidence of infection was found at autopsy in three cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Cochrane meta-analysis of eight randomized clinical trials (RCTs) concluded that the available evidence was insufficient to either support or refute the generalized use of GTX therapy in the most common neutropenic patient populations (ie, myeloablative chemotherapy with or without hematopoietic stem cell support) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an obvious need for large randomized controlled trials to demonstrate the efficacy of GTX in the management of neutropenic patients. Such a study has been proposed by the NHLBI Transfusion",
"    <span class=\"nowrap\">",
"     Medicine/Hemostasis",
"    </span>",
"    Clinical Trials Network [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/31\">",
"     31",
"    </a>",
"    ]. The trial will include neutropenic patients with proven or probable bacterial or fungal infections. Patients will be randomly assigned to receive standard antimicrobial therapy with or without daily GTXs from donors mobilized with G-CSF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . A positive outcome will be determined by improvement of infection at 42 days as well as overall patient survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplastic anemia is a rare acquired disorder in which there is a failure of the bone marrow to produce sufficient blood cells, resulting in pancytopenia. The failure of the stem cells to produce mature blood cells can vary from partial to almost complete, thus producing a disease of varying severity in different patients. Symptoms may be slow to emerge because the loss of stem cell function is gradual. However, patients are often diagnosed at a later stage of the disease with severe complications such as infections and bleeding.",
"   </p>",
"   <p>",
"    The only definitive cure is stem cell transplantation, but before it can be initiated, infection must be controlled. When bacterial or fungal infection is unresponsive to maximal antibiotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antifungal therapy, GTX should be considered. Due to the relatively normal immune function in aplastic anemia, patients have a high incidence of HLA alloimmunization following transfusions with RBCs and platelets.",
"   </p>",
"   <p>",
"    When patients' anti-HLA antibodies match with donor granulocyte HLA antigens, the risk of transfusion-related acute lung injury (TRALI) can be a real concern. An 11-year experience at the National Institutes of Health in using GTX as supportive therapy in aplastic anemia patients has been presented [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Among the 33 patients in the series, 25 percent had HLA alloimmunization before the initiation of GTX, but no TRALI was reported and there was no difference in mean post-transfusion absolute neutrophil count between the patients divided according to HLA alloimmunization status. Infections were evenly divided between invasive bacterial and fungal infections. Overall survival to hospital discharge was 58 percent. For patients with invasive fungal infection, survival to hospital discharge was 44 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic granulomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic granulomatous disease have a normal granulocyte count but have a defect in granulocyte function, leaving them susceptible to recurrent bacterial and fungal infection. Modern antimicrobials can prevent and control most of the bacterial and fungal infections in these patients. GTX has been used in patients who continue to deteriorate under maximum antimicrobial therapy. A number of small studies and case reports have documented the success of GTX in treating patients with chronic granulomatous disease with invasive aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neonatal sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with sepsis may become neutropenic due to an immature granulopoietic system. This population may also benefit from GTX. Three studies compared survival rates of septic neonates receiving GTX versus no transfusion or intravenous immune globulin (IVIG) therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. They concluded that there may be some survival benefit with GTX. However, a Cochrane meta-analysis of randomized and quasi-randomized studies on the use of GTX to treat neonatal neutropenic sepsis concluded that there is still insufficient evidence for its benefit in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prophylactic GTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic GTX remains controversial due to the potential adverse effects of GTX (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below). A 2009 Cochrane meta-analysis of 10 prospective clinical trials concluded that the 9 trials conducted in the 1970s and 1980s demonstrated that prophylactic GTX at a dose of at least 1 x 10",
"    <sup>",
"     10",
"    </sup>",
"    cells may reduce the risk of mortality from infection, but overall mortality was not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/43-47\">",
"     43-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most recent trial, reported in 2006, demonstrated that the percent of patients developing fevers and the number of days of intravenous antibiotic use were significantly less in the GTX group, although there were no significant differences in length of hospitalization or 100-day survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/46\">",
"     46",
"    </a>",
"    ]. With advances in standards of supportive care in the 1990s and 2000s, given the resource and cost considerations, prophylactic GTX should only be utilized in the setting of prospective clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DONOR ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the introduction of G-CSF and corticosteroid-stimulated granulocyte collection, it is now possible to collect enough granulocytes from a single donor to produce a substantial increment in ANC in a neutropenic patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Donor Selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both community donors and directed donors such as family members and friends of the patient can be utilized as granulocyte donors. Family members and friends tend to be highly motivated and cooperative, but most of them have not donated blood before. Therefore, they have not been screened with blood donor questionnaires and have not been tested for transfusion-transmitted infectious disease markers. It generally takes 2 to 3 days to screen and test these potential donors. Therefore, utilizing directed donors alone will delay the initiation of GTX.",
"   </p>",
"   <p>",
"    Community donors, taken from an established donor pool, may have been recently tested for these markers following a whole blood or platelet donation. Since community donors are likely to have demonstrated good venous access from prior donation, granulocyte collections may be more successful.",
"   </p>",
"   <p>",
"    One study has suggested that there may be benefit to utilizing community donors rather than directed donors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors found that the time interval between the request for granulocytes and transfusion was significantly less in patients receiving granulocytes collected from community donors. These patients also benefited from higher ANC increments than those receiving donations from relatives.",
"   </p>",
"   <p>",
"    From our own experience, we would recommend the use of both groups of donors to maximize the benefits, by initiating the GTX with community donors to get started, and then continuing GTX with family members and friends of the patient as they qualify after screening and testing. These family members and friends of the patient may be recruited as community donors for future GTX for other patients. Since they have seen that GTX can save their loved one's life, they are more motivated to help others with similar needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Donor Qualifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not everyone who is willing to donate granulocytes will be qualified to do so. Just as with whole blood or plateletpheresis donors, granulocyte donors have to meet the minimum standards in donor history and physical examination set by the United States Food and Drug Administration and possibly other country, state, and professional regulatory agencies. In addition to being qualified as a whole blood donor, granulocyte donors may have to meet the following requirements at our institution:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABO and Rh matched to the recipient. Due to the difficulties of separating the granulocyte layer and RBC layer during the apheresis collection procedure, granulocyte concentrates are usually heavily contaminated with RBCs. Therefore, patient and donor need to be cross-match compatible for RBCs. This is a limiting factor in directed donor recruitment, particularly for patients who are blood type O. When ABO-mismatched granulocytes need to be used in certain circumstances, RBC depletion techniques can be used to remove the unwanted RBCs from the granulocyte product [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tested negative for all blood transfusion-associated infectious disease markers within 30 days of granulocyte donation.",
"     </li>",
"     <li>",
"      Prospective donors with hemoglobinopathies or those who are pregnant cannot be utilized, because G-CSF is not approved for use in these populations.",
"     </li>",
"     <li>",
"      Good vascular access. Granulocyte collection is performed through apheresis collection which demands good venous access. The donor should be evaluated by the apheresis collection staff.",
"     </li>",
"     <li>",
"      No history of allergies to steroids or starch.",
"     </li>",
"     <li>",
"      A history of hypertension, diabetes, gastrointestinal ulcers, glaucoma, tuberculosis, or any fungal infections may be a contraindication to steroid administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Donor Stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the standard dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is 8 mg, there is variation in the dose of G-CSF across studies, ranging from 200 to 600 micrograms. One study compared the efficacy of an 8 mg dexamethasone dose with either 450 or 600 micrograms of G-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/49\">",
"     49",
"    </a>",
"    ]. The granulocyte yields and side effects were comparable with both regimens. From an economic perspective, the lower G-CSF dose results in significant cost savings for the blood center.",
"   </p>",
"   <p>",
"    At our center we administer G-CSF (300 microg subcutaneously) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8 mg orally) on the day prior to each collection. If the donor's precollection white blood cell count increases to",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL,",
"    </span>",
"    stimulation with G-CSF is suspended until the count falls below that level; however, collections continue as scheduled. Circulating neutrophil counts in G-CSF- and dexamethasone-stimulated donors are at maximal 12 hours after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/16\">",
"     16",
"    </a>",
"    ]. Accordingly, we stimulate the donor in the evening and start granulocyte collection the next morning.",
"   </p>",
"   <p>",
"    Some donor centers choose not to stimulate their donors before collection due to the difficult logistics in obtaining and administering the G-CSF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Some donor centers choose to administer dexamethasone only, without using G-CSF. In both of these scenarios, the numbers of granulocytes able to be collected are much lower than collections from donors stimulated by both G-CSF and dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients transfused with such inadequate products do not derive the full benefit of GTX therapy.",
"   </p>",
"   <p>",
"    There are no published guidelines as to the frequency of collection and total number of donations that are permissible for normal donors. At our institution, using platelet donation limits as a reference, we generally limit collections to twice per week with 48 hours between the two collections and a total of 24 donations per 12-month period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Side effects of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects seen among",
"    <span class=\"nowrap\">",
"     G-CSF/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"      dexamethasone",
"     </a>",
"     -stimulated",
"    </span>",
"    donors seem to be generally mild and self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/18,50,51\">",
"     18,50,51",
"    </a>",
"    ]. Headache, arthralgias, bone pain, fatigue, and insomnia are the predominant symptoms. The vast majority of donors experiencing such adverse effects report a willingness to give further neutrophil donations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/18,52\">",
"     18,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, circulating neutrophil counts return to normal a few days after cytokine administration is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/53\">",
"     53",
"    </a>",
"    ]. Longer term studies of G-CSF stimulated donors have demonstrated no obvious lasting side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Although there has been some concern about the development of posterior subcapsular cataracts attributed to the repeated administration of glucocorticoids in granulocyte donors, a statistically significant relationship between glucocorticoid use in such donors and the development of cataracts has not been shown [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, HES is routinely used during granulocyte collection for more efficient cell separation. Most studies of the short and long term safety of HES involve its use as a volume expander. No long term consequences have been demonstrated in these studies. Therefore, it is reasonable to consider it safe for use in granulocyte collection in normal donors. Side effects of HES include fluid retention, with mild increase of body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Burden on the donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complicated process of granulocyte donation may be very burdensome for donors. They must take three trips to the donor center in order to make the first donation (first for donor screening and testing, second for medication administration, third for granulocyte donation), and two trips each for subsequent donations. On the day of donation, the granulocyte collection procedure takes 4 to 5 hours.",
"   </p>",
"   <p>",
"    The unavoidable inconvenience to the donor may prove a limiting factor to the success of GTX for a given patient. Donors also must bear the risks associated with G-CSF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and the risks associated with the apheresis donation procedure itself (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GRANULOCYTE COLLECTION, PROCESSING, AND STORAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Granulocyte collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte harvesting is accomplished through the process of apheresis in which only granulocytes are removed from the donor, while RBCs and plasma are returned to the donor. In our experience, apheresis should be performed for at least 150 to 180 minutes to process 7 to 10 liters of blood in order to maximize the granulocyte yield.",
"   </p>",
"   <p>",
"    Citrate is commonly used as the anticoagulant, which may result in hypocalcemic symptoms in the donor.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     Calcium gluconate",
"    </a>",
"    may be added to the return line to counteract the effect of citrate. HES is added to the donor's blood as it enters the centrifuge to facilitate separation of granulocytes from RBCs and improve collection. Pain at the venipuncture site, fatigue, tingling around the mouth and lip area, mild vital sign changes are common adverse reactions during the collection process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Granulocyte concentrate processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a blood component, granulocyte concentrates should be labeled properly with unit number, blood type, collection date, expiration date, volume of the product, collection facilities.",
"   </p>",
"   <p>",
"    Granulocyte recipients may be immunodeficient and at increased risk for transfusion associated graft-versus-host disease. To prevent this complication, all granulocyte concentrates should be irradiated with approximately 25 Gy, which renders lymphocytes within the product incapable of dividing or attacking host tissues. A sample of the product should be tested for total white blood cell count and differential which can be combined with product volume to calculate the total number of granulocytes in the concentrates. Another sample of the product should be used to perform a crossmatch with the recipient's plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Storage of granulocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of GTX is somewhat limited by the inability to store granulocytes for long periods of time. In the past, it was recommended that the granulocytes be stored at room temperature (22&ordm;C) and transfused as soon after collection as possible. The improved quality of G-CSF stimulated granulocytes may allow for longer storage times. As an example, newer studies suggest that the granulocyte concentrates may be stored at room temperature for at least 24 hours, with excellent preservation of functional activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/21,58\">",
"     21,58",
"    </a>",
"    ]. Until the validity of such findings are confirmed, we recommend transfusing granulocyte concentrates within a few hours of collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TRANSFUSION OF GRANULOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion reaction rates are higher in GTX compared with RBC transfusion, with 25 to 50 percent having mild to moderate reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/59\">",
"     59",
"    </a>",
"    ]. Premedicating the patient with 500 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    is recommended to prevent or minimize such reactions.",
"   </p>",
"   <p>",
"    Granulocytes should only be transfused through a standard blood administration set containing a filter with a pore size of 170 microns. Bedside leukocyte reduction filters should never be used. Transfusion should start slowly, with close monitoring of vital signs, O2 saturation, and signs and symptoms of complications (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If no transfusion reaction is observed, the infusion rate can be increased to a rate as fast as the patient can tolerate, but care must be taken to avoid circulatory overload in elderly patients. The product should be transfused in 2 to 4 hours.",
"   </p>",
"   <p>",
"    If the patient develops signs and symptoms of a transfusion reaction, the infusion should be stopped temporarily. The IV line should be kept open with normal saline, but the granulocyte product should not be discarded. The blood bank should be notified, the patient should be evaluated by a physician, and once the patient recovers from the reaction, granulocyte transfusion can be resumed. Any decision to discard the granulocyte concentrate should be made by the patient's attending clinician, not by nursing staff or housestaff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-five to 50 percent of GTXs are accompanied by mild to moderate reactions, with a 1 percent incidence of severe complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/59\">",
"     59",
"    </a>",
"    ]. In general, the most frequently encountered reactions are fever and chills. Slow infusion of the granulocyte concentrate and premedication can reduce the incidence and severity of these side effects. Other complications include pulmonary adverse reactions, transfusion-associated graft-versus-host disease (TA-GVHD), HLA alloimmunization, and transfusion-transmitted infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pulmonary adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to severe pulmonary adverse reactions can occur during GTX. Symptoms include varying degrees of cough, dyspnea, hypoxia, and changes on the chest radiograph. In one series, pulmonary reactions occurred in approximately 5 percent of GTX episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/60\">",
"     60",
"    </a>",
"    ]. In one study, no changes were seen in O2 saturation measured before and after the GTX [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Transfusion-associated GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;TA-GVHD is caused by viable functional donor lymphocytes present in granulocyte concentrates, which may mount an immunologic attack against the recipient. Although usually occurring in immunodeficient patients, TA-GVHD can develop in the presence of intact immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We routinely irradiate our granulocyte concentrates with 2500 to 3000 rads prior to transfusion in order to eliminate this risk. Although such irradiation prevents lymphocyte blast transformation, granulocyte function is preserved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmunization is another potential risk of GTX [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/62\">",
"     62",
"    </a>",
"    ]. A retrospective review indicated that 17 percent of patients with severe aplastic anemia developed HLA antibodies during the course of GTX, and that patients with detectable HLA antibodies had lower post-GTX white blood cell increments [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of antibodies to HLA- or granulocyte-specific antigens can reduce in vivo granulocyte survival and cause abnormal migration of granulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, refractoriness to platelet transfusion increases in patients receiving prophylactic GTX, due to the production of anti-HLA antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H4#H4\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'HLA alloimmunization and platelet refractoriness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion-transmitted diseases are just as important a consideration in GTX as with the use of any other blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/65\">",
"     65",
"    </a>",
"    ]. This is especially true of granulocytes, which must be transfused as soon as possible after collection, before completion of infectious disease testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of CMV may be greater in granulocyte concentrates, since CMV is harbored in peripheral blood leukocytes. Accordingly, the standard of care is to select CMV seronegative donors in patients at risk for developing transfusion-transmitted CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], although two reports have questioned this policy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. These two latter studies suggest that the risk of transmission is actually very low. Therefore, it may be possible to transfuse a CMV seronegative patient with granulocytes from a CMV seropositive donor, as long as the patient can be closely monitored for CMV viremia. In this manner, antiviral treatment may be implemented early to prevent serious sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RECIPIENT RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipients of GTXs should be monitored for changes in absolute neutrophil count (ANC) and changes in signs and symptoms of the infection by using microbial culture and imaging studies. The post-transfusion ANC increment can be quite large in patients receiving granulocytes from G-CSF- and corticosteroid-stimulated donors. As an example, one study reported a mean ANC increment of",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    maintained for 1 to 1.5 days following a mean granulocyte dose of 5.1 x 10",
"    <sup>",
"     10",
"    </sup>",
"    cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daily GTX not only can provide a near-normal blood neutrophil count in severely neutropenic patients, but also these transfused granulocytes have normal function in bactericidal, fungicidal, and chemotactic activities and are capable of migrating to extravascular sites and localizing to areas of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. Pictures of a dramatic increase in neutrophil numbers along with pus formation in an arm wound debridement specimen from a patient after just a single GTX have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that past trials of GTXs have been impaired because of the inability to collect adequate doses of granulocytes for transfusion. The availability of G-CSF presages a new era of GTX for the treatment of septic, neutropenic patients as well as a possible role for prophylactic GTX.",
"   </p>",
"   <p>",
"    A NHLBI sponsored, randomized, controlled trial for therapeutic GTX in neutropenic patients with bacterial or fungal infection is underway and is expected to be completed in late 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4393/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. We believe that, until the trial results are available, it is reasonable to use GTX as part of the armamentarium for treating septic, neutropenic patients.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/1\">",
"      Dale DC, Liles WC, Price TH. Renewed interest in granulocyte transfusion therapy. Br J Haematol 1997; 98:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/2\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/3\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/4\">",
"      Dancey JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. J Clin Invest 1976; 58:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/5\">",
"      Graw RG Jr, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med 1972; 287:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/6\">",
"      Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 1977; 296:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/7\">",
"      Higby DJ, Yates JW, Henderson ES, Holland JF. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med 1975; 292:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/8\">",
"      Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 1977; 63:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/9\">",
"      Herzig RH, Herzig GP, Graw RG Jr, et al. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 1977; 296:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/10\">",
"      Winston DJ, Ho WG, Gale RP. Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 1982; 97:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/11\">",
"      Lowenthal RM, Grossman L, Goldman JM, et al. Granulocyte transfusions in treatment of infections in patients with acute leukaemia and aplastic anaemia. Lancet 1975; 1:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/12\">",
"      Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993; 81:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/13\">",
"      Vamvakas EC, Pineda AA. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher 1996; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/14\">",
"      H&uuml;bel K, Dale DC, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 2001; 183:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/15\">",
"      Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/16\">",
"      Liles WC, Huang JE, Llewellyn C, et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/17\">",
"      Dale DC, Liles WC, Llewellyn C, et al. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion 1998; 38:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/18\">",
"      Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G--CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G--CSF alone. Transfusion 2001; 41:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/19\">",
"      Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000; 95:3302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/20\">",
"      Joos K, Herzog R, Einsele H, et al. Characterization and functional analysis of granulocyte concentrates collected from donors after repeated G-CSF stimulation. Transfusion 2002; 42:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/21\">",
"      Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion 2000; 40:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/22\">",
"      Drewniak A, van Raam BJ, Geissler J, et al. Changes in gene expression of granulocytes during in vivo granulocyte colony-stimulating factor/dexamethasone mobilization for transfusion purposes. Blood 2009; 113:5979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/23\">",
"      Dutcher JP, Schiffer CA, Johnston GS. Rapid migration of 111indium-labeled granulocytes to sites of infection. N Engl J Med 1981; 304:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/24\">",
"      Adkins D, Goodgold H, Hendershott L, et al. Indium-labeled white blood cells apheresed from donors receiving G-CSF localize to sites of inflammation when infused into allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997; 19:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/25\">",
"      Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004; 127:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/26\">",
"      Mazzel CA, Pepkowitz SH, Klapper E, Goldfinger D. Granulocyte colony stimulating factor (G-CSF) and dexamethasone stimulation of granulocyte donors allows collection of clinically efficacious numbers of granulocytes. J Clin Apher 1997; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/27\">",
"      Lee JJ, Chung IJ, Park MR, et al. Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia 2001; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/28\">",
"      H&uuml;bel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002; 42:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/29\">",
"      Safdar A, Hanna HA, Boktour M, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/30\">",
"      Peters C, Minkov M, Matthes-Martin S, et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/31\">",
"      Price TH. Granulocyte transfusion therapy: it's time for an answer. Transfusion 2006; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/32\">",
"      Sachs UJ, Reiter A, Walter T, et al. Safety and efficacy of therapeutic early onset granulocyte transfusions in pediatric patients with neutropenia and severe infections. Transfusion 2006; 46:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/33\">",
"      Stanworth SJ, Massey E, Hyde C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005; :CD005339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/34\">",
"      Quillen K, Yau YY, Leitman SF. The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. Transfusion 2009; 49:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/35\">",
"      Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009; 94:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/36\">",
"      Bielorai B, Toren A, Wolach B, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/37\">",
"      Ikincioullari A, Dogu F, Solaz N, et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial 2005; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/38\">",
"      Ozsahin H, von Planta M, M&uuml;ller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/39\">",
"      Christensen RD, Rothstein G, Anstall HB, Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics 1982; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/40\">",
"      Cairo MS, Worcester CC, Rucker RW, et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis. J Pediatr 1992; 120:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/41\">",
"      Cairo MS, Rucker R, Bennetts GA, et al. Improved survival of newborns receiving leukocyte transfusions for sepsis. Pediatrics 1984; 74:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/42\">",
"      Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev 2003; :CD003956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/43\">",
"      Strauss RG, Connett JE, Gale RP, et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 1981; 305:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/44\">",
"      Kerr JP, Liakopolou E, Brown J, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003; 123:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/45\">",
"      Illerhaus G, Wirth K, Dwenger A, et al. Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Ann Hematol 2002; 81:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/46\">",
"      Oza A, Hallemeier C, Goodnough L, et al. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 2006; 46:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/47\">",
"      Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009; :CD005341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/48\">",
"      Wuest DL, Reich LM. Removal of ABO-incompatible red cells from lymphocytapheresis and granulocytapheresis components before transfusion. Transfusion 1997; 37:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/49\">",
"      Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion 2000; 40:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/50\">",
"      Heuft HG, Goudeva L, Sel S, Blasczyk R. Equivalent mobilization and collection of granulocytes for transfusion after administration of glycosylated G-CSF (3 microg/kg) plus dexamethasone versus glycosylated G-CSF (12 microg/kg) alone. Transfusion 2002; 42:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/51\">",
"      Worel N, Kurz M, Peters C, H&ouml;cker P. Serial granulocytapheresisunder daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion 2001; 41:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/52\">",
"      Heuft HG, Goudeva L, Blasczyk R. A comparative study of adverse reactions occurring after administration of glycosylated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donors. Ann Hematol 2004; 83:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/53\">",
"      Stroncek DF, Matthews CL, Follmann D, Leitman SF. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002; 42:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/54\">",
"      Tassi C, Tazzari PL, Bonifazi F, et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/55\">",
"      Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/56\">",
"      Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion 2009; 49:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/57\">",
"      Clayton JA, Vitale S, Kim J, et al. Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion 2011; 51:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/58\">",
"      Hubel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion 2005; 45:1876.",
"     </a>",
"    </li>",
"    <li>",
"     Petz, LD, Swisher, et al. Clinical Practice of Transfusion Medicine, 3rd ed, Churchill Livingstone, New York 1996. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/60\">",
"      Hester JP, Dignani MC, Anaissie EJ, et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher 1995; 10:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/61\">",
"      Capon SM, DePond WD, Tyan DB, et al. Transfusion-associated graft-versus-host disease in an immunocompetent patient. Ann Intern Med 1991; 114:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/62\">",
"      O'Donghaile D, Childs RW, Leitman SF. Blood consult: granulocyte transfusions to treat invasive aspergillosis in a patient with severe aplastic anemia awaiting mismatched hematopoietic progenitor cell transplantation. Blood 2012; 119:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/63\">",
"      Dutcher JP, Schiffer CA, Johnston GS, et al. Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. Blood 1983; 62:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/64\">",
"      Schiffer CA. Granulocyte transfusions: an overlooked therapeutic modality. Transfus Med Rev 1990; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/65\">",
"      Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/66\">",
"      Price TH. Granulocyte transfusion: current status. Semin Hematol 2007; 44:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/67\">",
"      Meny GM, Santos-Zabala L, Szallasi A, Stramer SL. West Nile virus infection transmitted by granulocyte transfusion. Blood 2011; 117:5778.",
"     </a>",
"    </li>",
"    <li>",
"     America's Blood Centers. Granulocyte transfusions. Blood Bulletin 2000; volume 2, number 4. file://www.americasblood.org (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/69\">",
"      Nichols WG, Price T, Boeckh M. Cytomegalovirus infections in cancer patients receiving granulocyte transfusions. Blood 2002; 99:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/70\">",
"      Narvios A, Pena E, Han XY, Lichtiger B. Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood 2002; 99:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/71\">",
"      Vij R, DiPersio JF, Venkatraman P, et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/72\">",
"      Adkins D, Spitzer G, Johnston M, et al. Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts. Transfusion 1997; 37:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/73\">",
"      Ein-Gal S, Pepkowitz SH, Hurvitz CH, Goldfinger D. Dramatic tissue response after a single granulocyte transfusion. Transfusion 2007; 47:2185.",
"     </a>",
"    </li>",
"    <li>",
"     The RING Study: file://clinicaltrials.gov/ct2/show/NCT00627393?term=RING+Study&amp;rank=1 (Accessed on February 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4393/abstract/75\">",
"      Strauss RG. Role of granulocyte/neutrophil transfusions for haematology/oncology patients in the modern era. Br J Haematol 2012; 158:299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7951 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4393=[""].join("\n");
var outline_f4_18_4393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY OF GRANULOCYTE TRANSFUSION DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS AND CLINICAL EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Minimal criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neutropenia from chemotherapy or transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic granulomatous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neonatal sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prophylactic GTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DONOR ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Donor Selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Donor Qualifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Donor Stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Side effects of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Burden on the donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GRANULOCYTE COLLECTION, PROCESSING, AND STORAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Granulocyte collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Granulocyte concentrate processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Storage of granulocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TRANSFUSION OF GRANULOCYTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pulmonary adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Transfusion-associated GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RECIPIENT RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10555\" title=\"table 1\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_18_4394="Overview of non-falciparum malaria";
var content_f4_18_4394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of non-falciparum malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Jason D Maguire, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4394/contributors\">",
"     J Kevin Baird, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/18/4394/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/18/4394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-falciparum malaria refers to malaria infection due to Plasmodium species other than P. falciparum: P. vivax, P. ovale, P. malariae, and P. knowlesi (",
"    <a class=\"graphic graphic_table graphicRef53291 \" href=\"UTD.htm?15/38/15981\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. P. falciparum carries the highest risk of a fatal outcome; patients infected by this species who are having uncomplicated illness may very rapidly deteriorate into a complicated and life-threatening condition. Among the non-falciparum malarias, severe and threatening illness also frequently occurs with both P. vivax and P. knowlesi [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although severe illness also occurs with P. malariae and P. ovale, these seem to be very rare events.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of non-falciparum malaria will be reviewed here. The approach to P. falciparum malaria is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasmodium vivax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the non-falciparum species, P. vivax has the greatest geographic range and burden of disease. Worldwide, estimates of P. vivax infections range between 130 and 390 million, with 2.6 billion individuals living at risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endemic vivax malaria occurs throughout most of the tropics, including Africa, Asia, the South Pacific, and Central and South America. It may occur at any latitude capable of supporting anopheline mosquitoes (even for brief periods) including temperate latitudes on the Korean peninsula, China, Russia, and countries in southwestern Asia such as Iran, Afghanistan, and Tajikistan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=see_link\">",
"     \"Mosquito vectors of infectious diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lack of anopheline mosquitoes in tropical Micronesia and Polynesia spares these regions, and the absence of Duffy factor on the surface of red blood cells among most Africans spares virtually all of west and central Africa of malaria due to P. vivax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=see_link\">",
"     \"Mosquito vectors of infectious diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasmodium ovale",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. ovale malaria has been described in tropical western Africa and with rare frequency in Southeast Asia and Oceania. According to a survey performed in 1966, the only endemic areas for P. ovale malaria outside of Africa were the Philippine archipelago and the island of New Guinea. In a report of 15,806 blood film examinations at several sites in Indonesia between 1973 and 1989, 34 infections due to Plasmodium ovale were identified; the frequency of P. ovale relative to P. falciparum and P. vivax was &lt;1:1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Plasmodium malariae",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. malariae tends to occur with relatively low prevalence in isolated pockets throughout the tropics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plasmodium knowlesi",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. knowlesi is an emerging human pathogen initially recognized in 2004 (although the first human case of naturally acquired infection was described in 1965) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Malaria due to P. knowlesi has been described in Malaysian Borneo; cases have also been reported in Thailand, Myanmar, Singapore, and the Philippines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. However, P. knowlesi infection in macaques occurs in India, across Indochina, the Philippine archipelago, and the Indonesian archipelago to the island of Lombok (just east of Bali). Humans living or traveling in all of these regions (eg, within range of distribution of the A. leucosphyrus mosquito vector), especially those living in proximity to macaques, may be considered at risk of infection by P. knowlesi [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria should be suspected in the setting of any febrile illness after exposure to a region where malaria is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Symptoms and signs of uncomplicated malaria may also include tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias. Physical findings may include jaundice, splenomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatomegaly.",
"   </p>",
"   <p>",
"    Manifestations of severe disease should prompt consideration of mixed infection with P. falciparum. These include hemodynamic instability, pulmonary edema, severe anemia, massive intravascular hemolysis, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, altered mental status, focal neurological deficits, and seizures. Febrile seizures are not a sign of severe malaria; a single seizure in the setting of a high temperature requires aggressive fever management with anti-pyretics to distinguish a febrile seizure from seizures associated with central nervous system complications of malaria. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Complicated disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The traditional description of cyclic fever in the setting of malaria reflected a relatively late finding, following synchronization of schizont rupture and release of merozoites from erythrocytes (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 1",
"    </a>",
"    ). With improvements in early diagnosis and treatment, this manifestation of malaria is observed less frequently than in earlier descriptions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     By species",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some circumstances, clinical manifestations may be a useful clue for the causative species, as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     P. vivax",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. vivax has been associated with severe pulmonary manifestations including acute lung injury and acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/3,18-37\">",
"     3,18-37",
"    </a>",
"    ]. These have been reported at increasing rates; more than 20 cases have been described since 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/20-37\">",
"     20-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Splenic rupture is a rare complication of acute P. vivax malaria; about 150 cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Other severe manifestations of P. vivax malaria include profound anemia, disseminated intravascular coagulation, renal failure, shock and cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/19,27-30\">",
"     19,27-30",
"    </a>",
"    ]. The mortality rate for severe P. vivax infection is generally low, although one report of 36 cases from West Papua, Indonesia noted a death rate of 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/3,31\">",
"     3,31",
"    </a>",
"    ]. In addition, P. vivax hypnozoites can cause relapsing disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A retrospective review of hospitalized infants in Papua Indonesia suggested that P. vivax is a major cause of morbidity in early infancy. Among 187 infants aged &lt;3 months admitted to a hospital in Indonesia during a four-year period, P. vivax was observed more frequently than P. falciparum (56 versus 30 percent), and infection was associated with greater risk of severe anemia and severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/42\">",
"     42",
"    </a>",
"    ]. Death rates for patients with vivax and falciparum malaria were comparable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     P. ovale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe manifestations of P. ovale malaria outside of mixed infection are relatively rare. Reports include one case of splenic rupture and some descriptions of thrombocytopenia and disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In addition, P. ovale hypnozoites can cause relapsing disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     P. malariae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria due to P. malariae causes mild symptoms with low parasitemia. However, low grade infection with P. malariae can persist for years, with recurrence of symptoms more than 40 years after known exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/36,37,43,44\">",
"     36,37,43,44",
"    </a>",
"    ]. In addition, chronic P. malariae infection in children has been associated with nephrotic syndrome due to a mixed IgM and IgG basement membrane immune complex nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Most patients die within two years of this diagnosis, although cure has been described with early recognition and prompt treatment with antimalarial and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of a microscopic diagnosis of P. malariae together with severe clinical manifestations, hyperparasitemia, and exposure to areas of Southeast Asia inhabited by macaques, P. knowlesi infection should be suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     P. knowlesi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human infection with P. knowlesi was first described among 120 patients in Malaysia in 2004, but polymerase chain reaction (PCR) analysis of blood films from patients previously diagnosed with P. malariae infections in Sarawak confirm that human P. knowlesi infections occurred as early as 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/53\">",
"     53",
"    </a>",
"    ]. Previously P. knowlesi had been recognized as a malaria parasite of Old World monkeys, particularly macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. P. knowlesi appears morphologically similar to P. malariae by microscopy, but the species can be distinguished by PCR-based assays and gene sequencing (",
"    <a class=\"graphic graphic_table graphicRef53291 \" href=\"UTD.htm?15/38/15981\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    P. knowlesi can cause a wide clinical spectrum of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/54\">",
"     54",
"    </a>",
"    ]. Severe manifestations include high parasite density (75,000 to 765,000",
"    <span class=\"nowrap\">",
"     parasites/microL),",
"    </span>",
"    hypotension, hypoglycemia, hepatorenal dysfunction, and respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/2,55,56\">",
"     2,55,56",
"    </a>",
"    ]. Although severe disease and hyperparasitemia may be attributable to the 24-hour periodicity of this species, known to occur in macaques, P. knowlesi periodicity in humans has not yet been established.",
"   </p>",
"   <p>",
"    P. knowlesi infection should be considered among individuals with severe manifestations of malaria initially diagnosed as P. malariae by microscopy (particularly in the setting of hyperparasitemia), in the setting of exposure to areas of Southeast Asia inhabited by macaques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperreactive malarial splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperreactive malarial splenomegaly (HMS), previously known as tropical splenomegaly syndrome (TSS), is a complication of chronic malaria. The prevalence is high in Eastern Indonesia and Papuan highlands where P. vivax and P. malariae are the predominant species, although it can occur in the setting of any plasmodia species [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis is believed to be related to overproduction of IgM in response to repeated infection, with subsequent formation of immune complexes that cause prolonged stimulation of splenic reticuloendothelial cells. Among patients in Indonesia with HMS and elevated P. vivax antibody titers, antibody overproduction has been linked to a decrease in T-suppressor lymphocytes that normally down regulate B-lymphocyte function and antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of HMS include left upper quadrant pain, fatigue, ascites, lower extremity edema, and dyspnea; these symptoms become debilitating as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/58\">",
"     58",
"    </a>",
"    ]. Plasmodial parasitemia is uncommon; the diagnosis is generally made among long-term residents of malarious areas based on presence of massive splenomegaly, high serum antimalarial antibody levels and polyclonal IgM hypergammaglobulinemia. PCR amplification of plasmodial DNA in the absence of parasitemia can confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of indefinite therapy with antimalarial medication for the duration of ongoing malaria exposure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    (300 mg base weekly) is effective in reducing spleen size and symptoms over several months in 70 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/58,62\">",
"     58,62",
"    </a>",
"    ]. In areas with known chloroquine resistance, alternative agents should be used for initial treatment followed by prophylactic doses. For individuals with severely debilitating massive splenomegaly unresponsive to chemoprophylaxis, splenectomy may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Chloroquine resistance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse may occur in the setting of infection due to P. vivax and P. ovale infection, since the life cycle of these two species includes hypnozoites, a quiescent stage in the liver (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 1",
"    </a>",
"    ). This liver stage does not cause clinical symptoms, but relapsing disease occurs in the setting of reactivation of hypnozoites with release into the systemic circulation. Late-onset or relapsing disease can occur up to many months after initial infection, even after appropriate treatment (or prophylaxis) of the primary blood stage infection.",
"   </p>",
"   <p>",
"    The timing, risk, and extent of relapse vary with geography of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In general, the risk of relapse for strains acquired in tropical Asia is about 80 to 100 percent; most relapses occur within 30 days of infection and up to two to four relapses may occur. In contrast, the relapse risk for strains acquired in temperate zones is about 30 percent; most relapses occur 6 to 12 months following infection, and more than one relapse is rare. In India, however, P. vivax seems to behave more like temperate than tropical strains in all of these regards [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among infants with P. vivax infection, relapse is usually due to a genetically homologous strain, while among adults, relapse may result from activation of heterologous latent hypnozoites from prior episodes of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse due to P. ovale is uncommon and data in this area is limited. Most reports describe relapse within 17 to 255 days although there is a report of relapse four years following infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapse may be prevented by administering presumptive anti-relapse therapy (PART). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Preventing relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major tools for diagnosis of non-falciparum malaria include light microscopy and rapid diagnostic tests (RDTs). The traditional method for diagnosis is microscopic examination of Giemsa-stained blood smears; this technique is effective in the setting of microscopic expertise for interpretation of blood smears (",
"    <a class=\"graphic graphic_figure graphicRef80296 \" href=\"UTD.htm?34/9/34966\">",
"     figure 2",
"    </a>",
"    ). RDTs are also useful diagnostic tools and can distinguish between falciparum and non-falciparum species. However, their sensitivity is diminished in the setting of low parasite density (more commonly seen among previously malaria-na&iuml;ve patients). Therefore, in such circumstances RDTs should be used in conjunction with blood smears when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to evaluate for the presence of mixed infection with P. falciparum. Because P. vivax and P. ovale infect only young red blood cells (reticulocytes), the parasite density for these infections is limited to one to 2 percent. In contrast, since P. falciparum, P. malariae and P. knowlesi can infect mature cells, patients with these infections may present with higher parasite density, particularly P. falciparum. Therefore, a parasite density higher than 2 percent should raise suspicion for P. falciparum infection. Distinguishing between species and establishing whether P. falciparum is present are important for guiding the approach to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of malaria\", section on 'Light microscopy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial blood smears to quantify parasite density every 8 to 12 hours in the first 24 to 48 hours (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"       \"Clinical manifestations of malaria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complete blood count (evaluating for severe anemia, thrombocytopenia) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver function testing, including fractionated bilirubin (evaluating for hepatitis, hemolysis)",
"     </li>",
"     <li>",
"      Basic metabolic panel (evaluating for renal failure, metabolic acidosis, hypoglycemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful diagnosis and initial evaluation for severity of illness are imperative for planning effective treatment. Patients with malaria caused by species other than P. falciparum may be treated as outlined in the following sections. However, patients with mixed infection that includes P. falciparum should receive definitive treatment for P. falciparum. In such cases, there is no need for an additional drug to treat the non-falciparum species, but liver hypnozoites of P. vivax and P. ovale must be eradicated to prevent relapse of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Preventing relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Uncomplicated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncomplicated malaria refers to infection that poses minimal risk for morbidity or mortality. In general, malaria species other than P. falciparum usually cause uncomplicated infection. After an incubation period of 9 to 40 days (varies by species), nonimmune patients usually develop a non-specific febrile illness, while semi-immune individuals living in endemic areas may be asymptomatic or present with an afebrile illness. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Uncomplicated infections can usually be managed on an outpatient basis in the absence of other comorbidities. The treatment of non-falciparum malaria consists of treating the erythrocytic forms and, for infections with P. vivax and P. ovale, eradicating liver hypnozoites to prevent relapse of infection. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Preventing relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug of choice for the treatment of the erythrocytic forms for all non-falciparum species is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67642 \" href=\"UTD.htm?15/47/16126\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Adult dosing for chloroquine is 600 mg base (= 1000 mg salt) orally immediately, followed by 300 mg base (= 500 mg salt) orally at 6, 24, and 48 hours. The total dose is 1500 mg base (= 2500 mg salt).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    is highly effective against P. malariae and P. ovale and is effective for most cases of P vivax.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is a second-line alternative to chloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/73\">",
"     73",
"    </a>",
"    ]. A useful table summarizing regimens for treatment of malaria may be found at the CDC web site:",
"    <a class=\"external\" href=\"file://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\">",
"     file://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    is usually well tolerated. Minor side effects, including bitter taste, gastrointestinal disturbances, dizziness, blurred vision, and headache, may be alleviated by taking the drug with food. It has been associated with triggering flares of psoriasis and pruritis (especially among dark skinned individuals), although serious side effects are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Chloroquine is safe for use in pregnancy.",
"   </p>",
"   <p>",
"    In a prospective study of 60 patients with uncomplicated P. knowlesi and P. vivax in Malaysian Borneo, a standard three day regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    (plus two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    as a gametocidal agent), cured 100 percent of patients followed up for 28 days after initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Chloroquine resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    -resistant P. vivax (CRPV) has been recognized since the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. This is an uncommon but increasing problem, particularly in the regions of Papua New Guinea and Indonesia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/81-89\">",
"     81-89",
"    </a>",
"    ]. Rare case reports of chloroquine-resistant P. vivax have also been documented in Burma (Myanmar), India, and Central and South America. Infections acquired anywhere except in Indonesia, East Timor, Papua New Guinea, and the Solomon Islands may be presumed to be chloroquine sensitive.",
"   </p>",
"   <p>",
"    Presumptive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    resistance is established clinically, since P. vivax is difficult to maintain in culture and molecular markers of chloroquine resistance have not been identified. Chloroquine resistance has been defined by epidemiologists as persistent parasitemia (eg, not decreasing) after four days of chloroquine therapy, or recurrent parasitemia within 28 days following chloroquine therapy with adequate whole blood concentrations (defined as &gt;100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    whole blood concentrations of chloroquine plus its metabolite desethylchloroquine) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/82,90,91\">",
"     82,90,91",
"    </a>",
"    ]. In such cases, alternative therapy should be initiated.",
"   </p>",
"   <p>",
"    Therapeutic options for CRPV include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67642 \" href=\"UTD.htm?15/47/16126\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/77,92-99\">",
"     77,92-99",
"    </a>",
"    ]. Mefloquine may be preferable given its availability, tolerability, reasonable cost, simple dosing regimen, and record of safety in pregnant women and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/92,100\">",
"     92,100",
"    </a>",
"    ]. Quinine-clindamycin is not appropriate for first-line treatment of P. vivax given limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/101\">",
"     101",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    base over three days) has demonstrated good efficacy (85 percent), although experience with high dose primaquine is relatively limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In areas where both P. vivax and P. falciparum are endemic and species diagnosis is unreliable, some experts advocate artemisinin combination therapy (ACT), such as dihydroartemisinin-piperaquine (DP), for treatment of P. vivax [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. Treatment with DP has been shown to be an effective alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    in a randomized trial including 500 patients with acute vivax malaria on the northwestern border of Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/106\">",
"     106",
"    </a>",
"    ]. The high risk of morbidity and mortality associated with inadequate treatment of improperly diagnosed P. falciparum may justify this approach, particularly in areas where chloroquine resistant P. vivax exists.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    remains the treatment of choice for treatment of P. ovale and P. malariae, even though rare cases of chloroquine failure have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/71,107-109\">",
"     71,107-109",
"    </a>",
"    ]. Some cases of extended clearance time for P. malariae parasitemia (seven days or longer) have been described; this observation may be related to a prolonged interval between stages in the P. malariae life cycle in comparison with the other species [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/110-114\">",
"     110-114",
"    </a>",
"    ]. Therefore, in some patients the parasites may still be emerging from the liver relatively late following initiation of antimalarial therapy. This may be an alternative explanation for suspected chloroquine failure or resistance in the setting of P. malariae infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/109,115-119\">",
"     109,115-119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very little data exist for the efficacy of other antimalarials against P. malariae. Alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    described in case reports include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/109,119,120\">",
"     109,119,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Preventing relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following treatment of infection due to P. vivax or P. ovale, presumptive anti relapse therapy (PART) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    to prevent relapse (by eradicating hypnozoite forms that may remain dormant in the liver) should be administered (",
"    <a class=\"graphic graphic_figure graphicRef70176 \" href=\"UTD.htm?16/23/16760\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/63,121-124\">",
"     63,121-124",
"    </a>",
"    ]. Late presentation or relapse due to liver hypnozoites among patients with P. vivax treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    alone occurs in more than 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    dosing for preventing relapse depends upon the species. To prevent relapse of P. vivax, primaquine should be dosed 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 14 days. To prevent relapse of P. ovale, primaquine should be dosed 15 mg",
"    <span class=\"nowrap\">",
"     base/day",
"    </span>",
"    for 14 days. Primaquine therapy should begin on the same day of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and supervised treatment may be helpful for optimizing efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    dosing for P. vivax is important for two reasons. First, there has been increasing evidence for failure of standard dose primaquine for prevention of P. vivax relapse; relapse in the United Kingdom has been reported in more than 10 percent of patients with P. vivax treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    followed by primaquine 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/127\">",
"     127",
"    </a>",
"    ]. Administering 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is more effective than 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in South Asia, the source of most imported infections in Britain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/123,128,129\">",
"     123,128,129",
"    </a>",
"    ]. In addition, certain strains of P. vivax have inherent primaquine resistance and require higher doses of primaquine to prevent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    is contraindicated in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and in pregnant women. Prior to primaquine administration a G6PD level must be determined and patients should receive primaquine only if G6PD deficiency has been excluded. For patients with mild G6PD deficiency a modified regimen of 45 mg (base) of primaquine weekly for eight weeks has been suggested, although the data for safety and efficacy of this regimen are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/123,131,132\">",
"     123,131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients unable to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    should be counseled regarding the possibility of developing relapsing infection (about 20 percent, range 5 to 80 percent) and the need to seek treatment if symptoms recur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with relapsing infection should receive repeat treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53291 \" href=\"UTD.htm?15/38/15981\">",
"     table 1",
"    </a>",
"    ). For patients unable to take primaquine who experience frequent relapse, chloroquine prophylaxis (300 mg base weekly for 12 months) may be administered, although later relapse may still occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/73\">",
"     73",
"    </a>",
"    ]. In the setting of chloroquine resistant P. vivax,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    prophylaxis (228 mg base weekly) may be used in place of chloroquine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    is contraindicated in pregnancy; following completion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    treatment, pregnant patients should receive weekly chloroquine prophylaxis until delivery. Following delivery, primaquine can be administered if G6PD testing in the mother and infant are normal. Testing in the infant is necessary if the infant is breast fed as it is unknown whether primaquine is excreted in the breast milk.",
"   </p>",
"   <p>",
"    Malaria acquired by blood transfusion or organ transplantation has no exoerythrocytic stage, so PART is not needed in such cases. In addition, PART is not required for P. malariae because it does not maintain a hypnozoite stage, although late recrudescence can occur. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;With appropriate treatment, fever and parasitemia usually resolve within two to four days, although this may vary depending on strain differences, host factors and type of antimalarial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/18/4394/abstract/133,134\">",
"     133,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serial blood smears should be collected after initiation of treatment to confirm cure and detect recrudescent infection. Smears should be obtained on days 1, 2, 3, 4, 7, and 28, even in the absence of symptoms. Recurrent symptoms at any time during follow-up should prompt additional testing. In general, following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    treatment the parasite density should be lower than pre-treatment levels by day 2, less than 25 percent of the pre-treatment density by day 3, and undetectable by day 4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to respond as described or recrudescence (re-emergence of blood stage forms following resolution of parasitemia) at any time during followup constitutes therapeutic failure, and clinicians should provide rescue therapy with an alternate agent. Options for alternate therapy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"      atovaquone",
"     </a>",
"     /proguanil,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ). The selection should be individualized based on antimalarial resistance patterns for the region where the infection was acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Complicated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of complicated malaria may include fever, pulmonary edema, hemodynamic instability, severe anemia, coagulopathy, hypoglycemia, metabolic acidosis, renal failure, hepatic dysfunction, cerebral involvement, massive intravascular hemolysis, and death. These are believed to occur as a result of high parasite density, adherence of parasitized red blood cells to the vascular endothelium, capillary sequestration and localized cytokine responses&mdash;all of which are not usually associated with the non-falciparum species.",
"   </p>",
"   <p>",
"    Severe manifestations in cases of P. vivax, P. malariae and P. ovale infections have therefore been attributed to unrecognized mixed infection with P. falciparum. For this reason, patients with severe malaria should be treated for presumed P. falciparum infection regardless of additional infecting species or geographic region of acquisition. This includes management in an intensive care setting for close monitoring of hemodynamics, parasitemia, hemoglobin, glucose and electrolytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing non-falciparum malaria in travelers is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-falciparum malaria refers to malaria caused by Plasmodium species other than P. falciparum: P. vivax, P. ovale, P. malariae, and P. knowlesi. The non-falciparum species usually cause febrile illness but are rarely fatal, although deaths have been reported in the setting of P. vivax and P. knowlesi infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endemic vivax malaria occurs throughout most of the tropics, including Africa, Asia, the South Pacific, and Central and South America. P. ovale malaria has been described in tropical western Africa and with rare frequency in Southeast Asia and Oceania. P. malariae tends to occur in with relatively low prevalence in isolated pockets throughout the tropics. P. knowlesi malaria has been described in Malaysian Borneo; a few cases have also been reported in Thailand, Myanmar, Singapore, and the Philippines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major tools for diagnosis of non-falciparum malaria include light microscopy and rapid diagnostic tests (RDTs). It is important to evaluate for the presence of mixed infection with P. falciparum. Distinguishing between species and establishing whether P. falciparum is present is important for guiding the approach to treatment. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malaria should be suspected in the setting of a febrile illness after exposure to a region where malaria is endemic. In some circumstances, clinical manifestations may be a useful clue for the causative species. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Relapse may occur in the setting of infection due to P. vivax and P. ovale infection, since the life cycle of these two species includes hypnozoites, a quiescent stage in the liver. Relapse may be prevented by administering presumptive anti-relapse therapy (PART). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Relapse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Preventing relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      for treatment of the erythrocytic forms for non-falciparum malaria species (",
"      <a class=\"graphic graphic_table graphicRef67642 \" href=\"UTD.htm?15/47/16126\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      for treatment of chloroquine-resistant P. vivax (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Mefloquine may be preferable over malarone or the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      given its availability, tolerability, reasonable cost, simple dosing regimen, and record of safety in pregnant women and young children. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment of malaria due to P. vivax or P. ovale, we recommend presumptive antirelapse therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      to prevent relapse (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Preventing relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mixed infection that includes P. falciparum should receive definitive treatment for P. falciparum. In such cases, there is no need for an additional drug to treat the non-falciparum species, but liver hypnozoites of P. vivax and P. ovale must be eradicated to prevent relapse of infection. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With appropriate treatment, fever and parasitemia usually resolve within two to four days, although this may vary depending on the malaria strain, host factors and type of antimalarial therapy. To confirm cure and detect recrudescent infection, smears should be obtained on days 1, 2, 3, 4, 7, and 28, even in the absence of symptoms. Recurrent symptoms at any time during follow-up should prompt additional testing and, if necessary repeat treatment with an alternate agent. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Follow up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe manifestations malaria are not usually associated with the non-falciparum species. For this reason, such patients should be treated for presumed P. falciparum infection regardless of additional infecting species or geographic region of acquisition. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complicated disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"       \"Treatment of severe falciparum malaria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/1\">",
"      Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004; 363:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/2\">",
"      Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/3\">",
"      Kochar DK, Saxena V, Singh N, et al. Plasmodium vivax malaria. Emerg Infect Dis 2005; 11:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/4\">",
"      Hay SI, Guerra CA, Tatem AJ, et al. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004; 4:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/5\">",
"      Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol 2006; 22:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/6\">",
"      Baird JK, Masbar S. Plasmodium ovale in Indonesia. Southeast Asian J Trop Med Public Health 1990; 21:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/7\">",
"      Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale--the \"bashful\" malaria parasites. Trends Parasitol 2007; 23:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/8\">",
"      CHIN W, CONTACOS PG, COATNEY GR, KIMBALL HR. A NATURALLY ACQUITED QUOTIDIAN-TYPE MALARIA IN MAN TRANSFERABLE TO MONKEYS. Science 1965; 149:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/9\">",
"      Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis 2011; 52:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/10\">",
"      Jongwutiwes S, Putaporntip C, Iwasaki T, et al. Naturally acquired Plasmodium knowlesi malaria in human, Thailand. Emerg Infect Dis 2004; 10:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/11\">",
"      Zhu HM, Li J, Zheng H. [Human natural infection of Plasmodium knowlesi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2006; 24:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/12\">",
"      Ng OT, Ooi EE, Lee CC, et al. Naturally acquired human Plasmodium knowlesi infection, Singapore. Emerg Infect Dis 2008; 14:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/13\">",
"      Luchavez J, Espino F, Curameng P, et al. Human Infections with Plasmodium knowlesi, the Philippines. Emerg Infect Dis 2008; 14:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/14\">",
"      Putaporntip C, Hongsrimuang T, Seethamchai S, et al. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. J Infect Dis 2009; 199:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Simian malaria in a U.S. traveler--New York, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/16\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/17\">",
"      Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/18\">",
"      Maguire JD, Fenton ME, Susanti AI, Walker JB. Plasmodium vivax-associated acute respiratory distress syndrome after extended travel in Afghanistan. Travel Med Infect Dis 2007; 5:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/19\">",
"      Islam N, Qamruddin K. Unusual complications in benign tertian malaria. Trop Geogr Med 1995; 47:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/20\">",
"      Torres JR, Perez H, Postigo MM, Silva JR. Acute non-cardiogenic lung injury in benign tertian malaria. Lancet 1997; 350:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/21\">",
"      Munteis E, Mellibovsky L, M&aacute;rquez MA, et al. Pulmonary involvement in a case of Plasmodium vivax malaria. Chest 1997; 111:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/22\">",
"      Curlin ME, Barat LM, Walsh DK, Granger DL. Noncardiogenic pulmonary edema during vivax malaria. Clin Infect Dis 1999; 28:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/23\">",
"      Carlini ME, White AC Jr, Atmar RL. Vivax malaria complicated by adult respiratory distress syndrome. Clin Infect Dis 1999; 28:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/24\">",
"      Lawn SD, Krishna S, Jarvis JN, et al. Case reports: pernicious complications of benign tertian malaria. Trans R Soc Trop Med Hyg 2003; 97:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/25\">",
"      Kotwal RS, Wenzel RB, Sterling RA, et al. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005; 293:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/26\">",
"      Price L, Planche T, Rayner C, Krishna S. Acute respiratory distress syndrome in Plasmodium vivax malaria: case report and review of the literature. Trans R Soc Trop Med Hyg 2007; 101:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/27\">",
"      Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/28\">",
"      Koh KH, Chew PH, Kiyu A. A retrospective study of malaria infections in an intensive care unit of a general hospital in Malaysia. Singapore Med J 2004; 45:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/29\">",
"      Rifakis PM, Hernandez O, Fern&aacute;ndez CT, et al. Atypical Plasmodium vivax malaria in a traveler: bilateral hydronephrosis, severe thrombocytopenia, and hypotension. J Travel Med 2008; 15:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/30\">",
"      Lomar AV, Vidal JE, Lomar FP, et al. Acute respiratory distress syndrome due to vivax malaria: case report and literature review. Braz J Infect Dis 2005; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/31\">",
"      Barcus MJ, Basri H, Picarima H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 2007; 77:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/32\">",
"      Facer CA, Rouse D. Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet 1991; 338:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/33\">",
"      Moudden MK, Boukhira A, Zyani M, et al. [Severe imported malaria: the experience of the Avicenna military hospital of Marrakech]. Sante 2006; 16:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/34\">",
"      Davis TM, Singh B, Sheridan G. Parasitic procrastination: late-presenting ovale malaria and schistosomiasis. Med J Aust 2001; 175:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/35\">",
"      Miyashita N, Karino T, Nagatomo Y, et al. [A case of Plasmodium ovale malaria with thrombocytopenia and an abnormality grade in FDP concentration despite the use of chloroquine as a malaria prophylaxis]. Kansenshogaku Zasshi 1995; 69:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/36\">",
"      Sukwa TY, Mulenga M, Chisdaka N, et al. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999; 60:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/37\">",
"      van der Berg JD, Duvenage CS, Roskell NS, Scott TR. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Ther 1999; 21:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/38\">",
"      LUBITZ JM. Pathology of the ruptured spleen in acute vivax malaria. Blood 1949; 4:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/39\">",
"      Gockel HR, Heidemann J, Lorenz D, Gockel I. Spontaneous splenic rupture, in tertian malaria. Infection 2006; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/40\">",
"      Jim&eacute;nez BC, Navarro M, Huerga H, L&oacute;pez-V&eacute;lez R. Spontaneous splenic rupture due to Plasmodium vivax in a traveler: case report and review. J Travel Med 2007; 14:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/41\">",
"      Jim&eacute;nez BC, Navarro M, Huerga H, L&oacute;pez-V&eacute;lez R. Spontaneous splenic rupture due to Plasmodium vivax in a traveler: case report and review. J Travel Med 2007; 14:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/42\">",
"      Poespoprodjo JR, Fobia W, Kenangalem E, et al. Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis 2009; 48:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/43\">",
"      Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/44\">",
"      Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004; 38:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/45\">",
"      GILLES HM, HENDRICKSE RG. Possible aetiological role of Plasmodium malariae in \"nephrotic syndrome\" in Nigerian children. Lancet 1960; 1:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/46\">",
"      Abdurrahman MB, Greenwood BM, Narayana P, et al. Immunological aspects of nephrotic syndrome in northern Nigeria. Arch Dis Child 1981; 56:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/47\">",
"      Abdurrahman MB, Aikhionbare HA, Babaoye FA, et al. Clinicopathological features of childhood nephrotic syndrome in northern Nigeria. Q J Med 1990; 75:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/48\">",
"      Vinetz JM, Li J, McCutchan TF, Kaslow DC. Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med 1998; 338:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/49\">",
"      Michaud E, Ninet J, Copp&egrave;re B, et al. [Nephrotic syndrome caused by Plasmodium malariae infection. A case with favourable outcome]. Presse Med 1992; 21:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/50\">",
"      Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 2006; 98:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/51\">",
"      Ehrich JH, Eke FU. Malaria-induced renal damage: facts and myths. Pediatr Nephrol 2007; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/52\">",
"      Neri S, Pulvirenti D, Patamia I, et al. Acute renal failure in Plasmodium malariae infection. Neth J Med 2008; 66:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/53\">",
"      Lee KS, Cox-Singh J, Brooke G, et al. Plasmodium knowlesi from archival blood films: further evidence that human infections are widely distributed and not newly emergent in Malaysian Borneo. Int J Parasitol 2009; 39:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/54\">",
"      Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009; 49:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/55\">",
"      William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011; 17:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/56\">",
"      Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/57\">",
"      Hoffman SL, Piessens WF, Ratiwayanto S, et al. Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med 1984; 310:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/58\">",
"      Vriend WH, Hoffman SL, Silaban T, Zaini M. Splenectomy in massive tropical splenomegaly: two-to six-year follow-up in 14 patients. Trop Geogr Med 1988; 40:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/59\">",
"      Paparello SF, Hoffman SL. Hyperreactive malarial splenomegaly: part I. Post Grad Med 1992; 15:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/60\">",
"      Moraes MF, Soares M, Arroz MJ, et al. [New concepts in hyperactive malarial splenomegaly]. Acta Med Port 2003; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/61\">",
"      Mothe B, Lopez-Contreras J, Torres OH, et al. A case of hyper-reactive malarial splenomegaly. The role of rapid antigen-detecting and PCR-based tests. Infection 2008; 36:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/62\">",
"      Gupta OP, Bajaj S, Gupta SC. A study on tropical splenomegaly syndrome and chloroquine prophylaxis. J Assoc Physicians India 1989; 37:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/63\">",
"      Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/64\">",
"      Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria--implications for chemoprophylaxis in travelers. N Engl J Med 2003; 349:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/65\">",
"      Joshi H, Prajapati SK, Verma A, et al. Plasmodium vivax in India. Trends Parasitol 2008; 24:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/66\">",
"      Imwong M, Boel ME, Pagornrat W, et al. The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis 2012; 205:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/67\">",
"      Chin W, Coatney GR. Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale. Am J Trop Med Hyg 1971; 20:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/68\">",
"      Chin W, Contacos PG. A recently isolated West African strain of plasmodium ovale. Am J Trop Med Hyg 1966; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/69\">",
"      TRAGER W, MOST H. A LONG-DELAYED PRIMARY ATTACK OF OVALE MALARIA. Am J Trop Med Hyg 1963; 12:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/70\">",
"      Rodr&iacute;guez-Morales AJ, S&aacute;nchez E, Vargas M, et al. Occurrence of thrombocytopenia in Plasmodium vivax malaria. Clin Infect Dis 2005; 41:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/71\">",
"      Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/72\">",
"      White NJ, Miller KD, Churchill FC, et al. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med 1988; 319:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/73\">",
"      Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/ith/countries/en/index.html (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/75\">",
"      Mali S, Steele S, Slutsker L, et al. Malaria surveillance--United States, 2006. MMWR Surveill Summ 2008; 57:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/76\">",
"      Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010; 9:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/77\">",
"      Vinetz JM. Emerging chloroquine-resistant Plasmodium vivax (Benign Tertian) malaria: the need for alternative drug treatment. Clin Infect Dis 2006; 42:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/78\">",
"      Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/79\">",
"      Schwartz IK, Lackritz EM, Patchen LC. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med 1991; 324:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/80\">",
"      Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/81\">",
"      Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/82\">",
"      Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Yellow Fever Vaccine Requirements and Information on Malaria Risk and Prophylaxis, by Country. wwwn.cdc.gov/travel/yellowBookCh5-MalariaYellowFeverTable.aspx (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/84\">",
"      Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 1996; 90:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/85\">",
"      Baird JK, Wiady I, Fryauff DJ, et al. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 1997; 56:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/86\">",
"      Fryauff DJ, Tuti S, Mardi A, et al. Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg 1998; 59:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/87\">",
"      Murphy GS, Basri H, Andersen EM, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 1993; 341:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/88\">",
"      Schuurkamp GJ, Spicer PE, Kereu RK, et al. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 1992; 86:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/89\">",
"      Sumawinata IW, Leksana B, Sutamihardja A, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/90\">",
"      Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/91\">",
"      Castillo CM, Osorio LE, Palma GI. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a Malaria transmission free area in Colombia. Mem Inst Oswaldo Cruz 2002; 97:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/92\">",
"      Maguire JD, Marwoto H, Richie TL, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/93\">",
"      Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002; 35:e92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/94\">",
"      Alcantara AK, Uylangco CV, Sangalang RP, Cross JH. A comparative clinical study of mefloquine and chloroquine in the treatment of vivax malaria. Southeast Asian J Trop Med Public Health 1985; 16:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/95\">",
"      Harinasuta T, Bunnag D, Lasserre R, et al. Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. Lancet 1985; 1:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/96\">",
"      Pukrittayakamee S, Chantra A, Simpson JA, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/97\">",
"      Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/98\">",
"      Looareesuwan S, Wilairatana P, Glanarongran R, et al. Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg 1999; 93:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/99\">",
"      Silachamroon U, Krudsood S, Treeprasertsuk S, et al. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 2003; 69:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/100\">",
"      Dixon KE, Pitaktong U, Phintuyothin P. A clinical trial of mefloquine in the treatment of Plasmodium vivax malaria. Am J Trop Med Hyg 1985; 34:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/101\">",
"      Bouchaud O, Monlun E, Muanza K, et al. Atovaquone plus proguanil versus halofantrine for the treatment of imported acute uncomplicated Plasmodium falciparum malaria in non-immune adults: a randomized comparative trial. Am J Trop Med Hyg 2000; 63:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/102\">",
"      Baird JK, Basri H, Subianto B, et al. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 1995; 171:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/103\">",
"      Krudsood S, Tangpukdee N, Muangnoicharoen S, et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 2007; 45:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/104\">",
"      Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/105\">",
"      Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/106\">",
"      Phyo AP, Lwin KM, Price RN, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 2011; 53:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/107\">",
"      Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/108\">",
"      Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 2007; 76:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/109\">",
"      Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/110\">",
"      Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002; 360:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/111\">",
"      Collins WE, Contacos PG, Chin W. Experimental infection in man with Plasmodium malariae. Am J Trop Med Hyg 1973; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/112\">",
"      Tan-ariya P, Pasuralertsakul S. First report of in vitro susceptibility of Plasmodium malariae Thai isolates to chloroquine. Southeast Asian J Trop Med Public Health 1994; 25:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/113\">",
"      Collins WE, Jeffery GM. Extended clearance time after treatment of infections with Plasmodium malariae may not be indicative of resistance to chloroquine. Am J Trop Med Hyg 2002; 67:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/114\">",
"      Barnadas C, Ratsimbasoa A, Ranaivosoa H, et al. Short report: prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar. Am J Trop Med Hyg 2007; 77:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/115\">",
"      Berman JD, Nielsen R, Chulay JD, et al. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans R Soc Trop Med Hyg 2001; 95:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/116\">",
"      H&oslash;gh B, Clarke PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet 2000; 356:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/117\">",
"      Chulay JD. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans R Soc Trop Med Hyg 1998; 92:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/118\">",
"      Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 1999; 60:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/119\">",
"      Lell B, Luckner D, Ndjav&eacute; M, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/120\">",
"      Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/121\">",
"      Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/122\">",
"      Phillips-Howard PA, Steffen R, Kerr L, et al. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998; 5:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/123\">",
"      Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/124\">",
"      Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2007; :CD004389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/125\">",
"      Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/126\">",
"      Goller JL, Jolley D, Ringwald P, Biggs BA. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 2007; 76:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/127\">",
"      Doherty JF, Day JH, Warhurst DC, Chiodini PL. Treatment of Plasmodium vivax malaria--time for a change? Trans R Soc Trop Med Hyg 1997; 91:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/128\">",
"      Fryauff DJ, Baird JK, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/129\">",
"      Pang LW, Limsomwong N, Boudreau EF, Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet 1987; 1:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/130\">",
"      Ehrman FC, Ellis JM, Young MD. PLASMODIUM VIVAX CHESSON STRAIN. Science 1945; 101:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/131\">",
"      ALVING AS, JOHNSON CF, TARLOV AR, et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ 1960; 22:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/18/4394/abstract/132\">",
"      . Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg 1993; 87:687.",
"     </a>",
"    </li>",
"    <li>",
"     file://wwwn.cdc.gov/travel/default.aspx (Accessed on September 26, 2008).",
"    </li>",
"    <li>",
"     CDC. Health information for international travel 2011-2012. DHHS, Atlanta, GA 2011.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5706 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4394=[""].join("\n");
var outline_f4_18_4394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasmodium vivax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasmodium ovale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Plasmodium malariae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plasmodium knowlesi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      By species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - P. vivax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - P. ovale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - P. malariae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - P. knowlesi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperreactive malarial splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Uncomplicated disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Chloroquine resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Preventing relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Complicated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5706|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/23/16760\" title=\"figure 1\">",
"      Plasmodium life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/9/34966\" title=\"figure 2\">",
"      Plasmodium blood smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/38/15981\" title=\"table 1\">",
"      Features of malaria spp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/47/16126\" title=\"table 2\">",
"      Rx nonfalcip malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=related_link\">",
"      Mosquito vectors of infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=related_link\">",
"      Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_18_4395="Agents causing fatal poisoning in young children";
var content_f4_18_4395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents causing fatal poisonings among children younger than six years of age*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Analgesic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fumes, gases, vapors (eg, carbon monxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough and cold preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insecticides and pesticides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidepressant drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cosmetics and personal care products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stimulants and illicit drugs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Excluding bites and envenomations.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Annual Reports of the American Association of Poison Control Centers Toxic Exposure Surveillance System.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4395=[""].join("\n");
var outline_f4_18_4395=null;
var title_f4_18_4396="Dosing novel beta lactams I";
var content_f4_18_4396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of novel beta-lactams",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal unit dose (route)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal dose interval, hours",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage change in severe renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin-sulbactam (1 g:0.5 g)",
"       </td>",
"       <td>",
"        3.0 g (IM, IV) (of combination)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin-clavulanic acid (3 g:0.1 g)",
"       </td>",
"       <td>",
"        3.1 g (IV) (of combination)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin-tazobactam (3 g:0.375 g",
"        <strong>",
"         OR",
"        </strong>",
"        4 g:0.5 g)",
"       </td>",
"       <td>",
"        3.375 g (IV)",
"        <strong>",
"         OR",
"        </strong>",
"        4.5 g (IV) (of combination)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem-cilastatin (1:1)",
"       </td>",
"       <td>",
"        500 mg (IV) (of imipenem)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        1-2 g (IV)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ertapenem",
"       </td>",
"       <td>",
"        1 g (IM, IV)",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doripenem",
"       </td>",
"       <td>",
"        500 mg (IV)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        1-2 g (IM, IV)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dose given at each normal dose interval.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4396=[""].join("\n");
var outline_f4_18_4396=null;
var title_f4_18_4397="TNM stage append carcinoid";
var content_f4_18_4397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging of appendiceal carcinoid",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Tumor 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor 1 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Tumor more than 1 cm but not more than 2 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 2 cm but not more than 4 cm or with extension to the cecum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm or with extension to the ileum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor directly invades other adjacent organs or structures, eg, abdominal wall and skeletal muscle&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"4\">",
"       <strong>",
"        pN0",
"       </strong>",
"       . Histological examination of a regional lymphadenectomy specimen will ordinarily include 12 or more lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not met, classify as pN0.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2, T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage III",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Tumor that is adherent to other organs or structures, grossly, is classified cT4. However, if no tumor is present in the adhesion, microscopically, the classification should be classified pT1-3 depending on the anatomical depth of wall invasion.",
"     <br>",
"      &bull; Penetration of the mesoappendix does not seem to be as important a prognostic factor as the size of the primary tumor and is not separately categorized.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4397=[""].join("\n");
var outline_f4_18_4397=null;
var title_f4_18_4398="Lifestyle and survival";
var content_f4_18_4398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Lifestyle factors and survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 213px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Additional years of life according to age associated with adoption or maintenance of a favorable physical-activity (&ge;4.5 metabolic equivalents, or METS) level and other characteristics between 1962 or 1966 and 1977, as estimated from mortality rates among 10,269 male Harvard alumni from 1977 through 1985. Prolongation of life was greater in younger men and with cessation of smoking, alone or particularly with exercise. The effect of each individual factor was adjusted for differences in other factors.",
"    <div class=\"footnotes\">",
"     HTN: hypertension.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Paffenberger RS Jr, Hyde RT, Wing AL, et al. N Engl J Med 1993; 328:538.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4398=[""].join("\n");
var outline_f4_18_4398=null;
var title_f4_18_4399="Postop neurologic evaluation";
var content_f4_18_4399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Postoperative neurologic evaluation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Consider arterial blood gas if the O",
"    <sub>",
"     2",
"    </sub>",
"    saturation is low and there is a history of pulmonary disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_18_4399=[""].join("\n");
var outline_f4_18_4399=null;
